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Abstract
Blood transfusion services around the world screen donations for antibodies to
hepatitis C virus (HCV). One potential problem of this is that the antibody
response only becomes detectable several weeks after infection and potentially
infectious donations in the "window period" go undetected. The screening ELISA
tests are based upon genotype 1 sequence. Six distinct HCV genotypes exist, which
show approximately 30 % amino acid sequence divergence in their encoded
proteins. Sequence variability is not uniform across the genome, being greatest in
the regions encoding envelope proteins and most restricted in the core gene.
Sequence variation in the antigenic determinants in core, NS3, NS4A/B and
NS5A/B proteins, may produce genotype-specific antibodies which do not cross-
react with the antigens used in current screening assays for detection ofantibody to
HCV. Reduction in test sensitivity caused by genotype-specific reactivity may
particularly affect detection of antibody around the time of seroconversion, as
antibody reactivity is likely to be weak and restricted to a limited number of
epitopes.
The extent of type-specific and type-common components of the humoral immune
response were investigated by measuring the antibody levels in samples of each
genotype with type-homologous and type-heterologous antigens. Reactivity
directed against the individual genotype 1 antigens used in a commercially
available anti-HCV screening assay (VK48; Murex Biotech) was compared with
corresponding core, NS3 and NS4A/B antigens of genotype 3, and NS3, NS4A/B
and NS5A/B antigens from genotype 4 using a panel of samples from individuals
infected with different genotypes (genotype 1: n=33, 3: n=34 and 4: n=43). A
combined ELISA was subsequently assembled using the core, NS3 and NS5A/B
recombinant proteins and NS4A/B synthetic peptide of genotype 3 a sequence, and
serological reactivity in this ELISA compared quantitatively with reactivity in the
(type 1-based) Murex VK48 assay, using a similar panel of samples from
individuals infected with different HCV genotypes. The overall proportion of type-
specific reactivity in the combined ELISAs was 46% (with the type-common
component making up the other 54%). Type-specificity ofreactivity to each region
depended on the extent of amino acid divergence between genotypes, with the
more conserved core region eliciting 26% type-specific reactivity, compared with
60% and 62-77% to the NS3 and NS5A/B regions.
15
To investigate whether antigenic variability influenced the effectiveness of type-1
based serological assays for screening, blood donor samples collected in regions
where non-genotype 1 HCV predominated, such as genotype 3 infection in
Pakistan and genotype 4a infection in Egypt and the Middle East, were screened by
ELISAs based on genotype 3a or 4a antigens. Additionally, samples from
seroconversion panels, individuals identified with a serum positive PCR result, but
a commercial assay negative result and individuals with cryptogenic hepatitis, were
tested for reactivity to antigens of genotype 2, 3 or 4. Although several samples
were identified with type-specific reactivity confined to non-type 1 antigens, none
were PCR positive. These results therefore indicate that while some (past,
resolved) HCV infections may not be detectable using commercially available type
1-based screening assays, the lack of detectable viraemia in the samples provides
no evidence at present that these serological "misses" risk the safety of blood
transfusion. However, the results do indicate that a proportion of past HCV
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1 Hepatitis C Virus
The Hepatitis C Virus (HCV) was discovered by the research group headed by
Michael Houghton at the Chiron Corporation in conjunction with the Centres for
Disease Control in 1989 (Choo et al., 1989). It is a small enveloped, ribonucleic
acid (RNA) virus that shows some similarities to plant pestiviruses and animal
flaviviruses, but is more closely related to another newly discovered vims, hepatitis
G vims (HGV) (Linnen et al., 1996) also described as GB vims C (Simons et al.,
1995). Transmission is by parenteral routes and the virus is prevalent throughout
the world. Infection results in a wide spectrum of disease from mild jaundice to
eventual hepacellular carcinoma. Approximately 55-85% ofthose infected become
chronic carriers and current treatment with interferons, anti-virals and combination
therapies have a limited effect. HCV infection is a major economic problem in
terms of lost working hours, cost of treatment and death.
1.1 Virion
Electron microscopy revealed that the vims exists as two types ofparticles, small
particles of 30-35 nm or 45-55 nm and large particles of 50-75 nm (Kaito et al.,
1994;Takahashi et al., 1992); (Li et al., 1995) (Prince et al., 1996;Shimizu et al.,
1996). The small particles are assumed to be non-enveloped nucleocapsids and the
larger particles complete virions.
The measurement ofbuoyant density in sucrose gives a range of values from 1.06
g/cm to 1.17 g/cm (Bradley et al., 1991;Carrick et al., 1992;Kanto et al.,
1994;Kanto et al., 1995), again suggesting several sizes of particles. The low-
density particles are more infectious than the high-density particles and tend to be
associated with /3 lipoprotein (Thomssen et al., 1992;Thomssen et al., 1993).
Addition ofanti- p lipoprotein to serum of an infected individual precipitates HCV
(Thomssen et al., 1992). The higher density particles may represent naked capsids
and enveloped virions bound to immunoglobulins (Choo et al., 1995;Hijikata et al.,
1993b;Kanto et al., 1995).
1.2 Similarity of HCV to other Virus families
HCV has been classed as a separate genus Hepacivirus in the Flaviviridae family
because it has a similar hydrophobicity profile but a limited sequence identity with
the two other genera of the family, the flaviviruses and the pestivimses. The newly
discovered GBV-A, GBV-B viruses of primates and the human HGV/ GBV-C
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virus are also classified as Flaviviridae because of their similarity with HCV. The
flaviviruses contain viruses transmitted by ticks and mites and other insect vectors,
including yellow fever virus, dengue virus and Japanese Encephalitis virus. The
pestiviruses include viruses of farmed animals, bovine viral diarrhoea virus,
classical swine fever and border disease virus of sheep. HCV shares a similar
highly conserved 5' untranslated region with pestiviruses but not with flaviruses.
Similarities with other viruses exist in the serine protease, helicase and polymerase
genes.
1.3 Viral organisation, structure and function
The positive stranded RNA virus genome consists of approximately 9400
nucleotides that form an open reading frame that codes for a 3300 amino acid
polyprotein. Host signal peptidases and two virally encoded protease enzymes
process this protein. The genome is organised into a N-terminal or 5' non coding or
untranslated region (5'NCR or 5'UTR), followed by a nucleocapsid or core protein,
two envelope genes designated El and E2, 6 non-structural genes NS2, NS3,



































The NCR is an internal ribosome entry site (Tsukiyama Kohara et al., 1992)
(Wang et al., 1993) essential for cap-independent translation of RNA. The 5'
non-coding region is 341 nucleotides in length it is highly conserved between
all the HCV genotypes and subtypes. The region forms a complex RNA
secondary structure including a large conserved stem loop (125-323
nucleotides), a pseudo-knot (305-311 and 325-331 nucleotides), and a small
stem-loop containing an AUG codon (331-354 nucleotides).
The first cleavage product of the polyprotein is the highly basic core protein,
forming the maj or constituent of the nucleocapsid (Yasui et al., 1998). Envelope
proteins (El and E2) are highly glycosylated type 1 transmembrane proteins.
Protein p7, located at the carboxyl terminus of E2, is a highly hydrophobic
polypeptide which functions as an ion channel (Pavlovic et al, 2003). Most of
the non-structural (NS) proteins 2-5B (the term indicates that these proteins are
not expected to be constituents of the virus particle) are required for replication
of the viral RNA (Lohmann et al., 1999). NS2 and the amino-terminal domain
of NS3 constitute the NS2-3 proteinase, catalysing cleavage at the NS2/3 site
(Grakoui et al., 1993a;Hijikata et al., 1993a;Elirowatari et al., 1993). NS3 is
both a serine-type proteinase responsible for cleavage at the NS3/4A, NS4A/B,
NS4B/5A and NS5A/B sites and, a NTPase/helicase, essential for translation
and replication of the HCV genome (Eckart et al., 1993;Grakoui et al.,
1993b;Gwack et al., 1996). In addition, NS3 may have other properties
involved in interference with host cell functions like inhibition ofprotein kinase
A-mediated signal transduction or cell transformation (Borowski et al., 1996).
NS4A is an essential cofactor of the NS3 proteinase and is required for efficient
polyprotein processing (Bartenschlager et al., 1994;Failla et al., 1994). The
function of the hydrophobic NS4B is so far unknown. NS5A is a highly
phosphorylatedprotein. The phosphorylation is mediated by an as yetunknown
cellular kinase (Ide et al., 1997). The role NS5A may play in RNA replication is
so far not known, but based on analogy with other RNA viruses, where
phosphoproteins are important regulators of replication; one could assume that
NS5A plays a similar role. NS5A appears to be involved in resistance of the
infected cell to the antiviral effect of IFN. At least forsome HCV isolatesNS5A
is able to bind to dsRNA dependent protein kinase (PKR), blocking the
translational reduction in the IFN-treated cell (Gale et al., 1997).
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NS5B was identified as the RNA-dependent RNA polymerase (RdRp) (A1 et
al., 1998;Lohmann et al., 1997) (Behrens et al., 1996).
The 3' untranslated region (UTR) can be divided into 3 domains by virtue ofthe
sequence composition. The first domain constitutes the most heterogeneous
sequence and is followed by a domain composed of a poly-A or poly-UC run of
variable length. The third domain consists of a highly conserved 3' tail of 98
nucleotides, which is important for initiation ofviral RNA replication (Tanaka
et al., 1996) (Kolykhalov et al., 1996).
1.4 HCV Receptor
Several cell surface molecules have been proposed as the HCV receptor: the
low density lipoprotein (LDL) receptor (Agnello et al., 1999), (Monazahian et
al., 1999), a tetraspanin molecule designated CD81(Pileri et al., 1998) and
human scavenger receptor class B type 1 (SB-BI) (Scarselli et al., 2002;
Bartosch et al, 2003). Due to the lack of cell culture systems for HCV,
alternative approaches were used to establish the link between HCV and the
proposed receptors. Agnello and colleagues demonstrated that HCV and other
Flaviviridae including GB virus C /HGV and bovine viral diarrhoeal virus
(BVDV) enter cells in culture mediated by the LDL receptor. Endocytosis
occurred in cell culture line G4 and HepG2 cells when HCV was complexed
with very low-density lipoprotein (VLDL) and LDL. Antibodies could inhibit
the intake ofHCV to the anti-LDL receptor, by cyclohexanedione that is known
to disrupt the LDL receptor-binding site and by completive inhibition with large
concentrations of LDL and VLDL (Wunschmann et al., 2000).
Pileri's group demonstrated that CD 81 binds to expressed recombinant E2
protein (Pileri et al., 1998). CD81 is a widely expressed 25 kD molecule and a
member of the tetraspanin super family (Levy et al., 1998) expressed on various
cell types including hepatocytes and B-lymphocytes. This cell surface protein
spans the cell membrane four times forming two extra cellular loops. The major
extra cellular loop is highly conserved in humans and chimpanzees the only two
species HCV is known to infect. Binding of HCV to CD81 was mapped to the
major extra cellular loop of CD81. The binding affinity of recombinant E2 to
the recombinant large extra cellular loop of CD81 is 1.8 nM at 25 °C and 9.1
nM at 37 °C (Petracca et al., 2000). This is similar to the binding affinity 1-4
nM reported for Human Immunodeficiency Virus (HIV) gp 120 binding to CD4
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(Moore et al., 1991). If the binding affinity values calculated in vitro are
representative of the situation in vivo, neutralising antibodies to the envelope
region would have to have affinity constants of higher than 10-9 M to prevent
viral attachment.
CD81 has a relatively poor ability to internalise ligands and it may serve as an
HCV attachment receptor rather than a receptor for virus entry.
The LDL receptor and CD81 attachment operate independently of each other
with antibodies to one failing to block attachment to the other (Wunschmann et
al., 2000).
Scarselli's group found that binding of recombinant E2 to CD81 was isolate
specific however E2 recognition by human hepatoma cell lines was not. They
isolated the receptor responsible for E2 binding to the cell line as SB-BI. They
were able to demonstrate that the binding was selective since neither mouse
SB-BI nor the closely related human scavenger receptor DC36 were able to
bind E2. Recognition ofE2 by SR-B1 could be competed out by the addition of
monoclonal antibodies specific for the E2 HVR (Scarselli et al 2002).
1.5 HCV in the cell
Hepatocytes represent the primary site ofHCV replication. Although extracted
peripheral blood mononuclear cells (PBMC) contain HCV RNA, (Bouffard et
al., 1992;Muller et al., 1993;Schmidt et al., 1997) it is unclear ifHCV replicates
in PBMC in vivo (Afonso et al., 1999;Fong et al., 1991;Lanford et al.,
1995;Wang et al., 1992). HCV RNA has also been found in T and B-
lymphocytes (Blight et al., 1994;Bouffard et al., 1992;Zignego et al., 1992).
It is difficult to determine the sites of active replication as this depends on the
identification of negative sense strands of RNA. The difficulty arises because
all methods of detection require synthesis of a negative strand. Methods have
been developed where specific primers or highly strand-specific rTth
(recombinant Thermus thermophilics DNA polymerase can be used to detect the
presence ofnegative strands (Yuan H et al., 2003). Our current understanding
of the molecular mechanisms of HCV replication is based on comparison with
the closely related flavi- and pesti-viruses and on the characterisation of
recombinant HCV proteins. The presumed life cycle ofHCV includes: binding
to cell surface receptor and internalisation into the host cell; liberation of the
genomic RNA from the virus particle into the cytoplasm; IRES medicated
translation of the input RNA; processing of the polyprotein; utilization of the
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input plus-strand for synthesis of a minus-strand RNA intermediate; production
of new plus-strand RNA molecules which in turn can be used for synthesis of
new minus strands for polyprotein expression or packaging into progeny virions
and release of virus from the infected cell (Figure 1.2).
1.5.1 Viral Kinetics
HCV infection is a highly dynamic process with a viral half life of only a few
hours and average daily virion production and clearance rates of up to more
than 1012 (Neumann et al., 1998).
1.6 Genome Variability
RNA virus replication requires RNA polymerase, which is prone to a high error
rate. This means that there are number of mismatches of base between the
template RNA strand and the newly synthesised strand. Mutations can occur for
many reasons including depurination, deamination, polymerase slippage and
oxidative damage to bases. These errors remain uncorrected since no proof
reading activity has been reported for RNA polymerases (Holland et ah, 1982).
There is a bias towards base transitions, i.e. pyrimidine to pyrimidine, purine to
purine rather than to transversions - pyrimidine to purine, purine to pyrimidine.
This may be caused by G to U mis-pairing (Both et ah, 1983). The average
error frequencies of virus RNA replicase and reverse transcriptase is of the
order of 10"3 to 10"5 per site (Holland et ah, 1992), yielding 10-100 viable
replacements per site per year. Therefore, most RNA viruses exist as a






Figure1.2HCVreplicationinthecell ThepresumedlifcyclofHCVinth tll;b dinglsurfacrecep or,intemalisat oho tc l ,un oatintviRNAtranslati polyproteinrocessi g,RNAreplicat onmaturationandr lefromh sc ll. 26
The reported nucleotide sequences of HCV show a varying degree of
divergence from each other (Choo et al., 1991). Variation is seen between
sequences isolated from different individuals and among different isolates from
the same individual (Okamoto et al., 1991). The nucleotide sequence mutation
rate was calculated for the complete genome of HCV as 1.44 X10"3 base
substitutions per site per year (Okamoto et al., 1992a). However, the variation
was not uniformly distributed over the genome. The fidelity in several sites
remained constant; others contained several substitutions while yet other
regions appeared to be mutational hot spots.
Whether a given nucleotide substitution results in a viable mutant is site
dependent; different regions of the HCV genome vary in their level of genetic
conservation. Highly conserved areas include the 5' NCR and the core protein.
Nucleotide substitutions in these regions are less likely to be viable, because
changes may result in an altered structure that affects the function. This will
apply to the RNA structure of regions with a replication function and to the
regions where the function of the translated protein is disrupted. Other regions
of the genome are more tolerant of nucleotide substitution.
There are two regions of the envelope genes that are highly variable in their
nucleotide sequence. They have been called hypervariable region 1 (HVRl) and
hypervariable region 2 (HVR 2). HVRl is located at amino acid position 396-
407 and HVR2 at amino acid position 3 80-436 in the E2 envelope glycoprotein
(Weiner et al., 1992). These regions show similarity with the V3 loop of gpl20
in HIV which also displays a high degree of variability, and it has been
suggested that this variation is associated with escape from neutralising
antibody binding (Kato et al., 1998;Weiner et al., 1992). The method of
introduction of mutations in these regions is different from the rest of the
genome. Throughout the genome the ratio of transitions to transversions is 3.92
but in the HVR it is 1.10. Also, analysis of variation in complete genomes
found 62% of changes occurred in the 3rd nucleotide position of a codon, but in
the HVR all the nucleotide changes were in the first or second codon positions.
In an infected individual, the variation among quasispecies gives rise to
populations of viruses that have different properties. There is a range of
replicative efficiencies among the quasispecies and not all quasispecies are
infective (Sugitani and Shikata, 1998). Studies have indicated that quasispecies
differ with respect to the alanine amino-transferase (ALT) elevations they
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induce, which is indicative of liver damage and some data suggest that greater
diversity in HCV quasispecies correlates with more severe liver disease
(Gonzalezperalta et al., 1996;Hayashi et al., 1997;Yuki et al., 1997).
Quasispecies also appear to differ in their response to IFNa therapy (Mizokami
et al., 1994;Pawlotsky et al., 1998) which reduces the viral sequence diversity
as viral replication decreases (Gonzalezperalta et al., 1996). After INFa
therapy, different HCV quasispecies may become dominant. Patients with more
than two major quasispecies tend to respond poorly to IFNa therapy
(Gonzalezperalta et al., 1996), (Toyoda et al., 1997). Different quasispecies
may be found in different locations within an individual. Sequence variation
has been found between the liver and the plasma (Maggi et al., 1997) and it is
possible that in this case mutations have given a selective advantage for
individual tissues or cell types. The quasispecies profile in an individual also
often changes after liver transplantation. This implies a role for the liver, as
well as host immune responses, in selection of predominant quasispecies
(Lawal et al., 1997;Yun et al., 1997). Approximately 90% of liver transplant
recipients become reinfected, however, few develop severe HCV associated
liver disease. In vertical transmission the predominant viral sequence in the
child may not have been the predominant one in the mother at the time of the
transmission (Kudo et al., 1997).
Again this shows that the possession of the diverse gene pool of quasispecies
makes HCV very adaptable to environment changes.
Artefactual genome variation may be introduced to a specific sequence by
laboratory methods used for sequencing the RNA. All methods of amplifying
the RNA sequence utilise enzymes that have a degree of replication error.
Substitutions can be introduced during copying of virus RNA by reverse
transcriptase or during the 25-50 cycles ofreplication by Taq DNA polymerase,
producing combined error rates in DNA clones of 2.5-5xl0~3 depending on
sequence and reaction conditions. Therefore, the inferred RNA sequence
derived may include several different bases to the original RNA template
extracted. Laboratory methods to obtain a given sequence should involve
repeating the sequencing reaction several times and combining the results to
obtain a consensus sequence and careful interpretation ofsequence data must be
applied (Simmonds, 1993).
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1.6.1 Classification system for HCV
Initially published sequences of complete HCV genomes were compared using
computer programmes based on mathematical modelling that estimated the
variation or pair wise distances between two sequences and predicted
phylogenetic relationships. Using a model for molecular evolution (Felsenstein,
1988). HCV was shown to consist of isolates which shared approximately 88%-
100% sequence identity, subtypes which shared 74-86% identity and genotypes
which shared 54-72% identity (Figure 1.3) (Simmonds et ah, 1993a;Simmonds
et al., 1994). Six major genotypes of HCV exist with more than 80 subtypes.
Additionally, analysis was carried out on the El, core, and NS5 regions which
showed that analysis of NS5 region nucleotide positions 7975 to 8196
completely concurred with sequence analysis of complete genomes. Thus
complete genome sequencing was not necessary for genotyping analysis
(Simmonds et ah, 1994).
Sequence analysis found that several mutations were shared by isolates of the
same genotype. This allowed methods of identification of the genotype or
subtype to be devised which did not require full-length sequencing. Several
methods were developed including, type-specific primers for amplification of
the 5'NCR and core regions (Chayama et ah, 1993;Okamoto et ah, 1992b),
restriction enzyme digestion ofPCR products (Davidson et ah, 1995;McOmish
et ah, 1993;McOmish et ah, 1994;Murphy et ah, 1994) and labelled
hybridisation probes (Stuyver et ah, 1993b;Van Doom, 1994). Overall
concordance between the different genotyping methods exceeds 93% (Lau et
ah, 1995). The serotype of infection, which normally concurs with the
genotype, can be detected by determining type-specific antibody to core or NS4
regions. This will be discussed in section 1.10.4.
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In a clinical setting genotyping is carried out by amplification of the 5 "NCR
region by PCR after infection is confirmed. This is because methods which
utilise the 5 'NCR are more rapid and RNA detection is frequently higher for the
5'NCR than for other regions of the genome (Bukh et al., 1992;Castillo et al.,
1992;Xu et ah, 1994). Genotype-specific sequence polymorphisms exist
throughout the 5 "NCR except for a highly conserved 60-nucleotide region at the
3' terminus. The genotyping methods utilise the genotype-specific sequence
polymorphisms to deduce the genotype of the virus. The line probe assay
(LiPA) involves the hybridisation of 5'NCR RT-PCR products to type-specific
oligonucleotides under conditions where single base mismatches prevent
hybridisation (Stuyver et ah, 1993a;Vandoorn et ah, 1994), the Trugene HCV
5'NC Genotyping kit (Visible Genetics, Toronto, Canada) (Ansaldi et ah, 2001,
Ross et al, 2000) is based on direct sequencing ofPCR amplicons and sequence
comparison with a reference database, while for restriction fragment length
polymorphism (RFLP) analysis, virus genotype is predicted from the
electrophenotypes produced from RT-PCR products after restriction digestion
(Davidson et ah, 1995;McOmish et ah, 1993;McOmish et ah, 1994). The
accuracy of the methods, RFLP and LiPA, is approximately 96% and 84%
respectively for the prediction of virus type with higher accuracies for
distinguishing subtypes la/lb, 2a/2b and 3a/3b (Smith et ah, 1995).
Phylogenetic analysis found no evidence of recombination between HCV
genomes (Simmonds et ah, 1994). Recombination has been described in two
Honduran patients (Yun et ah, 1996) where the core sequence of genotype 1
was found with sequence analysis and type-specific core primers, and genotype
3 found by sequence analysis of E2 and NS5 regions. This may have been a
mixed infection where the type-specific primers for core of type 3 did not bind
to the genotype 3 sequence present, and genotype 1 sequence did not amplify in
E2 and NS5 regions. If recombination does take place then it would be
exceptionally rare, since for recombination to occur two viruses of separate
genotypes must infect the same cell. The low incidence of HCV infection and
the restricted genotype distribution in most communities make such an event
unlikely, although an exception might be haemophiliacs who have been
multiply infected with mixtures of virus genotypes over many years through
regular infusions of blood products (Jarvis et ah, 1994).
31
1.7 Prevalence
HCV infection has been reported from countries throughout the world. The
World Health Organisation estimates 200 million people are carrying the virus.
The prevalence in the UK and USA is between 0.1-1% In Scotland alone 10
thousand people are on the national infection database and double that number
are suspected to be infected (Scottish Centre for Infection and Environmental
Health web site). Many parts of the developing world have a higher prevalence
of disease. The World Health Organisation lists the following countries as
having a prevalence of greater than 10%: Bolivia, Burundi, Cameroon, Egypt,
Guinea, Mongolia, Rwanda and Tanzania. Furthermore, Gabon, Libya, Papua
New Guinea, Surinam; Vietnam and Zaire have prevalences ofbetween 5-10%
(World Heath Organisation Weekly Epidemiological Record. N° 49, 10
December 1999 [Figure 1.4]). In some countries, for example, Pakistan,
prevalence as high as 40% has been reported in rural areas (Dr A Saeed
personal communication). A proportion of these infections has to be attributed
to mass vaccination campaigns where sterilization ofequipment was not carried
out between vaccinations.
The true prevalence ofHCV infection in many countries may actually be higher
than official figures since many of the prevalence studies were carried out in
blood donor screening centres. Blood donors are screened by interview to reject
those who have engaged in any practices which are associated with risk factors
for infection with HIV or hepatitis viruses, such as injecting drug abuse,
tattooing, body piercing, homosexual sexual practices and multiple sexual
partners.
The genotype of HCV found in each region of the world differs with rarely
more than 3 types or subtypes prevalent in any particular location. Genotype 1
is ubiquitous and accounts for two-thirds of HCV-infected individuals in the
United States, with approximately equal numbers infected with genotypes la
and lb. 10% of the US infected population carry genotype 2, and 6% are
infected with genotype 3. Approximately 10% are infected with mixed
genotypes, and the genotype cannot be determined in the remainder (Lau et al.,
1996). As in the USA, genotype 1 (specifically lb) is predominant in Europe.
Genotypes 2 and 3 are typically found in 15% to 30% of infected Europeans.
Genotype 3 is very common in Scandinavia and Scotland, where 40% ofHCV
infections are genotype 3. Genotype 3 is also prevalent in the Far East
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(especially in Thailand), Pakistan, parts of India and in Australia. Genotype 4 is
found almost exclusively in the Middle East. Genotype 5 is the most prevalent
infection in South Africa, and genotype 6 is mainly found in Hong Kong
(Figure 1.5) (McOmish et al., 1994;Mellor et al., 1995). In Scotland 50% of
infections are genotype 1 (90% la and 10%lb), 10% are type 2 and 40% are
type 3 (McOmish et al., 1993). In the United States infection is most common
in the 30 to 50 year age group. Prevalence of infection is very high among
intravenous drug abusers and haemophiliacs who received clotting factor
preparations prior to the implementation ofviral inactivation steps (Jarvis et al.,
1994).
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HCV infection is acquired by exposure to infected blood, or bodily fluids. Risk
factors for HCV infection are transfusion of blood or blood products,
transplantation of solid organs from an infected donor, injecting drug abuse, use of
unsterile medical equipment, occupational exposure to blood, and birth to an
infected mother or sex with an infected partner.
Following the introduction ofHCV screening the incidence of infection following
transfusion or blood product is very low. In the US prescreening the rate of
infection was 1 per 200 units of blood now following screening and nucleic acid
detection the rate is less than 1 per 1 000 000 units (Centers for Disease Control
report).
Prior to virus inactivation steps (heat treatment, pasteurization and solvent -
detergent treatment) by blood product manufacturers many people receiving blood
products were exposed to HCV infection. Anti-RhD inoculations following birth of
a Rhesus D positive child to a Rhesus D negative mother caused many women to
become infected. Many haemophiliacs, thalassemics, and people with
hypogammaglobulinaemia also became infected during the course of their
treatment with blood products. Reinfection was observed in haemophiliacs, with
different genotypes of the virus found in the same individual. A Dutch study
(Vrielink et al., 1995) suggested that 81% of recipients of PCR positive blood
components became HCV infected.
The major cause of new infections in the developed world is injecting drug abuse
and use of unsterilised syringes is the major cause in the developing world.
The prevalence of HCV in different age groups shows three different tends
associating with different geographic regions suggests different transmission
profiles (Walsey et ah, 2000). The first pattern is observed in the United States
where infection in those younger than 20 is low, there is an increased amount in the
middle age range and low rate in the elderly. This indicates a HCV infections
occurred in the recent past, for example drug abuse in the 1960-1980s. There is a
predominance of genotype 3 infection in these more recent infections compared to
the genotype la in the older population. In France the trend is genotype la and 3a
infection is associated with injecting drug abuse and genotype lb nosocomial
infection (Elghouzzi et al., 2000). Another profile which is observed in Italy and
Japan where the prevalence is low in the young and younger adults but high in the
elderly, this suggests most infections occurred 30-50 years ago (Guadagnino et al.,
1997). This appears to correlate well with immunisation programmes around the
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time of the second world war. The third profile which is evident in Egypt is
prevalence steadily increasing with age indicating high rate of past and recent
infection. This appears to correlate with a large reservoir of infected people, who
were infected during the schistosomisis programme, transmitting the infection by
current unsterile medical practices.
The Infectivity in needle stick exposure is about 1.8% and there is no
recommended prophylactic treatment (Memon et al, 2002, Wasley A et al., 2000).
Treatment with anti-virals is not recommended and the American Advisory
Committee on Immunisation Practices do not advise the use of anti-HCV serum
globulin in infection prophylaxis following accidental exposure. Transmissions via
blood splashes to the eye have been reported (Sartori et al, 1993), but these
represent a few isolated occurrences.
Cases of sexual and vertical transmission have been reported, but they are thought
to represent only a small fraction of infections (Capelli et al, 1997). There is no
evidence that the virus can be spread by contact with the saliva or breast milk from
an infected individual, and transmission by insects or other animal vectors is
thought unlikely.
Infected individuals, once traced, are offered counselling and given advice on
prevention of spread of the disease to household contacts and others. Infected
people are requested to refrain from donations ofblood, tissues, organs and semen.
They are advised not to share toothbrushes and razors with others. There are no
contrary guidelines with respect to pregnancy, breast-feeding and sexual contact
within a current monogamous relationship, although the possibility of sexual and
vertical transmission should be explained.
1.7.2 Symptoms and Markers of Infection
Hepatitis C has a mean incubation period of 7 weeks with a range ofbetween 3 and
20 weeks. However, during this time markers of infection can be detected. HCV
RNA can be detected within 3 weeks of infection (Farci et al., 1991; Thimmeetal.,
2001). Anti-HCV antibody can be detected, with 3rd generation assays, within
approximately 12 weeks following infection. The liver enzymes alanine and
aspartate transferase become elevated with peak increases 10 fold higher than
baseline (Thimme et al., 2001; Alter et al, 2000) (Figure 1.6).
In about 20-33% of individuals, symptoms or jaundice appear during acute
infection, these symptoms generally only last for between 2 and 12 weeks. Patients
who develop chronic infection are less likely to have symptoms and jaundice than
those with acute resolving infection (Alter et al, 2000).
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In 5-45% of cases, acute, self-limiting infection results, the HCV RNA becomes
undetectable and the ALT levels gradually return to normal (Takaki et al. 2000). At
least 55% develop chronic HCV infection, where the symptoms ofacute infection
resolve, but the HCV RNA remains detectable, and in most cases, the ALT remains
elevated. Although, the factors which determine chronic infection are not yet
clearly defined, they may be due to the virus heterogeneity, viral proteins inhibiting
immune response pathways, weak immune responses, activation of the CD4 T
helper 2 pathway, rather than the T-helper 1 pathway, HLA haplotype, viral
kinetics over whelming the host responses, compartmentalisation in the liver and
cytokine profile ofT helper response. Viral genotype has been shown not to affect
the progression of disease although the genotype many influence the outcome of
interferon therapy (Bukh et al., 1992; Liang et al., 2000). Of chronically
individuals in this "healthy carrier" state, approximately 33% have normal ALT
levels while others have normal levels with intermittently raised episodes (Conry-
Cantilena et al., 1996). Liver biopsies in patients with normal ALT levels show
histological changes in virtually all patients, demonstrating that ALT level does not
correlate well with histological finding. Long-term follow up shows that most
patients with progressive liver disease who develop cirrhosis have prominent
intermittent ALT elevations. Approximately 20% of chronic carriers develop
symptoms and signs of liver disease. Patients with higher ALT are more likely to
have symptoms. The frequent symptoms experienced include: fatigue, headache,
nausea, poor appetite, myalgia, arthralgia, feverishness, weakness and weight loss.
These symptoms are rarely incapacitating, but decrease quality of life. Chronic
HCV infection can lead to cirrhosis and end-stage liver disease. This can develop
rapidly or slowly within 2-3 decades.
The levels of viral RNA in the liver do not correlate with the histological findings
of damage to the liver and, therefore, there must be several host factors that
influence progression to cirrhosis. These factors are a combination of intrinsic and
extrinsic factors. Of the intrinsic factors, the gender (Kenny-Walsh, 1999),
immunocompetance and age at time of infection (Sasaki et al., 1997) appear to be
the most important in determining the spread of progression to cirrhosis. The
individual's HLA type, underlying disease (such as diabetes, haemophilia and
haematochromatosis) are intrinsic factors that may also affect progression to
cirrhosis. The dominant extrinsic factor is use of alcohol, but other, unproven,
factors include smoking, environment and geographic location
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1.7.3 Associated Disease
Other extrahepatic conditions have been associated with infection including;
Essential mixed cryoglobulinemia, Lymphoma, Glomerulonephritis, Porphyria
cutanea tarda, Diabetes mellitus, Corneal ulceration, Uveitis, Autoimmune
phenomena, Sialadenitis, Peripheral neuropathy (Gumber et al. 1994, Pawlotsky
JM et al.1995, Koff et al. 1995).
Hepatitis C vims-related cryoglobulinemia is the most common extrahepatic
manifestation. Testing ofpatients with chronic hepatitis C shows that up to half
have low levels of cryoglobulins. Blood tests show the presence of globulins
that precipitate in the cold that include rheumatoid factor, complement, and
complexes of HCV RNA and anti-HCV. (Ikeda et al., 1991) Symptoms of
cryoglobulinemia including fatigue, skin rash, purpura, arthralgias, renal
disease and neuropathy are only present in 1 % of those infected. Skin biopsies
show leukocytoclastic vasculitis. This disease can lead to progressive renal
disease and severe vasculitic complications.
The disease responds to interferon therapy but relapse is common at the end of
treatment (Misiani et al., 1994).
Hepatitis C has also been linked to B-Cell non Hodgkin lymphoma in several
case series and cohort studies (Hausfater et al. 2001). The majority of patients
with HCV related lymphoma have a history of cryoglobulinemia and it is
unclear if this is a malignancy of a consequence of cryoglobulinemia and
chronic B cell stimulation.
Glomerulonephritis can occur with immune complexes deposition in the
kidneys, this condition also benefits from antiviral treatment of the underlying
hepatitis C.
It is unclear if other conditions; sero-negative arthritis, keratoconjunctivitis
sicca (Haddad et al., 1992), lichen planus (Tanei et al., 1995), neurological
disorders (Heckmann et al. 1999) and porphyria cutanea tarda (Bonkovsky et al.
1998) are related to hepatitis infection or are consequences ofunderlying liver
disease or immune stimulation from the chronic infection.
Porphyria cutanea tarda occurs in many liver diseases and is commonly found
in hepatitis C infection (Bonkovsky et al. 1998). The disease responds to
phlebotomy to deplete Iron levels.
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1.8 Immune response
The immune response to HCV is polyclonal and multi specific, both in terms of
antibody and cellular immune responses
HCV antibodies develop between 7 to 31 weeks after infection (Chien et al.,
1992). The humoral immune response is multi-specific and targets the core,
envelope NS3 and NS4 (Akatsuka et al., Simmonds et al., 1993). There is
limited evidence from chimpanzee studies and tissue culture systems that
neutralising antibody exists which is directed at the envelope proteins
particularly the hypervariable region (Farci et al., 1996).Immunisation of
chimpanzees with recombinant envelope proteins conferred protection on
challenge with low dose homologous virus (Choo et al., 1994).
Study ofHVR evolution from single source infection demonstrated amino acid
replacements limited to particular sets of amino acids which share similar
properties (McAllister et al., 1998). This is hypothesised to be linked to host
immune selection pressure. Affirming this in immuno-compromised individuals
the sequence variation in the HVR is lower than that in immuno-competent
individuals (Ray et al., 1999).
Neutralisation could prevent the virus interacting with the cell receptor, cross
link the viral proteins preventing uncoating of the virus and therefore
replication. Also antibody coated virus is more readily phagocytized by
macrophages than free virus.
A neutralising of binding assay has been described where antibody from
patients who resolved chronic HCV was tested for effect on reduction in
binding of recombinant E2 to CD81 (Peleri et al, 1998). Epitopes which
triggered responses which prevented binding in this assay were regions which
were conserved between genotypes (Ishii et al., 1998).
Antibody antigen complexes play a major role in several complications and
associated conditions of HCV infection (see section 1.7.3).
Emerging evidence indicates that cellular immunity mediated by both CD4+
and CD8+ T cells is more important in acute HCV. Individuals who recover
from HCV infection appear to have a quantitatively more vigorous CD4+
proliferative responses against one or more HCV proteins compared to those
individuals who develop chronic disease (Diepolder et al., 1997). The most
commonly recognised CD4+ T cell epitopes are core amino acids 21-40, NS3
1251-1272, NS4 1767-1786 and NS4 1909-1929 (Lamonaca et al., 1999,
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Diepolder et al., 1997). These sequences are conserved between HCV
genotypes. HLA class II molecules from most MHC restrictions can bind these
epitopes. HLA Class II allele (DRB1*01) is associated with spontaneous viral
clearance (Barret et al., 1999).
The cytokine profile of T helper cells in resolved infection appears to be
predominantly TH1, where as the TH2 profile is associated with chronic
infection (Tsai et al. 1997). Studies suggest that ribavirin may modulate the T
helper Thi/Th2 subset balance in HCV infection (Hultgren et al., 1998) (Fang et
al, 2000).
HCV-specific CTL can be readily isolated from the liver and PBMC of
chronically infected individuals, and recognize multiple epitopes. Responses
may play a critical role in recovery, and may persist for years after acute
infection. CTL epitopes have also been identified in all viral proteins. In
chimpanzees the onset of a multispecific intrahepatic CTL response correlated
with viral clearance (Cooper et al., 1999). Uninfected individuals who have
been multiply exposed to HCV exhibit peripheral blood HCV specific helper
and CTL responses in the absence ofAnti-HCV antibody or HCV RNA (Koziel
et al., 1997; Scognamiglio et al., 1999 ). These CD8+ CTL may also cause
tissue damage once chronic infection is established. Cytokines produced by
these and other cells likely play a role in liver fibrosis. Destruction of HCV
infected hepatocytes can occur by FasL/ Fas ligand binding triggering
apoptosis, or Tumour Necrosis Factor a (TNFa) or perforin release from CTLs.
One hypothesis is that the HCV-specific immune response is too weak to clear
HCV from all infected hepatocytes once a persistent infection is established.
MHC Expression ofHCV antigens is low, 1 %-l 0% of cells express antigen, 1-
5% of mononuclear cells and an even smaller number of biliary epithelial or
sinusoidal lining cells express HCV antigen (Nouri-Arai et al. 1995).
Reports indicate that individual HCV proteins may actively suppress the
immune response of the host specifically, core, E2, and NS5A (Large et al.,
1999). Numerous regulatory roles of HCV core that affect signal transduction,
expression ofviral and cellular genes, cell growth and proliferation are known.
In addition, E2 and NS5A have been shown to interfere with the antiviral
actions of interferon alpha (IFNoi). IFNceis induced by the presence of doubles
stranded DNA or RNA, as produced in the replication of viruses. IFNa acts by
binding to a cell surface receptor and prevents translation of viral mRNA
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without affecting cellular mRNA. The method of action involves induction of
RNA activated protein kinase phosphorylation of translation initiation factor
(eIF2a) for cell protein synthesis, activation of 2,5-oligonucleotide synthetase
which synthesizes adenine trinucleotide and adenine trinucleotide activates an
endonuclease which degrades viral mRNA.
An E2 sequence of IFN resistant genotypes but not interferon sensitive
genotype exhibits homology with the phosphorylation sites of IFN inducible
protein kinase and translation initiation factor.
Regions ofNS5 have been described as the interferon sensitivity-determining
region. Many groups have disproved this association of sequence and response,
however it is interesting that this protein binds and inhibits IFN inducible
protein kinase (Gale et al., 1998).
NS3/4A has been shown to specifically inhibit a key immune system molecule,
interferon regulatory factor-3 (IRF-3). IRF-3 orchestrates a range of antiviral
responses. Without this master switch, antiviral responses never begin, and
HCV can gain a foothold and persist in its host (Foy et al, 2003).
Studies suggest that circulating HCV has a half-life ofonly about 3hr indicating
relatively efficient virus replication and release, at least in patients with high
levels of viral load (Neumann et al., 1998). This dynamic process, capable of
continuously generating viral variants, allows genetic variation to be an
important strategy for the establishment and maintenance ofpersistent infection
in order to adapt quickly to humoral or cellular.
1.9 Treatment
The end point of successful treatment is defined as sustained virological
response (SVR). This is defined as the absence of detectable HCV in the serum
by RT PCR at the end point of therapy and 24 weeks after the end of treatment.
Treatment is with interferon a, or pegylated interferon a or a combination ofan
interferon and ribavirin. Interferon is a naturally occurring glycoprotein that is
secreted by cells in response to viral infections. The interferon a works by
binding to a membrane receptor and initiating a series of intracellular signalling
events that leads to up-regulation of certain genes. This leads to target cell
killing by lymphocytes and inhibition of virus replication in infected cells.
Interferon injections are given subcutaneously, usually three times per week
with dosage depending on the weight of the patient. Treatment is associated
with several side effects including flu-like symptoms such as headaches, fever,
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fatigue, loss of appetite, nausea, vomiting, and thinning of hair. In some
instances, treatment with interferon can worsen the liver disease and be fatal.
Pegylated interferon is interferon a- 2b with polyethylene glycol side chains,
which increase the half-life of the drug in the system. Ribavirin is an oral
antiviral agent that is given twice a day. It is a synthetic guanosine nucleoside
analogue. The way it works in the treatment of Hepatitis C is not completely
understood, although it has been suggested that it works as a mutagen.
Ribavirin treatment causes liver function tests to return to normal in some
patients. Studies suggest that ribavirin may modulate the T helper Th,/Th2
subset balance in HCV infection rather than acting directly on the virus
(Hultgren et al., 1998) (Fang et al, 2000). Combination treatment is associated
with more side effects, such as severe anaemia, and depression. The
combination of interferon a-2b and ribavirin gives SVR of 31-35% within 24
weeks of treatment and 38-43% after 48 weeks (McHutchison and Poynard,
1999). Use ofpegylated interferon with ribavirin can increase the response rate
to 65% (Manns et al., 2001). As with previous studies with interferon a
(Jenkins et al., 1996) infection with genotype 1 resulted in lower rates of SVR
(42%) than those with genotype 2 and 3 (82%) (Manns et al., 2001).
It is unclear how to treat patients who do not respond to therapy after 48 weeks
or less. However, it was demonstrated that up to 40% of non-responders
developed evidence of a histological response on biopsy despite persistence of
HCV RNA (Shiffman et al., 1999). Indicating a case for interferon or interferon
plus ribavirin maintenance therapy.
1.9.1 New therapies
Several new therapies are being investigated for treatment of HCV. Research
has focussed on compounds, which specifically target HCV. The HCV encoded
serine protease, the HCV encoded helicase, HCV encoded RNA dependent
RNA polymerase and the HCV RNA internal ribosome entry site have all been
considered for potential therapy target sites.
Several groups have antisense oligonucleotide therapies in development with
one compound ISIS 14803 (ISIS Pharmaceuticals, Carlsbad, CA., USA,)
currently in human trials. In antisense therapies, synthetic stabilized DNA
sequences bind highly specifically with target complimentary RNA or DNA
sequences. The formation of the hybrid induces host ribonuclease RNAse H to
degrade the heteroduplex, resulting in down regulation of gene expression. The
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investigational agent ISIS 14803 targets HCV RNA at the core protein initiation
codon. The antisense nucleotides can tolerate base pair mismatches, and
therefore are not expected to be affected by sequence variation between
different genotypes.
Similarly there is research in ribozyme therapy. The mode ofaction is similar to
oligonucleotide therapy but instead ofhost enzyme degradation ofduplex, with
the ribozymes therapy, a small sequence of the ribozyme designated the
catalytic core causes the RNA cleavage. Several groups have reported in-vitro
inhibition of HCV gene expression using ribozyme against the 5' non-coding
region. Ribozyme Pharmaceuticals (Boulder, CO., USA) have a compound,
Hepazyme in human trials following encouraging results in animal
experiments.
Another therapy which is in clinical trials is VX-497 a reversible non¬
competitive inhibitor of the enzyme inosine 5'-monophosphate dehydrogenase
which catalyses a step in the synthesis of guanine nucleotides necessary for
nucleic acids.
1.10 Detection
Prior to the isolation of the HCV genome non-A non-B, post transfusion
hepatitis could only be diagnosed by testing the levels of the liver enzymes
alanine and aspartate amino transferase in the serum. Now HCV infection can
be detected by identifying one or more markers of infection. ELISA can screen
blood for the presence of antibody to HCV and even very small amounts of
viral RNA can be detected in blood or tissues using molecular biology.
1.10.1 Initial Serology
Three generations of EIA antibody testing have been developed since 1989.
The EIA antibody is the main screening test for hepatitis C. The first-generation
EIA antibody, which incorporated the c 100-3 epitope from the non-structural
NS4 region, was used until 1992, at which time it was replaced by a second-
generation EIA (EIA-2). EIA-2 contains hepatitis C antigens from the viral core
and from areas of the non-structural NS3 and NS4 regions (Barrera et al.,
1995), the third-generation EIA that contains reconfigured core and NS3
antigens, and incorporated antigen from the NS5 region (Figure 1.7, Figure 1.8,
Figure 1.9 ). EIA-3, with a sensitivity of 97%, offers slightly improved
sensitivity over the 95% sensitivity seen with EIA-2 (Barrera et al., 1995).
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There is no specific antibody associated with active infection; the presence of
anti-HCV antibodies can be evidence of either a past, resolved infection or
current infection. Haemodialysis or immunocompromised patients may have
anti-HCV antibody titres below the threshold for detection by ELISA, resulting
in false-negative serology (Thio et al., 2000)
Detection of antibodies to HCV utilizes indirect ELISA technology. Yeast or
bacterially expressed recombinant HCV proteins or synthetic peptides are
coated onto the solid phase of an ELISA plate, polystyrene bead or
nitrocellulose strip. Anti-HCV antibodies in the sample to be tested bind to the
captured antigen. The antibodies are visualized by adding anti-human
immunoglobulin that is tagged to a marker. These markers are either
radioactive compounds, or enzymes that catalyse chemiluminescent or colour
change reactions in added reagents. The results can be determined by
measuring radioactivity, visualised by colour change, measured
spectroscopically from the colour absorption of the reaction or the energy
produced by the chemiluminescence
1.10.2 Confirmatory Serology
Following a positive serology result a confirmation test is carried out. In high-
risk populations the specificity of HCV screening is very high, however in
lower risk populations, for example blood donor populations, the specificity is
only about 60%. To resolve false positive results a confirmational test is carried
out. The most common assay used is the recombinant Immunoblot (RIBA).
This assay consists ofnitrocellulose strips coated with separate bands ofeach of
the HCV antigens, core, NS3, NS4 and NS5 (Figure 1.9). The positive
screening result is confirmed only if a colour change is detected in two or more
of these bands
In high-risk patients the screening result is more often confirmed by PCR. This
way the HCV genotype or viral titre can also be determined. The use ofnucleic
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1.10.3 Determination of clearance/ chronic carriage
The demonstration ofhepatitis C viral particles in blood confirms the diagnosis
ofhepatitis C infection. Methods used to detect hepatitis C viral RNA are target
amplification and RNA amplification
RNA amplification assays such as the polymerase chain reaction (PCR) rely on
sequence-specific primers and a heat-stable DNA polymerase to generate a
large number of copies of a portion of the viral genome. Signal amplification,
as used in bDNA assays, uses a series ofhybridisation reactions between probes
specific for several regions of the target molecule and subsequent hybridisation
to a DNA amplifier (Gretch et al., 1995).
The specificity of the current RNA detection test is 98-99%. The lower limit of
the assay cut-off is 50KJ/ ml. The IU is defined against the WHO HCV RNA
standard.
1.10.4 Genotyping
Linear antigenic determinates were identified in core and NS4 regions which
were known to differ among the HCV genotypes (Tsukiyama Kohara et al.,
1993), (Simmonds et al., 1993b). Peptide ELISAs were constructed which
allowed identification of the type-specific response to the genotype of infection.
Serotype 1 and 2 were detected with core (Mondelli et al., 1994) or NS4
antigens (Tsukiyama Kohara et al., 1993), (Tanaka et al., 1994). Use of a
solution of competing peptides allowed the determination of serotype 1, 2 or 3
(Simmonds et al., 1993b) or serotypes 1-6 with NS4 branched peptides
(Bhattacherjee et al., 1995). Murex Diagnostics Ltd. marketed the ELISA
constructed with genotype 1 -6 branched peptides. Chiron Diagnostics marketed
a confirmation RIBA incorporating genotypes 1, 2 and 3 NS4 and 1 and 2 core
antigens (Digit et al., 1995).
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1.10.5 Viral Load Testing
The World Health Organisation has established an international standard for
universal standardization of HCV RNA quantification units (Sultana et al.,
1999). An IU for HCV RNA has been arbitrarily defined using this standard, it
represents amount of RNA in a sample rather than copies per ml. All
quantitative assay now report in these units.
The HCV RNA level can be quantified by means of target amplification
techniques; polymerase chain reaction or transcription-mediated amplication, or
signal amplification ("branched DNA" assay).
1.10.6 HCV core antigen
Total core antigen can be detected and quantified by means of an EIA assay,
Ortho-Clinical Diagnostics). It has been shown that HCV core antigen titers (in
pg/ml) correlate with HCV RNA levels (Bouvier-Alias et al. 2002). It can be
used as a surrogate marker of HCV replication. It has been estimated that 1 pg
of total core protein antigen per ml is equivalent to approximately 8000 IU. It is
detected 1-2 days later during the acute infection period than HCV RNA by
current assays and the limit of detection is 20000 IU/ml which limits its use in
the clinical setting.
1.11 Aims of the project
1.11.1 Investigation of HCV genotype-specific antibodies
Extensive genomic sequence variation (30-33% at nucleotide level) exists
between the different genotypes ofHCV. The extent of variation differs among
genomic regions. Structural and functional constraints are thought to influence
the extent of variation in certain areas. The first aim of this project was to
investigate whether the immunogenic regions and epitopes are influenced by
genetic variation and to investigate the implications this has for anti-HCV
antibody screening.
Commercial screening assays are based on genotype 1 sequence, as this is the
most prevalent genotype in the U.S.A. and Europe. The other genotypes of
HCV are prevalent in other areas of the world. Areas of the developing world
have extremely high, and often increasing, prevalence ofHCV. It is important
to prevent further transmission; therefore, anti-HCV detection in blood
donations must be sensitive and accurate.
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Reliable rapid screening for HCV antibodies in donated blood ultimately
requires a single ELISA to detect infection with a variety of genotypes. The
antigen used in such an assay must therefore have epitopes that react with all
genotypes. Ideally, this would detect antibodies in all infected individuals
regardless of the infecting genotype.
Through experiments on the reactivity of sera from genotype 1 and non
genotype 1 infections, using genotype 1 and non type 1 antigens, I aimed to
determine the extent of genotype-specific reactivity and cross reactivity. The
overall aim is to ascertain which combination of antigens best detects infection
with all genotypes.
1.11.2 Investigation of level of detection of heterologous HCV genotype
infection
I aim to measure reactivity, by comparing to a standard, to assess ifthe detected
reactivity in heterologous genotype infection is adversely affected by the type-
specific component. I also aim to test blood donations from areas ofnon type 1
prevalence to investigate the serological detection rate compared to the
molecular biological detection rate of infectious sera.
1.11.3 To investigate if the use of heterologous antigens can detect
infections undetectable by current serological methods, but
detected by molecular biology
I aim to use single antigens from heterologous genotypes and a heterologous
genotype screening assay to screen samples from risk groups in areas where
genotypes other than 1 are prevalent to try to detect additional HCV infections.
I also aim to investigate samples from blood donors and patients whose HCV
infections have been discovered by molecular biological techniques and is
repeatedly undetectable by third generation assays.
1.11.4 To investigate if use of heterologous HCV genotype antigens can
resolve confirmational assay indeterminate samples
In areas where HCV prevalence is low, definitive evidence of serological
reactivity to HCV depends on reactivity to at least two independent antigens as
a small proportion of individuals (approximately 0.5%) may show non-specific
serological reactivity to HCV antigens. A Chiron RIBA immunoblot assay is
often used as such a confirmatory test. Samples showing non-specific reactivity
usually react weakly with only one antigen and this is classed as an
indeterminate. However, a small proportion of indeterminate samples may be
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found in individuals infected with HCV but who show a highly restricted
serological response to infection. One reason for non-reaction to antigens in the
confirmation test is antigenic variation, particularly amongst the non-structural
proteins, NS3, NS4 and NS5. It is therefore possible that inclusion of antigens
from other genotypes may help in the identification of the anti-HCV positive
samples. An indeterminate sample often will be sent for PCR testing for
confirmation. I aim to investigate if a heterologous antigen assay could confirm
these infections.
1.11.5 Investigation to determine if heterologous HCV antigen assays
can increase sensitivity of detection in the "window phase"
The window phase is the time between infection and detection of infection.
This is the most critical time for blood donation centres as infected donations
may pass undetected. At this time, PCR positivity and elevated alanine
transferase levels are the only indications of infection. I aimed to test
prospectively followed patients, acutely infected with non-genotype 1 variants
ofHCV. This would investigate whether serological-testing with antigens from




2 Materials and Methods
2.1 Polymerase chain reaction
Polymerase chain reaction (PCR) was used for amplifying large quantities of
deoxyribonucleic acid (DNA) from small concentrations ofthe starting product.
This process was extremely sensitive and was capable of isolating the required
sequence by copying it several thousand fold in a short time. The reagents
required for PCR were: a DNA template or a complementary DNA (cDNA)
template (constructed from a ribonucleic acid (RNA) sequence by a reverse
transcriptase reaction), deoxynucleotide triphosphate (dNTPs), two
oligonucleotide primers one sense and the other antisense, reaction buffer
containing magnesium and a thermostable DNA polymerase. The reactions
took place in a thermocycler that controlled the temperature and length of time
at any given temperature.
Each PCR reaction consisted of 20-30 cycles and each cycle consisted of three
stages: denaturing, annealing and extension. In the first stage the template was
denatured by heating to around 94 °C for 20 seconds which destabilised the
base pairing interactions that held the nucleic acid strands together. The second
stage cooled the temperature to between 40-60 °C, depending on the nature of
the primer, for 21 seconds. This allowed the primers to anneal to the single
strands. The third stage extension increased the temperature to 72 °C, which
allowed the thermostable DNA polymerase enzyme to utilise the added dNTPs
to synthesise new double stranded material. This was followed by the
denaturing step of the second cycle.
Nested or secondary PCR reactions were carried out to further select the desired
sequence and to increase the amount ofproduct. Primers were designed which
corresponded with sequence downstream from the site of the primary primer
sites and the PCR was performed under the same conditions, but a smaller
volume of reactants was used and a smaller sized amplicon produced.
Amplification was logarithmic, with each cycle producing double the start
product amount, but was limited in the final stages by the concentration of
reactants.
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The DNA polymerase enzymes used were heat stable as they were obtained
from organisms which could tolerate high temperatures, for example, Thermus
aquaticus from which the Taq enzyme was isolated and Thermus flavus the
source of the Tfl enzyme.
2.1.1 Detection of viral RNA by using PCR amplification
2.1.1.1 Preparation of serum sample
Blood specimens were obtained by venepuncture and collected in sample tubes.
These were transported to the laboratory, where they were centrifuged at5 000 g
to pellet erythrocytes. The upper serum layer was gently removed by Pastette
(Alpha, Eastleigh, UK) and collected in 1.5 ml Eppendorf tubes (Anachem,
Luton, UK), which were immediately sent for analysis or stored at -20 °C
refrigeration.
Plasma samples were obtained from blood donations, where the blood drawn
was treated with buffered sodium citrate anticoagulant and the red cells were
removed by fractionation.
2.1.1.2 Extraction of nucleic acid from serum using polyadenylic acid
as a carrier.
An aliquot of 100 pi serum was mixed with 400 pi extraction mix (Appendix
1), which had been pre-incubated in a water bath at 37 °C which inactivated
RNases, then incubated at 37 °C in a water bath for two hours. The extraction
mix contained: sodium dodecyl sulphate (SDS), which lysed cells present;
proteinase K, which digested proteins in the sample for efficient phenol
chloroform removal; and polyadenylic acid (poly A), a large carrier molecule
that helps precipitate the nucleic acids. The mixture was agitated with 450 pi
phenol (Rathbum Chemicals, Walkerbum, UK) for 15 minutes then centrifuged
at 12 000 g for 15 minutes. The resulting supernatant was removed to a 1.5 ml
Eppendorf tube containing 450 pi of 50:1 chloroforrmisoamylalcohol mixture
(BDE1, Lutterworth, UK), which was, again, agitated for 15 minutes, then
centrifuged at 12 000 g for 15 minutes. The final supernatant was removed to
another 1.5 ml Eppendorf tube where the nucleic acids were precipitated by the
addition of 40 pi 3M sodium acetate pH5.2 (BDH) and 600 pi 100% ethanol
(BDH) and refrigerated at -20 °C for a minimum of 6 hours. The precipitated
nucleic acids were collected as pellets in the bottom of the tube spinning at
100 000 g in a centrifuge, previously cooled to 0 °C, for 30 minutes. The
56
supernatant was poured off and the pellets were washed with 500 pi chilled
80% ethanol and centrifuged for 5 minutes. The excess ethanol was gently
removed with a pipette and the pellet was dried on a hot block at 37 °C for 5
minutes to evaporate the residual ethanol. The pellet was dissolved in 20 pi of
diethyl pyrocarbonate (DEPC) (Sigma, Poole, Dorset) treated water by slowly
pipetting the liquid up and down. The dissolved nucleic acid was either used
immediately for a reverse transcription reaction or stored at -40 °C
refrigeration.
2.1.1.3 Reverse transcription reaction
Before PCR can be used, single stranded nucleic acid must be converted to
double stranded. The enzyme RNasin was used to inhibit any ribonucleases
from degrading the RNA and HCV RNA was converted to cDNA by the
enzyme reverse transcriptase. For this reaction, an aliquot of 5 pi of nucleic
acid, dissolved in DEPC treated water, was incubated on a hot block at 42 °C
for 30 minutes with: 10 units reverse transcriptase from avian myeloblast virus
(AMV RT), 10 units RNasin (both Promega, Southampton, UK), IX RT buffer
[50 mM Tris (hydroxymethyl) methylamine hydrochloride (Tris-HCl) pH8
(BDH), 5 mM magnesium chloride (MgCl2) (BDE1), 5 mM dithriothreitol
(DDT) (BDH), 50 mM potassium chloride (KC1) (BDH) and 0.5 mg/ ml bovine
serum albumin (BSA)] (Promega), ImM external reverse primer (Figure 2.1),
20% dimethylsulphoxide (DMSO) (Sigma), 600 pM each of
deoxyribonucleotide triphosphates dNTPs (deoxyriboadenosine triphosphate
dATP, deoxyribothymine triphosphate dTTP, deoxyribocytidine triphosphate
dCTP, deoxyriboguanine triphosphate dGTP), and 4.5 pi DEPC treated water.
The cDNA was either used immediately for PCR, or placed in -40 °C storage.
2.1.1.4 Polymerase chain reaction primary reaction
The cDNA from the reverse transcription stage was amplified by 20-30 cycles
in a PCR machine, depending on the region to be amplified and the primers
used. A volume of 5 pi of the cDNA was dispensed into a PCR tube containing
a final concentration of: 1 unitTaq enzyme (Promega), lXTaq buffer (1.5 mM
MgCl2, 10 mM KC1, 2 mM Tris-HCl pH8, 0.01 mM ethylene diamine tetra-
acetic acid (EDTA), 0.1 mM DDT, 5% glycerol, 0.05% Nonidet P-40 and
0.05% Tween 20)(Promega), 33 pM each dNTPs, 1 pM external sense primer
(Table 2.1), 1 pM external antisense primer (Figure 2.1) and DEPC treated
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water to 50 pi. Gentle pipetting up and down mixed the contents, before 2 drops
of liquid paraffin (William Ransom, Hitchin, UK) was added which prevented
the solution from evaporating. The PCR tube was placed on a thermocycler
(Genie, Techne Anachem, Luton, UK) and the programme set. For the 5' non
coding region (NCR), this was: denaturing at 94 °C for 18 seconds, annealing at
50 °C for 21 seconds and extension at 72 °C for 90 seconds for 25 cycles,
followed by a final extension at 72 °C for 6 minutes to remove any single
stranded product. Different primers and PCR conditions were used for
amplification of each region (Figure 2.1, Table 2.1).
2.1.1.5 Nested or secondary PCR reaction
To increase the specificity of the amplification and increase the amount of
DNA produced, a secondary, or nested, PCR was carried out. This consisted of
the same conditions as the above primary reaction, but the internal sense and
anti sense primers were used, instead of the external ones and the reaction was
carried out in a 20 pi volume.
2.1.1.6 Agarose gel electrophoresis and ultra-violet radiation detection
of nucleic acids
20 pi of secondary PCR product was subjected to electrophoresis on a 2%
agarose gel (Flowgen, Litchfield, UK), containing 0.5 mg/ ml ethidium bromide
(Sigma). The gel was placed in a gel tank in IX Tris Borate EDTA (TBE)
solution (Appendix 1) and the voltage differential set at 150 Volts for 10
minutes. The amplified nucleic acid was visualised by fluorescence under ultra¬
violet light. Resulting bands in the gel were photographed by a Polaroid camera
(HayWest X-ray, Edinburgh, UK).
2.1.1.7 Controls
The success of the PCR could be determined by the results of the control
sample that was always included with any batch of samples. The control sample
was of approximate RNA titre 1X104 copies/ ml and was titrated in negative
sera in dilutions, ranging from 1:10 to 1:1 000 000 and 100 pi of these
extracted. A batch of PCR reactions was considered successful when 1:10-
1:10 000 dilutions were positive. A negative control sample was also used in
every batch to detect false positives arising from contamination. A size marker




209 NCR GGT GCA CGG TCT ACG AGA CCT
939 NCR GTG TGA GGA ACT ACT GTC TT
211 NCR CAC TCT CGA GCA CCC TAT CAG GCA GT
940 NCR TTC ACG CAG AAA GCG TCT AG
954 CORE ACT GCC TGA TAG GGT GCT TGC GAG
410 CORE GAG CGG AAT GTA CCC CAT GAG GTC GGC
236 CORE GGT AGA CCG GAT CCbC ATG AGC ACG AAT CCT AAA
597 CORE GAA AGA AGC TTA GAC GAG CGG AAT GTA CCC
751 NS3 TTY CGG GCN GCY GTG TGC ACC
753 NS3 GCG TCA TAG CAC TCA CAG AGG AC
594 NS3 ACC RCT GCA GAY CCY AAC ATN GAG GAR GT
593 NS3 CAC AAG CTT ARC AGT AGT CKA TSA CNG ART C
750 NS3 TGG TYA CNN GNN AYG CYG ATG TCA TYC C
007 NS3 ACC TCG AGT ATC CCA CTG ATG AAG TTC CAC AT
991 NS5 TGG CNA GCT CNT CNG CNA GCC A
993 NS5 GGC TCC CCC TCA AGG GRG GCA TRG A
3155 NS5 GGA TCC AAY ATN ACY CGY GTR GAG TCW SA
3156 NS5 AAG CTT GTG GTG GYA AGG CAC AYC C
PRIMERS USED FOR AMPLIFICATION OF SEQUENCE FROM pTAg
VECTOR
8819 pTag GCT ATG ACC ATG ATT ACG CCA A
9130 pTag ACA CGT GTG GTC TAG AGC
Figure 2.1 Primers used for amplification of NCR, CORE, and NS3 AND NS5
regions.
a IUPAC ambiguity codes (Y:C/T; R:A/G; N:G/C/A/T; K:G/T; S:C/G; W:A/T
'Cleavage sites for restriction enzymes underlined: CTGCAG PstI, AAGCTT Hind III, GGATCC BamHI
939, 940 (Okamoto et al., 1990) 209,211 (Garson et al., 1990)
410, 954 (Mellor et al., 1995)
236, 597 Murex Biotech.
751, 753, 593, 750, 007, 991, 993, 3155, 3156 (Molecular Virology lab)
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2.1.1.8 Nucleic acid extraction using glycogen as carrier
The Access kit (Promega) method of extraction differed from the direct
extraction above by the use of glycogen as the carrier molecule to extract RNA.
The AMV-RT reaction and the primary PCR occur in the same reaction vessel
and the enzyme Tfl was used in preference to Taq. The Access protocol
required 250 pi of plasma or serum, mixed with 250 pi of Access Extraction
Mix incubated for 1.5 hours at 37 °C in a water bath. Phenol and
chloroform:isoamylalcohol (50:1) extractions were performed as above. The
supernatant of the chloroform:isoamylalcohol extraction was dispensed into a
1.5 ml Eppendorf tube with 1 pi ofglycogen, 40 pi 3 M NaC02CEl3 pH 5.2 and
800 pi of 100% ethanol. This was refrigerated at -20 °C for a minimum of 6
hours, before nucleic acids were pelleted by 12000 g for 15 minutes in a
centrifuge, and then washed with 80% ethanol to remove any soluble
contamination. The collected nucleic acids were suspended in 20 pi DEPC
water. The combined reverse transcription and primary PCR reaction utilised
5 pi RNA mixed with final concentration of 5 units AMV-RT, 5 units Tfl DNA
polymerase, 1 mM magnesium sulphate (MgS04), 1 pM sense primer (Figure
2.1), 1 pM antisense primer (Figure 2.1), 0.2 mM dNTP, 1 X AMV-RT/Tfl
reaction buffer and 23 pi DEPC water. The PCR tube contents were overlaid
with liquid paraffin and placed on a thermocycler set for 1 cycle at 48 °C for 45
minutes, the conditions for the RT reaction; 1 cycle at 94 °C for 2 minutes, to
inactivate the AMV-RT enzyme; followed by 40 cycles of denaturing at 94 °C
for 30 seconds; annealing at 60 °C for 60 seconds and extension at 68 °C for
120 seconds. Secondary PCR was carried out using the same protocol as section
2.1.1.5 above.
2.1.2 Restriction fragment length polymorphism
Restriction fragment length polymorphism (RFLP) was used to distinguish
between genotypes and subtypes ofHCV (McOmish et al., 1993), (McOmish et
al., 1994) and (Davidson et al., 1995). RFLP is based upon the phenomenon
whereby two almost identical DNA or cDNA sequences are distinguished from
each other by the difference in size and/or number of product fragments
produced when cut by restriction endonucleases.
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These variations, caused by small differences in nucleotide sequence in the
palindromic sites the restriction enzymes, recognise lead to a distinction
between excisions in the sequences, visualised by distinctly different product
band patterns on metaphor agarose gel electrophoresis.
2.1.2.1 RFLP of 5'NCR - Genotypes
Genotypes ofHCV were determined as described by Mc Ornish and colleagues
(McOmish et al., 1994). A 5'NCR PCR fragment amplified with primers 939
and 209, followed by a secondary PCR reaction, performed using the same
reagent volumes as a primary reaction using 940 and 211, was pipetted into two
aliquots of 20 pi. One aliquot was digested with 1 unit Rsa I and 1 unit Hae III
in 3 pi buffer C (10 mM Tris-HCl, 10 mM MgCl2 50 mM NaCl, pH 7.9) (all
Promega). The other aliquot was digested with 1 unit Mval and 1 unit Hinfl in
3 pi buffer B (6 mM Tris-HCL, 6 mM MgCl2, 50 mM NaCl, pH 7.5) (also all
Promega). Both were left at 37 °C for between 6 and 24 hours. The product was
visualised by electrophoresis on a 4% metaphor agarose (Flowgen) gel
containing 0.05 mg/ ml ethidium bromide for 60 minutes at 150 Volts in IX
TBE buffer (Appendix 1). Different patterns were representative of different
genotypes (Figure 2.2).
2.1.2.2 RFLP of 5'NCR - Subtypes
Subtype la could be distinguished from subtype lb by restriction digest with
the BstUl enzyme. Subtypes a and b of genotypes 2 and 3 could be
differentiated with ScrFl enzyme digest.
Primary and secondary PCR reactions with primers 209,939 and 211,940 were
carried out as described previously. An aliquot of 20 pi PCR product was
digested with either 5 units of BstUl, 0.3 pi 1M MgCl2, 0.375 pi 0.1 DDT and
3.5 pi distilled water at 60 °C for a minimum of 4 hours, or 5 units of ScrFl in
3 pi of 10 x ScrFl buffer at 37 °C for 6 hours. The subtype could be identified
by the pattern of digested fragments (Figure 2.3) of PCR product produced
following electrophoresis on a 4% metaphor agarose (Flowgen) gel containing
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2.2 Cloning
Cloning was the technique used to manipulate PCR fragments into vectors for
sequencing, transport and recombinant protein expression. These fragments
were inserted into the plasmid cloning vectors by one of two methods: use of a
thymidine over-hang vector to complement the poly-adenine present at the end
of fresh PCR product; or restriction enzyme site incorporation into the
secondary primer sequence. The first method described was used for
sequencing and transport. The restriction sites within the secondary primers
were utilised by the research facility at Murex Biotech Ltd to excise the
required DNA sequence and insert it in the correct orientation into the protein
expression systems. The clones constructed were transformed into Escherichia
coli (E.coli) cell cultures and multiple copy plasmid DNA and recombinant
protein produced. Stock cell preparations of these clones were stored in
glycerol at -70 °C for future use and production.
2.2.1 pTAg Vector - LigATor kit use of A-T pairing for insertion into
vector
The LigATor cloning (R and D systems, Abbingdon, UK) system was used to
sub-clone PCR fragments for sequencing and for transport to Murex
Diagnostics where cloning into expression systems took place.
The pTAg vector contained thymidine base overhangs at the insertion site,
which facilitated the cloning of fresh PCR product, which contains
complementary adenine bases, into these sites. The plasmid vector contains the
LacZa gene that was used as a reporter gene. This allowed selection of white
colonies of insert containing recombinants from blue colonies ofrecombinants
that do not contain insert, when grown on 5-bromo-4-chloro-3-indolyl-/3-D
galactoside (X-gal) containing media. The plasmid also contained genes for
resistance to ampicillin, tetracycline and kanamycin that were used to select
only plasmid containing colonies. The kanamycin resistance reporter gene
facility was not utilised. Tetracycline prevented the loss of the F' plasmid
containing LacZ Ml5 in the competent cells which would cause the loss of




PCR product fresh from a secondary PCR reaction was treated by shaking with
an equal volume of 24:1 chloroform:isoamylalcohol to remove traces of
paraffin oil and nucleases. This was centrifuged and the aqueous layer removed
for use. A phenokchloroform extraction and precipitation with ethanol and
sodium acetate was carried out if the DNA concentration was too dilute.
Alternatively, the required band ofPCR product was excised from a 0.8% low
melting point Agarose (Flowgen) gel following electrophoresis for 10 minutes
at 150 Volts in 1XTBE (Appendix 1). The excised band was placed in a 1.5 ml
Eppendorf tube, diluted 1:1 in Tris-EDTA (TE) solution (Appendix 1) and the
gel dissolved at 65 °C in a water bath. This solution was extracted twice with an
equal volume ofphenol to remove the agarose before a 1:1 phenol:chloroform
extraction, followed by nucleic acid precipitation at -20 °C for 2 hours with
1/10 volume NaC02CH3 and 2 volumes 100% ethanol.
The nucleic acids were collected by a 15-minute spin at 10000 g in a centrifuge
and then diluted in 10 pi distilled water.
2.2.3 Ligation Reaction
The ligation reaction was set up in a 1.5 ml Eppendorf tube with 1 pi of
50 ng/ pi (0.03 pmol) pTAg vector, 1 pi 10 X ligase buffer (200 mM Tris-HCl
pH7.6, 50 mM MgCl2), 0.5 pi 100 mM DDT, 0.5 pi 10 mM ATP, 2 pi of fresh
PCR product (approx 0.2 pmol) and 4.5 pi of sterile water. The ligation was
catalysed by the addition of 0.5 pi T4 ligase (2-3 Weiss Units). This was gently
mixed with a pipette then incubated at 16 °C overnight.
A ligation control reaction containing 2 pi (5 ng) of a 50 base pair control insert
(instead ofPCR product) and a self ligation control reaction using 2 pi ofwater
(instead of PCR product or control insert) was also carried out.
2.2.4 Transformation Reaction
Aliquots of frozen competent cells, genotype endAl /LSY/R17(rk12~mkl2+)
supE44thi-\ recA 1 gyrA96 relA 1 lac\V' proA B lad M15::Tnl0(TcR)], were
removed from -40 °C storage and allowed to defrost slowly on ice. A 1.5 ml
Eppendorf tube for each reaction was cooled in the ice and 20 pi of cells were
transferred to each tube. After the cells were cooled, 1 pi of the ligation
reaction was added and gently mixed. The mixture was left for 30 minutes on
ice before a 40 second "heat shock", which transformed the plasmid into the
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cells, was carried out by placing the tube in a 42 °C water bath for 40 seconds.
The tubes were then placed on ice for a further 2 minutes, before 80 pi of SOC
medium (Appendix 1) was added and the tubes transferred to a rotary shaker
that was incubated at 37 °C for 1 hour.
In the test plasmid control 1 pi of test plasmid was added to the cells in the
place of ligation reaction. After the incubation, 50 pi of the transformants (20
pi of test plasmid control) were spread on Luria-Bertani agar (Appendix 1),
supplemented with 50 pg/ ml ampicillin and 15 pg/ ml tetracycline and a
coating of 100 pi isopropyl-thiogalactoside (IPTG) and 20 pi 50% X-gal and
incubated at 37 °C for 16 hours. White colonies were picked out using sterile
technique and tested by PCR for the presence of the insert, using either pTAg
primers (8819, 9130) or the initial nested PCR primers (Figure 2.1).
The PCR products were subjected to electrophoresis for 15 minutes at 150
volts, on a 2% agarose gel containing 15 pi 0.05 mg/ ml ethidium bromide in 1
X TBE (Appendix 1) solution. The colonies that contained inserts of the
required sizes were grown as mini preps.
2.2.5 Mini-Prep for Extraction of DNA
Colonies known to contain the required insert were picked with a sterile
toothpick and placed in 3 ml of LB broth (Appendix 1) in a 10 ml centrifuge
tube and incubated in the rotary shaker at 37 °C for 16 hours. The culture was
then decanted into 1.5 ml Eppendorf tubes and spun at 12 000 g for 15 seconds:
this pelleted the cells to the bottom. The supernatant was removed and the cells
resuspended in 100 pi glucose-Tris-EDTA-lysozyme solution (GTE-lysozyme)
(Appendix 1), 200 pi of freshly prepared sodium hydroxide SDS solution
(Appendix 1) and placed on ice for 5 minutes. A 150 pi volume of potassium
hydroxide-glacial acetic acid solution (Appendix 1) was then added and the
tubes were vigorously shaken. This mixture was left on ice for 5 minutes. GTE-
lysozyme broke down the cellular components. NaOH-SDS denatured the
cellular DNA: plasmid DNA is super coiled and can renature. Potassium
hydroxide-glacial acetic acid aggregated the denatured DNA, which was
pelleted when spun for 8 minutes at 12 000 g in a centrifuge. The supernatant
was removed to another 1.5 ml Eppendorf tube containing 290 pi of
isopropanol, which was left to incubate at room temperature for 15 minutes,
before being spun for 10 minutes at 12 000 g.
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After the supernatant was discarded, the pellet was washed with 500 pi 70%
ethanol before it was dried and resuspended in 40 pi Tris EDTA solution
containing RNase. This was stored at -40 °C for later use or used for
sequencing reactions.
2.3 Sequencing
Sequencing was carried out using the Sanger method. This technique utilized
2',3'-dideoxynucleotide triphospates (ddNTPs), molecules that differed from
deoxynucleotides by a hydrogen atom attached to the 3' carbon instead of an
OH group. These molecules terminated DNA chain elongation because they
could not form a phosphodiester bond with another deoxynucleotide.
Sequencing was carried out on single stranded DNA, therefore, double stranded
DNA was denatured with NaOH. For each sequence in question four Sanger
reactions were carried out. Each of the reactions contained one of the
dideoxynucleotides with the four deoxynucleotides, for example, ddATP with
dATP, dTTP, dCTP and dGTP. A Sanger sequencing reaction consisted of the
following: a strand to be sequenced (one of the single strands which was
denatured using NaOH), DNA primer, radioactively labelled dATP, a mixture
of a particular ddNTP and the four dNTP. The concentration ofddNTP was 1%
of the concentration of dNTPs. After DNA polymerase was added, the
polymerisation took place and terminated whenever a ddNTP was incorporated
into the growing strand. As the ddNTP was only 1% of the total concentration
of dNTP, a whole series of labelled strands resulted with the lengths of these
strands dependent on the location of the base relative to the 5' end. This reaction
was performed four times using a different ddNTP for each reaction. When
these reactions were complete, a polyacrylamide gel electrophoresis (PAGE)
was performed. Each reaction was loaded into one lane for four lanes. The gel
was transferred to filter paper and autoradiography performed. The DNA
sequence was deciphered by noting the order of migration of each of the bands
on the film.
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2.3.1 DNA preparation for sequencing reactions
The DNA strands obtained from a mini-prep were denatured by taking an
aliquot of 20 pi resuspended DNA, which was incubated at 37 °C, with 2 pi of
2 M NaOH/ 2 mM EDTA solution for 30 minutes. This salt solution was
removed by precipitating with 2 pi NaC02CH3 and 60 pi 100% ethanol at
-40 °C for 1 hour. The denatured DNA was collected by spinning at 12 000 g
for 10 minutes and resuspended in 6 pi distilled water.
Sequencing was carried out using the T7 sequenase version 2.0 DNA
polymerase kit from Amersham Life Science.
2.3.2 Annealing Reaction
The denatured DNA was pipetted into a 0.5 ml Eppendorf tube containing 2 pi
sequenase reaction buffer (200 mM Tris-EICL, pH7.5,100 mM MgCl2,250 mM
NaCl) and 1 pi primer (Figure 2.1). The tube was heated for 2 minutes at 65 °C
then slowly cooled to 35 °C over 15 minutes. In a microtitre plate 2 pi ofdGTP,
dATP, dTTP, dCTP termination mixes (80 pM of each dNTP, 8 pM of the
required ddNTP and 50 mM NaCl) were pipetted into wells and incubated at 37
°C. Labelling mix was diluted 1:4 in distilled water and Sequenase polymerase
was diluted 1:6 in dilution buffer (10 mM Tris-HCl, 5mM DTT, 0.5 mg/ ml
BSA) to ensure the correct concentrations were present.
The radio labelled S35 dATP (0.5 pi of 1500 Ci/mM S35 dATP per reaction) was
mixed with; 2 pL labelling mix (7.5 pM dGTP, 7.5 pM dCTP, 7.5 pM dTTP),
1 pi 0.1M DTT and 2 pi of sequenase polymerase. The labelling mix was then
added to the cooled annealing reaction, mixed, and then 3.5 pi was added to
each of the dNTPs termination mixes in the microtitre plate. This
polymerisation reaction was stopped after 2 minutes with the addition of 4 pi
stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue,
0.05% xylene cyanol). The reactions in the microtitre plate were loaded onto a
polyacrylamide gel or stored at -20 °C refrigeration. The microtitre plate was
heated at 95 °C to denature the base pairing between the strands and 5 pi of
each reaction was loaded onto a polyacrylamide gel.
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2.3.3 Denaturing Polyacrylamide Gel Electrophoresis (PAGE)
Two glass sequencing plates were cleaned with alternating solutions ofdistilled
water, acetone and methanol, to ensure that there were no impurities on the
glass which would cause bubble formation when the gel was poured. The two
plates were separated with 1 mm spacer bars and the edges of the plates were
either taped together or held together with bulldog clips. The gel solution was
prepared by dissolving 21 g urea (BDH), 0.05 g ammonium persulphate, 6 ml
RapidGel-XL acrylamide gel, 5 ml 1 OX Sanger TNE buffer (Appendix 1), to a
final volume of 50 ml in distilled water. Running hot water around the
perimeter of the flask facilitated dissolution. The solution was left for 10
minutes to cool before 20 pi N,N,N',N'-tetramethylethylediamine (TEMED)
was added to initiate polymerisation.
The denatured DNA was loaded on to the polyacrylamide gel in the order G, A,
T, C. Running buffer was loaded into the anode and cathode trays of the
electrophoresis apparatus. PAGE was carried out for the required length of time
depending on the length of the sequence. The two blue marker bands from the
dyes in the stop solution gave a reference ofhow far the products had travelled.
The two glass plates were slowly separated and the gel was then transferred to
blotting paper, covered with cling film and then dried on a gel drier for 30
minutes. The cling film was removed from the dried gel, which was then taped
into a gel cassette. Autoradiography film (Kodak Biomax MR) was inserted
into the cassette, in the dark, and left for 24 hours before the film was removed,
in the dark, and developed by a gel developer.
Approximately 200 bases were visible in each 4-lane sequence. They were read,
taking care the gel was in the correct orientation, into Genebank, which
checked that it was the required product. The sequence was entered into
Simmonic software version 2000 and sequence manipulation, translation and
phylogenetic analysis were carried out using the programme, Molecular
Evolutionary Genetic Analysis version 1.02 and version 2.0 (Mega).
2.3.4 Use of dITP sequencing for Core sequences
Sequencing as above was carried out on the core sequences with the use of
dITP instead of dGTP. In regions which are GC rich, such as the start of the
core gene, secondary structure of the DNA forms, which is not fully denatured
during electrophoresis. These fragments migrate faster causing bands that are
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compressed together, which make the sequencing gel hard to decipher. Inosine
is a base analogue of guanosine, which forms weaker secondary structures
reducing problems with compression of bands on gels.
2.4 Use of restriction enzyme sites in primers to
position DNA sequence in plasmid
Each of the internal primers used in the secondary PCR reactions contained
restriction enzyme sites. This allowed the required DNA sequences ofHCV to
be cut out of the pTAg vector once the sequence was known and inserted in the
correct orientation and frame into the expression vectors.
2.5 Expression of Recombinant Proteins
This work was carried out at Murex Biotech Ltd. by Mr S. Tucket, Ms R.
Mason and Dr B. Rodgers. Sequences for the core, NS3 and NS5 regions from
HCV genotypes 3 and 4 were subcloned into E.coli or baculovirus expression
vectors as appropriate, using the restriction enzymes in the secondary primers.
The NS3 and NS5 sequences of each genotype were ligated into E.coli vector
pTrcHis (Invitrogen BV, Netherlands) and transformed into TOP 10 cells.
Cultures were grown in 2YT medium and expression of recombinant protein
induced by the addition of IPTG to 1 mM. Cells were harvested 3 hours post
induction and lysed by treatment with lysozyme and DNase in the presence of
protease inhibitors.
The core sequence was transformed into the baculovirus expression vector
pBlueBacHis2 (Invitrogen) and recombinant virus was derived by co-
transfection into insect cells along with linear autographa califomica nuclear
polyhedrosis virus (AcNPV) DNA. Recombinant virus expressing core antigen,
as judged by western blot, was plaque purified and amplified to give high titre
virus stock. To express recombinant proteins, Sf. 9 insect cells were expanded
in serum-free medium in an LH Series 210 bioreactor to approximately 2 x 108
cells/ ml and then infected with recombinant virus at a measure of infectivity
(m.o.i.) of 2 units. After 48 hours, cells were harvested and nuclei isolated by
lysis with 1% Nonidet P-40. The nuclear located recombinant protein was
released by treatment with 0.2% sodium deoxycholate and digestion with
DNase.
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Both the E.coli and baculovirus expression vectors placed a tract of 6 histidine
residues at the amino terminus of each recombinant protein. Recombinant
proteins were purified by metal chelate chromatography on Probond nickel
affinity resin (Invitrogen).
2.6 Preparation of antigen coated ELISA plates
To optimise plate coating, purified antigens were titrated to levels giving
acceptable specificity and sensitivity and approximately equivalent amounts of
protein/ well. Binding of antigen was assessed both by enzyme immunoassay
with positive and negative sera and by probing for the histidine tag present on
each protein using horseradish peroxidase chemically modified to bind nickel
ions. All antigens were coated overnight in 50 mM Tris pH 8.5 containing
0.02% SDS. Plates were blocked by the addition of 2% degraded gelatin and
dried.
The plates were tested using serum from blood donations from the Tooting
Blood Transfusion Centre. The distribution of reactivity measured with these
samples was similar for each antigen irrespective of genotype.
2.6.1 ELISA for detection of antibody to single antigens
The recombinant proteins of core, NS3 and NS5 from Murex Diagnostics
production strain HCV-UK (of genotype lb) and the equivalent proteins ofcore
and NS3 of genotype 4a, and NS3 and NS5 of genotype 3a, were coated on to
ELISA plates. Aliquots of 20 pi from each titration were added to 180 pi of
sample diluent, mixed, then added to the ELISA well. A solution of 1:50 E.coli
blocker was added to the diluent for all assays of NS3 genotype 2a and 3a
antigens. This was necessary to prevent antibody, produced against E.coli,
reacting with any E.coli proteins remaining after antigen purification. The
plates were then incubated at 37 °C for one hour in a water bath. Following
incubation the plates were washed five times with glycerate-borate wash buffer,
before 100 pi of horseradish peroxidase labelled antibody to human IgG
conjugate was added. After 30 minutes incubation in a water bath at 37 °C, the
plates were washed five times with glycerate-borate wash buffer before the
addition of 100 pi 3,3',5,5'-tetramethylbenzidine (TMB) substrate. Following a
further 30 minutes incubation at 37°C in a water bath, 50 pi 2 M H2S04 stop
solution was added. The optical density (OD) of each plate was measured at
470 nm on a spectrophotometer. A 20 pi aliquot of anti-HCV negative plasma
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used in the dilutions was used to blank the spectrophotometer to discount
background serological reactivity. All assay plates included a high titre
genotype la control.
2.6.2 ELISA for detection of antibody directed against genotype 3a
Core, NS3, NS4 and NS5 antigens
The genotype 3 antigen plates were the nearest match to the Murex VK48 assay
as could be provided. The genotype 3 plates contained recombinant protein
from core region amino acids 1-140, NS3 region amino acids 1360-1454 and
NS5 region amino acids 2238-2321 expressed as a tripartite fusion protein.
Branched peptides from region 1 amino acids 1691-1708 and region 2 amino
acids 1710-1728 (Bhattacherjee et al., 1995) of NS4 of genotype 4 were also
coated onto the ELISA plates. The difference between the genotype 3 assay and
the VK48 assay was that linear NS4 peptides were included rather than
branched peptides.
The specificity and sensitivity of the plates was compared using samples from
the local Tooting Blood Donor Centre. A coating level of approximately 200
ng/well of tripartite protein and 25 ng/well peptide gave a comparable
sensitivity and specificity to the VK48 assay.
The test was performed as in 2.6.1 above.
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2.6.3 Quantification of antibody levels
Antibody reactivity in each of the test sera to each recombinant protein was
determined by titration and reference to a standard positive control as described
(Dhaliwal et al., 1996). This method was based upon the observation that
optical density over the range of values 0.02 to 1.0 shows a linear relationship
to the concentration of antiserum. Therefore, antibody could be expressed
relative to the reference control.
Calculation of levels of antibody, expressed here as units (u), could be
represented by the following formula:
Test antibody level = Test O.D. x Reference concentration
Reference O.D. x Test concentration
For each antigen plate a number of control samples were titrated in serial
dilutions in negative sera and 20 pi of each dilution tested in the assay. The
optical density was measured for each dilution. A graph was plotted ofantibody
level against optical density measured (Figure 2.4).
Once each antigen had been tested to ensure that plates had even coating and a
linear relationship of antibody level to optical density could be measured a
relative antibody level for each sample for each antigen could be calculated.
To measure the antibody level in a sample relative to the standard for any given
antigen, the control sample was titrated out in negative serum and duplicate
aliquots of 20 pi added to each well in the upper two rows. The concentration
of the titration depended of the sensitivity of the assay.
For each plate a graph was plotted of concentration of antibody to optical
density measured figure 2.5.
Again each sample is titrated according to the sensitivity of the assay for single
antigens titrations were 1:40 -16:40 for most samples, only those with O.D
measured above 1.0 at the 1:640 dilution would need to be titrated further.
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To measure the antibody level in a sample the OD in the linear range would be
used for the calculation. Ifmore than 1 titration gave and OD in the linear range
the all would be calculated. If the difference in relative antibody level measured
was greater than ten fold between the two dilutions then the sample would be
repeated.
The antibody level relative to the control standard could be calculated using the
titration concentration of the control, the measured OD at that concentration
and the OD and concentration of the standard in the linear range of the graph.
For example in figure 2.5 the control has anO.D of 1.1017 at 1:320 (0.003125)
and 0.701 at 1:640 (0.0015625) dilution. The sample we wish to compare
relative to the standard has an OD of 0.8 at a dilution of 1:640. Using the
reference value of OD 0.701 at 1:640, these values are substituted into the
formula above to give;
Test antibody level = Test O.D. x Reference concentration
Reference O.D. x Test concentration
Test antibody level = 0.8. x 0.0015625
0.701 x 0.0015625
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2.6.4 Plate to plate variation
It was often found that the plates varied in intensity of colour change on
different test occasions, by as much as 30%, despite the test conditions being
identical. This phenomenon, despite the use of the control standard, caused
values taken on one occasion to vary slightly on repeat testing.
Repeat testing of samples showed good correlations with the original antibody
level result. A selective bias to any one genotype group, was avoided by
ensuring each plate tested contained an equal number of samples of each
genotype. This problem is unlikely to influence the results as the number of
samples involved should balance out the anomaly.
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Plate is coated with antigen
Incubate human serum on antigen coated plate, IgG in the serum will binds to the antigen on
the plate
Addition of conjugated anti-human IgG which has which binds to IgG which is bound to
the antigen.
The conjugated enzyme indicates the presence of the bound compound by catalyses a
colour change when a substrate is added




The Murex 3rd generation ELISA used contained recombinant proteins from
core, NS3, NS4 and NS5 regions of HCV. The test procedure consisted of four
stages: incubation of sample with antigen, addition ofconjugate which binds to
any anti-HCV antibodies from the sample, colour change of substrate catalysed
by conjugated enzyme and reading of optical density.
Prior to carrying out the test procedure, all the reagents were allowed to reach
room temperature and the solutions of conjugate, conjugate diluent, substrate
and substrate diluent were mixed. In each test two volumes of the anti-HCV
positive control and three volumes of the negative control were included.
The first stage of the test consisted of 20 pi of fresh or stored serum being
mixed with 180 pi of the supplied diluent, and then dispensed into a well on the
96 well plate, which was covered and incubated at 37 °C in a water bath for one
hour. During the incubation, antibodies contained in the sera bound to the
antigens captured on the ELISA plate. The plate was washed four times with
the supplied glycerate borate wash buffer, diluted 1:20 in distilled water, which
removed any unbound serum antibodies. The second stage involved the
addition of 100 pi conjugate (horseradish peroxidase labelled mouse
monoclonal antibody to human immunoglobulin G protein) to each well that
was covered and incubated under the above conditions for a further 30 minutes.
The plate was washed four times to remove any unbound conjugate, before the
addition of 100 pi substrate TMB and hydrogen peroxide. The reaction was
allowed a 30 minute incubation before it was stopped by the addition of 50 pi
of 2 M H2S04 stop solution. A colour change of pink to blue occurred in the
TMB in wells when anti-HCV antibody was present. The colour recorded was
proportional to the amount of conjugate antibody bound and, therefore,
proportional to the concentration of anti-HCV in the original serum sample.
This colour change reaction was halted by the addition of sulphuric acid,
changing the colour to yellow. The optical densities (OD) in each well were
measured at 470 nm wavelength on a spectrophotometer. The cut-off OD was
0.6 units plus the mean OD of the three negative controls. Any OD above the
cut-off was positive, anything below negative.
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2.7.1.1 Changes made to the protocol above
The Murex VK48 protocol was modified when measuring the antibody level in
a particular sample on this assay. The changes involved a run of 20 pi aliquots
of a designated standard control in dilutions 1:320 - 1:160 000 in rows Al-10
and B1-10 and negative controls in A11, A12, B11 and B12. The sample tested
was diluted 1:10-1:10 240 and 20 pi of these used in the wells. The protocol
above was followed until reading the ODs in the wells. The spectrophotometer
set at 470 nm was blanked, using one of the negative controls in wells All,
A12, B11 or B12, and then the absorbencies measured in each well. Then, using
the formula shown in section 2.6.3 above, choosing a dilution within the range
where the concentration and absorbency are linearly related, the relative
antibody level in each sample was calculated.
2.7.2 Abbott 3rd Generation Enzyme Immunoassay (EIA)
The Hepatitis Reference Laboratory in Edinburgh used this commercial assay
to test human sera for anti-HCV antibodies. A volume of 10 pi of test sample or
control was pipetted into a test tube, 400 pi of specimen diluent was added and
200 pi of this mixture was then transferred to the reaction well of the assay
plate. One recombinant HCV coated bead was added to each well, and then the
plate was incubated for 1 hour at 40 °C under humid conditions. After
incubation, the diluent was aspirated from around the beads and the beads were
washed four times with deionised water. The beads were then incubated with
200 pi bovine and goat anti-human antibody conjugate at 40 °C for 30 minutes.
The conjugate was removed by aspiration and the beads washed, before
removing each bead to a labelled test tube. The substrate solution was mixed as
directed: 1 o-phenylenediamine dihydrochloride (OPD) tablet in 5 ml substrate
diluent, for every 13 beads used. To each sample test tube and the two substrate
controls, 300 pi freshly prepared substrate was added. This was incubated for
30 minutes at room temperature before 1 ml of 1 M H2S04 was added. The
substrate control test tubes were used to blank and set the spectrometer at 490
nm. Three positive and three negative samples were tested per assay. The cut¬
off of the assay was determined as the mean of the three negative samples plus
a quarter of the mean of the three positive samples.
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2.7.3 Ortho 3rd generation EIA
The assay components were allowed to reach room temperature for 30 minutes
prior to commencing this assay. The 1A well of the ELISA plate was the
substrate blank. This meant that only substrate, and no other reagents, was
added to this well. On each plate there was one substrate blank, two positive
controls and three negative controls. A 200 pi volume of sample diluent was
added to all wells except 1 A, before 10 pi of sample or control was added into
each well and mixed. The plate was incubated under humid conditions at 37 °C
for 30 minutes, before washing five times with supplied buffer. The plate was
blotted dry and 200 pi conjugate was added to all wells except 1A, and then
incubated again at 37 °C for 30 minutes. Sufficient substrate OPD was freshly
prepared. The ELISA plate was washed as before and 200 pi fresh substrate
solution was added to all wells and incubated in the dark at room temperature
for 30 minutes. The colour change was halted by the addition of 50 pi 2 M
H2S04 to all wells. A spectrometer was blanked using the substrate blank well
1 A, before reading the absorbencies of all of the samples at 490 nm. The plate
cut-off was determined as the mean of the 3 negatives plus 0.330 OD units.
Any sample or control with an optical density measured greater than this value
was considered positive.
2.7.3.1 Modifications to the Ortho 3rd generation EIA
The above assay was modified to allow relative antibody level measurements in
a sample to be calculated. The standard control was titrated 1:10-1:160 000 and
two aliquots of 20 pi volumes of each dilution were added to each plate for
reference. Each sample tested was titrated 1:10-1:10 240 and 20 pi of each of
these titrations was tested. The above protocol was followed until reading the
ODs in the wells. The spectrometer, measuring wavelength 470 nm, was
blanked using one of the negative control samples, and then the absorbencies
were measured in each well. Then, using the formula described in section 2.6.3
above, choosing a dilution within the range where the concentration and
absorbencies are linearly related, the relative antibody level in each sample was
calculated. The serum samples were allowed to thaw, then were gently pipetted
up and down to ensure homogeneity throughout the specimen. The standard
control was titrated 1:320 -1:10 240 in the anti-HCV antibody negative serum,
two aliquots of 20 pi volumes of each dilution were added to each plate for
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reference. Each sample tested was titrated 1:10-1:10 240 in negative serum; 20
pi of each of these titrations was tested. If the sample's measured optical
density (OD) was less than 0.4 units, the sample was titrated 1:10, 1:20 and
1:40 and 20 pi of these dilutions was tested in the assay. Three aliquots of20 pi
of the anti-HCV negative serum in place of the negative control were included
in each plate. The plate cut-off for each plate used was calculated as the mean
of the 3 negatives plus 0.6 OD units. Anything above this value was considered
positive. The antibody level in each sample was assigned relative to the
standard sample as described previously in section 2.6.3. The antibody levels
assigned to each sample were then divided by five. This represented a five fold
loss of sensitivity.
The cut-off for each plate was calculated as an antibody level by the formula
and by assigning the concentration of the control as one.
Cut-off antibody level = Cut-off O.D. x Reference concentration
Reference O.D. x 1
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2.7.4 Chiron Recombinant Immunoblot Assay 3.0 (RIBA)
The RIBA assay was used as a confirmatory assay for samples already found to
be positive by ELISA. This strip immunoblot was based on a western blot
where immunogens were attached to a nitrocellulose strip and positive samples
detected by enzyme catalysed colour change. The antigens used were
recombinant proteins c33c (NS3 amino acids 1192-1457), NS5 (amino acids
2054-2995), synthetic peptides clOOp (NS4 amino acids 1920-1935), 5-1 -lp
(NS4 amino acids 1694-1735) and c22p (core amino acids 10-53). Each
antigenic region was coated as a separate band, allowing the specific antigen of
anti-HCV reactivity to be observed. Both the c33c (expressed in E.coli) and
NS5 (expressed in yeast Saccharomyces cerevisiae) antigens contain the tagged
sequence of human superoxide dismutase hSOD. hSOD was also coated onto
the strips to discount any reactivity with the expressed proteins that is really due
to the reactivity to this sequence. Also there were two IgG control antigens
blotted onto each RIBA strip.
A conjugated enzyme catalysed a colour change by the action of hydrogen
peroxide and 4-choro-l -naphthol creating a blue-black insoluble band on strip.
The colour of the band was graded from 1 to 4 by comparison with a reference
high and low titre standard.
The assay components were allowed to reach room temperature before
beginning testing. The required number of strips were removed from sealed foil
pouches and placed in the assay plate in their respective wells, one well per
specimen and one well for the positive and negative kit controls required. A list
of specimen numbers and corresponding RIBA strip numbers was prepared.
RIBA specimen diluent (1 ml) was added to each sample well, then 20 pi ofthe
appropriate specimen or control was pipetted to the corresponding well. The
assay plate was placed on a plate rocker and rocked at 16-20 cycles per minute
for 4 to 4.5 hours at room temperature. The specimen diluent was then aspirated
and discarded, and was replaced with 1 ml of fresh specimen diluent and the
plate restored to the rocker for a further 30 minutes. The specimen diluent was
then removed and 1 ml of assay supplied working wash buffer was added to
each well. The strips were removed from each well into wash vessels
containing 30 ml of working wash buffer. The working wash buffer was
removed and replaced a further 3 times, before the conj ugate was added, 1 ml
for each strip used. The wash vessel was rotated on a rotary shaker for 15 -20
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minutes at room temperature. After incubation, the conjugate was decanted and
the strips were washed again three times in 60 ml of working wash buffer.
Working substrate 1 ml per strip was added to each wash vessel and the wash
vessel was rotated on a rotary shaker for 15-20 minutes at room temperature.
The substrate was then aspirated and the strips were washed twice in 60 ml
distilled deionised water. The strips were removed from the wash vessel using
forceps and transferred to absorbent paper to blot excess moisture. The strips
were air dried in the dark for at least 30 minutes at room temperature. The
results of the test were interpreted by comparing the intensity of any band
present with the reference chart.
2.7.5 Murex Serotyping Assay
The assay utilised the finding that anti-HCV antibodies directed to the NS4
region are often type-specific. Each of the wells in the assay plate was coated
with peptide from all six of the HCV genotypes. Solutions of the peptides in a
ten fold higher concentration than that of the concentration of the assay wells
were prepared. Of the solutions prepared, one contained all six of the
genotypes' peptides. Another six solutions were prepared where each only
contained five ofthe genotypes. The solutions were added to the wells so that in
a row: one well had no competing peptide solution, one well had competing
solution containing all genotypes, one well had competing solution from all
genotypes except genotype 1, one well had competing solution from all
genotypes except genotype 2 and so forth. When a sample was added to these
wells, the type-specific antibody bound to the more concentrated peptides in
solution rather than to the peptides coated on the solid phase of the assay. The
type-specific antibody, which bound to antigen in solution, was washed away,
with the exception of the well where the genotype, which corresponded to the
particular genotype of the sample, was not contained in the competing solution.
In that well the antibody bound more strongly to the solid phase antigen and
was detected on incubation with conjugate and colour change of added
substrate.
On commencing the assay all components were allowed to reach room
temperature, the wash buffer was diluted 1:20 and the conjugate and substrate
were mixed with their respective diluents. One strip of eight coated wells was
required for each patient sample or control. Aliquots of 10 pi of the appropriate
competing solution (6 with one different genotype missing in each and one with
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all genotypes included) were added to the relevant wells. Sample diluent (180
pi) was pipetted into each well, and then 10 pi of sample or control was added
to each of the eight wells of one strip and mixed thoroughly. The wells were
covered with a plate sealer and the plate incubated for 1 hour at 37 °C under
humid conditions. After incubation, the plates were washed five times and 100
pi ofconjugate added to each well. The plate was then returned to the incubator
for a further 1 hour under humid conditions. The plates were again washed five
times after the second incubation and 100 pi of substrate was added to each
well. The plate was then incubated for 30 minutes at 37 °C under humid
conditions. The plate was then removed and the colour development stopped by
the addition of 50 pi of 2M H2S04 to each well. The absorbencies of each well
were measured at 450 nm using a microplate spectrometer. The genotype ofthe
sample was determined from the well (or wells in a mixed infection) that gave a
high absorbency value. If a high absorbency was measured in many or all wells,
the test was repeated utilising only 5 pi of test serum.
2.8 Statistics
Statistics were analysed using the Systat version 5.0 statistical analysis
computer package. Dot plot representations were used for all antibody level and
ratio level comparison between genotypes, also median, mean, minimum and
maximum values were calculated for each distribution. Kruskal-Wallis non -
parametric analysis was used to determine the p values for comparisons
between distributions. Correlations between different genotypes' antibody





3.1 Determination of the Genotype-common and
Genotype-specific Components of Antibody
Response to Single Antigens
All current anti-HCV antibody screening assays are based on the most
prevalence genotype sequence, type 1, despite the fact that six distinctly
different genotypes exist. Countries where genotype 1 is not the most prevalent
type report higher than expected occurrences of post transfusion hepatitis
suggesting that current screening assays may not be sufficiently sensitive in
detecting non type 1 infections. The extent of genotype-specific response to
screening antigens is explored in this work to assess the impact of genotype on
antibody detection by screening assay.
HCV sequence is highly variable, and the extent ofthe variability is constrained
by the functional and structural aspects of each region. Four antigenic regions
are used for commercial screening assays; core, NS3, NS4 and NS5. Regions
such as the core are highly conserved between genotypes, but the NS regions
are much more variable. This variability between the genotypes will be
reflected in the antigenic regions and will affect the antibody response produced
to these antigens and therefore influence detection on screening assays.
A screening assay utilising recombinant antigens of any other genotype has not
been reported. Therefore the extent of reactivity in sera to homologous
antigens, ie. genotype 4 antisera for genotype 4 antigens, has never been
compared to sera reactivity for heterologous antigens, ie. genotype 4 sera for
genotype 1 antigen.
Antibody reactivity is usually reported as the dilution ofthe last reactive sample
in limiting dilution titration. However, this method is affected by antigen
coating ofwells and by the reaction conditions. Comparisons can only be made
between samples on one plate and not relative to the antigen. Using limiting
dilution, the antibody reactivity measured is on a logarithmic scale, therefore,
the endpoints of very similar samples may vary by large amounts. To
circumvent this problem a method was devised (Dhaliwal et al., 1996) which
compares sample reactivity to a standard sample. The concentration ofantibody
in a sample is linearly related to the optical density measured in the substrate of
the reaction well over the range 0.2 units to 1.0 until substrate saturation occurs.
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This method allows reactivity in samples to be compared relative to each other
and relative to each antigen.
Therefore, by comparing the reactivity to homologous and heterologous
recombinant antigens, of each region, in infection with each genotype the type-
specific and type-common component of response could be assessed.
3.2 Methods
3.2.1 Samples
Sera from HCV infected individuals were collected, RNA amplified by RT-
PCR and the genotype determined by sequence analysis and by RFLP of the 5'
non coding region (section 2.1.2.1). Samples were obtained from individuals
infected with genotypes 3a (serum sample number LJ516) or 4a (serum sample
numbers EG21, ED43) virus. cDNA sequences were amplified from the core,
NS3, and NS5A regions of LJ516, the core region of EG21 and the NS3 and
NS5A region ofED43. These sequences were cloned into transport vectors and
sent to Murex Biotech. There, the sequences were subcloned into expression
vectors and used for the synthesis of recombinant protein antigens (sections
2.4-2.6). Unfortunately, the expression vector core clone derived from LJ516
and the NS5A clone of ED43 did not express recombinant protein. The
equivalent recombinant antigens from core (amino acids positions 1-140), NS3
(amino acids 1360-1454) andNS5 (amino acids 2238-2321) ofHCV-UK(type
lb) were derived from an existing commercial anti-HCV assay (VK48).
Serum samples were obtained from 110 anti-HCV positive individuals with
chronic hepatitis C attending hospital liver clinics in Edinburgh, London,
Karachi and Cairo. Serum RNA was confirmed by RT -PCR and the genotypes
were identified by RFLP of the 5' non coding region as 33 genotype lb, 34 of
genotype 3a and 43 of genotype 4a.
3.2.2 Antigenic Sequence
The generated clones from the amplified PCR products were given unique
identification numbers. The clones which were used in the manufacture of the
recombinant proteins were DX506, genotype 3a NS3; DX507, genotype 3a
NS5; DX387, genotype 4a core and DX499 genotype 4a NS3. The sequences
were entered into the GenBank sequence database. They were allocated the
following GenBank unique identifying "accession" numbers DX 506,
AF029297; DX507, AF029299; DX387, AF0292928; DX499, AF029296. The
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inferred sequence of the recombinant proteins expressed from the cloned PCR
products was analysed and compared with other published sequences and
grouped with the expected genotypes.
3.2.3 Assay techniques
ELISA plates coated with each of the recombinant proteins; genotype lb core,
NS3, NS5, genotype 3a NS3, NS5, genotype 4a core and NS3, were provided
for estimation of antibody response with samples of each genotype. Murex
Biotech Ltd also provided the reagents; sample diluent, 10 X wash buffer,
conjugate and conjugate diluent, substrate and substrate diluent. ELISAs were
carried out with each of the 110 patient serum samples, to estimate the relative
antibody level in each sample. Two, one litre packs of anti-HCV negative
serum were obtained from South West of Scotland Blood Transfusion Service
for use as a diluent in titrations of the anti-HCV positive samples. A high
antibody titre genotype la sample, obtained from a HCV infected patient
attending the Edinburgh Royal Infirmary Liver Unit, was used as a positive
control.
3.2.4 Quantification of antibody level
Antibody reactivity in each of the test sera to each recombinant protein was
determined by titration and reference to a standard positive control (section
2.6.3).
3.2.5 Calculation of the Genotype-specific and Genotype-common
Components of the Antigenic response.
The ratio of antibody levels measured to type-homologous and type-
heterologous antigens indicated the relative proportions of type-specific and
cross-reactive reactivity elicited on infection. Antigenicity for the purposes of
this calculation represents the overall response to an antigen contained in an
individual sample. This allows for any differences in levels of antibody
produced and any differences in the antigen presentation when bound to the
solid phase of an ELISA plate to be discounted.
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A mathematical formula to estimate the proportion of type-specific and type-
common components of response was derived by Dr Donald Smith
(mathematical working listed in Appendix 3). The proportion of antibody
reactivity that is cross-reactive between genotypes is measured by reciprocal
assays ofreactivity between sera and antigens from two genotypes, A and B. In
the following relations, Eba represents the antibody reactivity of a serum of
genotype B with antigen of genotype A, Aab is the overall antigenicity of the
genotype A antigen relative to that of genotype B, and Tc and Ts are the
proportions of the antibody response that are type-common and type-specific
respectively, such that Tc + Ts = 1.
Ebb
_ Ebb _ 1
Eba Ebbx AabxTc AabxTc
Eab





_ Aab _ 1
Eab/Eaa Aabx(Tc) (Tc)
From this the proportion of type-common reactivity can be derived as follows:
Tc~
Eab/Eaa





(Eaa/ Eab)x(Eba / Ebb)
These relations make the assumption that the relative proportions of type-
specific to type-common reactivity in a type A antiserum is the same as that
found in a type B antiserum.
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3.3 Results
3.3.1 Sequence analysis and phylogenetic comparison
Phylogenetic analysis of nucleotide sequences was used to confirm the
identification ofDX506 and DX507 as type 3a, and DX387 and DX499 as type
4a (Figure 3.2, Figure 3.4, Figure 3.6). The amino acid sequences of the
recombinant proteins were deduced from the nucleotide sequences of the
corresponding clones, (Figure 3.1, Figure 3.3, and Figure 3.5). Extensive amino
acid differences existed in the non structural proteins while the structural core
protein was more conserved. In the core protein 11 amino acids differed
between genotype lb and 4a over the 140 amino acid length (7.8% divergence).
Substitutions were generally conservative and only one resulted in a change of
ionic charge. The NS3 sequences exhibited more variability than the core
protein. Genotype lb differed from genotype 3a by 15 out of 95 amino acids
(16% divergence) and from genotype 4a by 13 amino acids, while genotypes 3 a
and 4a differed from each other by 16 amino acids. NS5 was also more variable
than core with 22 differences between genotypes lb and 3a over a length of 83
amino acids (26% divergence). Seven of these substitutions affected the charge
of the protein: three of basic amino acids for non-polar groups and two
substitutions of acidic groups for uncharged groups, one acidic for non polar
substitution and one unpolar to basic substitution.
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Region Genotype Genotype Genotype Amino Percentage
lb 3a 4a acid divergence
Clone Clone Clone changes
Core DX501 DX706 10 7.2
Core DX501 DX387 11 7.9
Core DX706 DX387 11 7.9
NS3 DX458 DX506 15 15.8
NS3 DX458 DX499 13 13.7
NS3 DX506 DX499 16 16.8
NS5 DXT1 DX507 22 26.5
Table 3.1 Divergence between genotype in the recombinant antigens
DX706 refers to a clone for genotype 3a core; this is discussed in chapter 4.
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Figure 3.2 The phylogenic relationship predicted using UPGMA analysis of the
core region
Samples (C10851 and EG21) and the recombinant clones (DX760 and DX387) are compared with other
published HCV sequences. The samples and the clones grouped with other published sequences of the
expected genotype in all cases. The recombinant clone DX505C3A failed to express protein. The clone
DX501 represents genotype 1 proteins.
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Figure 3.4 The phylogenetic relationship predicted using UPGMA analysis of
the NS 3 region between the samples amplified and the recombinant clones.
Samples LJ516 and ED43 (sequence published as HCV 4APOLY) and the
recombinant clones DX499 and DX506 compared to other published HCV
sequences. Clone DX458 was used for the production of genotype 1 NS3
antigen.
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Figure 3.6 The phylogenetic relationship predicted using UPGMA analysis of
the NS 5 region
The recombinant clones DX507 compared to other published HCV sequences.
The genotype 4 NS3 sample sequence was not available nor was the sequence
of the nucleotide genotype 1 b clone.
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3.3.2 Genotype dependence of serological reactivity.
The serological reactivity of the 110 collected sera from patients infected with
HCV was measured. Sera collected from individuals infected with different
genotypes: 33 genotype lb infection samples, 34 genotype 3a infection samples
and 43 genotype 4a infection samples, varied in their frequency of reactivity to
core, NS3 and NS5 antigens of genotypes lb 3a and 4a (Table 3.2).
In the core region, high frequencies of reactivity were observed for both type-
homologous (95%-97%) and type-heterologous combinations (86%-97%),
indicating the greater antigenicity of this region of the genome and/or a greater
proportion of shared epitopes between genotypes.
For NS3, frequencies of reactivity for type lb, 3a and 4a antisera to type-
homologous NS3 proteins were 85%, 100% and 76% respectively, compared
with a range of 27%-76% for type-heterologous combinations.
Similarly, the frequency of reactivity of genotype lb sera with genotype lb
NS5 antigen (64%) was higher than that ofheterologous sera (47% and 51%),
as was reactivity to genotype 3a NS5 (58% type-homologous reactivity,
compared with 24% and 45% for type-heterologous combinations).
3.3.3 Quantification of Antibody Levels
Each of the 110 sera samples was allocated an antibody level, relative to the
control positive sample, for each antigen as described in section 2.6.3. The
relative antibody level values were collated and analysed by Stystat statistical
analysis package. For each antigen, the relative antibody levels for each
genotype of samples were grouped and dot plots produced of genotype against
relative antibody level. The median values for each distribution of relative
antibody levels were calculated and the statistical significance between each of
the distributions was calculated (Figure 3.7, Figure 3.8, Figure 3.9). There were
significant differences in antibody reactivity to the type lb core protein between
genotype lb samples and those of genotype 4a (p=0.033) but not of genotype
3a (p=0.811). The distribution of antibody levels directed to the genotype 4a
core antigen showed no significant difference between genotypes, but the mean
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The reactivity directed to the NS3 antigen was much more genotype dependant.
On the genotype lb antigen plates, samples of genotype lb had significantly
higher reactivities than the genotype 3a (p=0.004) and 4a samples (p=0.005),
also having a median value 100 times that of than of genotype 3a and 10 times
greater than genotype 4a. The same trends were observed with the genotype 3 a
NS3 antigen where significant differences were observed between the
distributions of the relative antibody level values of genotype 3a with that of lb
(p=0.008) and that of genotype 4a (p<0.001); the median value of genotype 3
samples was 4 times greater than that of genotype lb and 20 times greater than
genotype 4a. The distribution of relative antibody levels from samples from
genotype lb was not significantly different from the distribution of genotype 4a
samples reactivity to genotype 4a NS3 antigen. However there was a significant
difference in distribution between samples of genotype 3a and genotype 4a
(pO.OOl).
Only 54% of samples reacted with the NS5 genotype lb antigen and 43% with
the genotype 3 a antigen. The median antibody level ofgenotype lb sera (0.031)
was eight fold higher than that of type 3a samples (0.004) and three fold higher
for lb antigen than type 4a (0.012). The distribution of antibody levels amongst
genotype lb samples was significantly higher than genotype 4a samples
(p=0.029) but not the genotype 3a distribution.
Reactivity of type 3a sera against NS5 of genotype 3a was significantly greater
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3.3.4 Reproducibility of Results
To investigate the reproducibility of the method used to quantify antibody
levels, each of the sera was assayed in replicate against the type lb and 4a core
proteins (Figure 3.10 and Figure 3.11). A close correlation was observed
between the two measured antibody levels, with non-parametric correlation
coefficients ranging from 0.877, 0.889 and 0.862 for type lb, 3a and 4a antisera
respectively. For the type 4a core antigens, the corresponding correlation
coefficients were 0.784, 0.721 and 0.802
3.3.5 Correlation between Reactivity to Different Antigens
There was also a close correlation between reactivity to the core protein of type
lb with that to type 4a, with correlation coefficients of 0.834, 0.765 and 0.767
for type lb, 3a and 4a antisera. Significant correlations were also consistently
observed between the reactivity of antisera to NS3 proteins of types lb, 3a and
4a, as well as between the NS5 proteins of type lb and 3a. In contrast, there
was little if any correlation between antibody reactivity to different regions of
the genome. For example, the reactivity of sera from type lb-infected
individuals to the type lb core protein showed no correlation with reactivity to
type lb NS3 or NS5 proteins (correlation coefficients of -0.118 and -0.181;
Table 3.3). The only exceptions were weak correlations (0.443 and 0.471)
between the reactivities to 3a NS3 and NS5 (but only for type lb sera) and
between NS5 of type lb with NS3 of 4a (restricted to 3a sera).
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lb lb -0.118 0.023 (1)
3a 0.133 0.279 (1)
4a 0.100 -0.035 (1)
3a lb -0.270 -0.066 0.456 (1)
3a 0.153 0.274 0.363 (1)
4a 0.159 0.030 0.627 (1)
4a lb 0.048 0.224 0.710 0.518 (1)
3a 0.215 0.130 0.570 0.393 (1)
4a -0.058 -0.087 0.497 0.272 (1)
NS5
lb lb -0.181 -0.220 0.150 0.275 0.157 (1)
3a 0.066 0.000 0.218 0.265 0.471 0)
4a 0.058 -0.192 0.069 0.168 0.055 (1)
3a lb -0.141 -0.43 0.247 0.443 0.348 0.630 (1)
3a 0.051 0.172 0.216 0.266 0.202 0.649 (1)
4a -0.076 -0.108 0.186 0.179 0.041 0.303 (1)
Table 3.3 Correlation between reactivity to different antigens.
aSpearman's rank correlation coefficient
Separate values shown for antisera of each genotype
Significant values (p<0.05) underlined.
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3.3.6 Ratio of Reactivity to a Homologous Genotype antigen:
Reactivity to a Heterologous Antigen.
The ability to measure the reactivity of the same antiserum to antigens of
different genotypes allowed an estimation of the relative levels of genotype-
specific and cross-reactive serological reactivity. For the core proteins, antibody
levels of each of the type lb and 4a sera to the genotype lb antigen were
divided by their levels to the genotype 4a antigen (Figure 3.12). The median
ratio ofreactivity to type lb: type 4a antigens for the type lb antisera was 1.49,
compared with a median ratio of 0.809 for the type 4a sera. This indicates that
type lb sera react more strongly against the type lb (homologous) core protein,
while the type 4a sera reacted slightly more strongly against the type 4a
antigen. If it were shown that both core proteins were coated equivalently on
the solid phase, and showed equal antigenicity, then type-specific reactivity to
these proteins could be calculated from the difference from the ratio of 1
expected from exclusively type-common reactivity. However, it is possible that
some antigens are present in higher available concentrations than others,
through differences in binding to the solid phase or solubility. These differences
were taken into account using the derivation described. In this instance, the
term EAB/EAA represents the median of the ratio of reactivity between type 4a
sera with type lb and type 4a antigens (0.809). The term EBB/EBA is similarly
represented by the median ratio of the type lb antisera (1.49). Therefore, the
proportion of type-common reactivity can be calculated as 0.74, with type-
specific reactivity forming the remainder of the reactivity (0.26).
The median ratio of reactivity of the type 3a sera to type 3a and lb NS5
antigens (0.654) was substantially lower than that of type lb sera (median of4;
table 3.4), therefore the proportions of type-common and type-specific
reactivity were 40% and 60% respectively, ie. the majority of serological
reactivity to this antigen was type-specific. Finally, three sets of pairwise
comparisons can be made for the NS3 region, where antigens for all three
genotypes were available. 62% ofserological reactivity between type lb and 3a
proteins was type-specific, similar to 61% between type lb and 4a, and 77%
between type 3 a and type 4a.
no
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3.4 Discussion on Single antigens
3.4.1 Antigenic variability of HCV
The aim of this study was to investigate the degree of type-specific serological
reactivity to antigens used in current 3rd generation screening assays. The use
of recombinant antigens expressed from different genotypes in the EIA allowed
reciprocal measurements of type-homologous and type-heterologous reactivity,
which provided a more rigorous assessment of the type-specific components of
reactivity to core, NS3 and NS5. This addresses a potential criticism of
previous investigations that showed weaker reactivity of sera from individuals
infected with non-type 1 genotypes in either screening ELISA or to individual
antigens in the RIBA confirmatory assay (Chan et al., 1991), (Claeys et al.,
1995), (Dhaliwal et al., 1996), (Dow et al., 1996), (McOmish et al., 1993) and
(Zein et al., 1995), in that there is a possibility that these observations resulted
from a generally weaker serological response to infection than elicited by type
1. In the current study we were able to consistently show stronger reactivity of
sera to antigens of homologous type than to heterologous types.
From pairwise reciprocal measurement of antibody reactivity (such as type lb
and 4a antisera against type lb and 4a antigen), it was possible to quantify the
relative contributions of type-specific and cross-reactive antibody reactivity
using the relation derived in section 3.2.5. These calculations were independent
of possible differences in the strength of the serological response elicited by
infection with different genotypes, and were also independent ofdifferences in
antigen concentration or overall antigenicity between proteins of different
genotypes (expressed as the ratio Aab). This removes the potential criticism that
the coating efficiency ofantigens from different genotypes onto the solid phase
was not compared prior to measurement of antibody levels. From this analysis
we found a relationship between the degree ofamino acid sequence divergence
between recombinant proteins and their degree of cross-reactivity. The core
protein was the most conserved and showed approximately 25% type-specific
reactivity while the more divergent sequences NS3 and NS5 showed
substantially greater proportions of type-specific reactivity. These results are
consistent with previous comparisons of the type-specific component of
reactivity to peptides corresponding to linear epitopes in NS4. By absorption in
solution with peptides ofheterologous genotypes, it was shown that reactivity
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to type-homologous peptides was reduced, but rarely eliminated (Bhattacherjee
et al., 1995;Simmonds et al., 1993b), and which therefore formed the basis of a
sensitive and specific serological typing assay. The type-specific component of
serological reactivity to NS4 and, in some studies to the core protein, have been
also used in typing assays without cross-absorption, as it has been consistently
observed that reactivity is stronger to type-homologous antigens in these (Dixit
et al., 1995;Machida et al., 1992;Mondelli et al., 1994) and other regions
(Zhang et al., 1995).
3.4.2 Implications for screening assays
The effect of the demonstrated antigenic variability of components of third
generation screening assays on its overall sensitivity for screening is difficult to
estimate with precision for two reasons. Individuals vary in their serological
response to different antigens, and therefore in the extent to which this may
cross-react with antigens ofheterologous genotypes. For example, if reactivity
were directed solely to the core protein, this would cross-react with antigens of
heterologous genotypes, whereas sera that are monoreactive with NS3, such as
found upon seroconversion, would be expected to be predominantly type-
specific.
Furthermore, each of the three antigens investigated is likely to contain a range
of linear and conformational epitopes, and these will vary in their degree of
cross-reactivity. Recognition of different epitopes in the antigens may be one
explanation of the wide range of ratios of reactivity to type-homologous and
heterologous antigens observed between sera of the same genotype. In the
extreme case, it is possible that reactivity confined to epitopes in the core
protein that are type-specific would lead to poor or absent reactivity to the core
protein of other genotypes. Conversely, the high degree of cross-reactivity
observed between certain sera with NS3 or NS5 proteins of heterologous
genotypes may have resulted from their recognition of shared epitopes.
114
The observed differences in reactivity of sera to homologous and heterologous
proteins would only lead to false-negative results on serological screening if
antibody levels in samples to be tested were close to the cut-off sensitivity of
the assay. Low antibody levels, and reactivity to a restricted range of epitopes,
such as those in NS3 are found in acutely infected individuals (Lelie et al.,
1992), and it is likely that earlier detection of seroconversions, and therefore a
reduction in the "window period" associated with non-type 1 infection, may be
achieved using assays containing NS3 and other antigens from a wider range of
genotypes.






4.1 Determining the Genotype-Common and Genotype-
Specific Components of Antibody Response to
Combined Antigens.
Having found that an element of type-specific and cross-reactive immunity to
each HCV antigen exists in each individual's serum, the logical progression
was to measure the type-specific and type-common component to the
combination of all HCV antigens in a screening assay. A genotype 3 based
screening ELISA was constructed, to compare serum reactivity with the
genotype 1 commercial assay, VK48. Serum samples were obtained from
individuals infected with genotype 1,2,3 and 4 infections and the antibody
level in each sample was measured, as before, (see section 2.6.3), relative to the
standard control for each screening assay. The extent of the type-specific and
type-common humoral immunity to these HCV antigens was determined.
4.2 Methods
4.2.1 Samples
The sera studied were obtained from blood transfusion centres and had been
sent to the Molecular Virology Department at Edinburgh University for
supplemental testing. These sera came from individuals identified, during
routine donation screening, as HCV infected, during routine donation screening
or from follow-up of recipients ofcontaminated blood or blood products. All of
the samples were confirmed as containing viral RNA. The genotype in each
sample was identified by RFLP of the 5' NCR as described in section 2.1.2.1.
The subtypes of genotype 1 were further distinguished by RFLP using BstUl
(see section 2.1.2.2). The samples consisted of36 genotype 1 (of these 10 were
subtype la and 26 were subtype lb), 7 genotype 2, 23 genotype 3 and 10
genotype 4. Samples of genotype 1 and genotype 3 infections were obtained
from the Republic of Ireland Blood Transfusion Services from individuals
whose main risk factor for infection was receiving contaminated anti-Rhesus D
immunoglobulin. These two cohorts were particularly well matched for sex,
age, health and HCV disease progression.
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4.2.2 Antigenic Sequence
In addition to sample LJ516, sample CI0851 was used in the production of
genotype 3a recombinant protein antigen. Baculovirus expression vector clone
DX505C3A of the LJ516 core sequence did not produce recombinant antigen.
Other clones were created in the hope of expressing genotype 3 core protein.
Sample C10851 belonged to a patient identified as having been the recipient of
a batch of contaminated anti-Rhesus D immunoglobulin. Sequence analysis of
the viral genome identified the virus genotype as type 3a, this was confirmed
when this isolate grouped with other genotype 3 samples in phylogenetic
analysis (Figure 3.2). The expression vector clone DX760, containing the
amplified core sequence of CI0851 alone, also did not express sufficient
protein. The recombinant protein in the experimental genotype 3 screening
assay was expressed as a tripartite fusion protein of core, NS3 and NS5. The
protein consisted of sequences from the clones DX760, DX506 and DX507, ie,
core region amino acids 1-140 from individual C1085I and NS3 region amino
acids 1360-1454, NS5A regions amino acids 2234-2321 from individual LJ516.
The predicted amino acid sequence of these clones is shown in figure 3.1,
figure 3.3 and figure 3.5. The sequence of the genotype lb antigens in the
VK48 screening assay are also recorded in these tables as DX501, DX458 and
DXT1. Branched synthetic peptides from regions NS4A and NS4B amino acids
1691-1708 and 1710-1728 ofboth genotype 1 and 3 were also incorporated in
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4.2.3 Assay
The 92 serum samples were removed from -40°C storage and allowed to
defrost. The thawed samples were titrated in negative serum in dilutions 1/10 -
1/10 240. Negative serum was obtained from the Scottish National Blood
Transfusion Service and the same serum was used throughout this experiment.
The standard control, a high antibody titre positive sample that was used in the
single antigen plate analysis, was again used in this study. This reference
standard control was titrated in the same negative serum; dilutions 1/320 - 1/
81920 were added to each ELISA plate. Two wells of negative serum were
present on each plate as a negative control. These were also used as the
negative blank to discount for background reactivity. The ELISA plates were
supplied by Murex Biotech: the commercially available genotype lb based
VK48 ELISA and the genotype 3 antigen coated plate BHC129. The genotype
3 ELISA was as near a match to the VK48 assay in terms of specificity and
sensitivity as could be provided. However, the genotype lb plate contained
linear NS4 peptides whereas the genotype 3 plate contained branched peptides.
The assays were carried out with Murex-supplied reagents (as described in
section 2.6.2). The optical density observed in the wells was read at 470 nm.
4.2.4 Measurement of Antibody Level
The reactivity of samples to the commercially available Murex Biotech HCV
screening assay (VK48) was compared with the experimental genotype 3a
antigen assay, designated reference code BHC129. The OD measured in the
reference control titrations was plotted against level of dilution to ensure a
linear relationship between OD measured and concentration of antibody
present. Each sample was assigned an antibody level relative to the standard
control sample as previously described for single antigens (section 2.6.3). The
samples were tested on the plates with a mixture of genotypes on each plate to
prevent plate-to-plate variation from influencing the results.
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4.2.5 Ratio of Reactivity
The extent of type-specific and cross-reactive reactivity could be estimated by
comparing the reactivity of antisera to type-homologous and type-heterologous
antigens, assuming the antigens were equivalent. The reactivity in each sample
was converted into an antibody level by comparison with the standard control
sample as described in section 2.6.3. The distribution of the relative antibody
levels in samples of each genotype was analysed. The median of the
distributions of the genotype 1 and type 3 samples were used in the formula
derived in section 3.2.5 to estimate the extent of type-specific and type-
common reactivity to antigens in a screening assay.
4.3 Results
4.3.1 Sequence
The amino acid sequence of the recombinant protein of genotype 3 a core was
deduced from the nucleotide sequence of the constituent clone DX760. The
sequence is shown in figure 3.1. Pair wise analysis produced the figure, which
confirmed the sequence groups together with other sequences known to be
genotype 3 (Figure 3.2).
Within region 1 of the NS4 peptides (table 4.1), there was a high degree of
divergence between genotype lb sequence and genotype 3 sequence. The
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4.3.2 Genotype dependence of serological reactivity and quantitation
of antibody levels
4.3.2.1 Genotype lb antigens (VK48)
The distributions of antibody levels for sera with each genotype were plotted
(Figure 4.2). The median value for type 1 a was 0.268, subtype b 0.185, for type
2: 1.604, for type 3: 0.151 and for type 4: 0.809. Significant differences were
observed between genotype 1 and 2, 1 and 3, 2 and 3.
4.3.2.2 Genotype 3a antigens (BHC129)
Relative antibody levels were plotted against sera with genotype for type 3
antigens (Figure 4.3). ). The median value for type 1 subtype a was 0.084, b
0.19, for type 2: 3.04, for type 3: 0.708 and for type 4: 0.809. Significant
differences were observed between genotype 1 and 3 and between genotypes 2
and 3.
4.3.3 Correlation between reactivity to different antigen
The correlation coefficient was found to be 0.86 between the relative antibody
level of a sample in the VK48 assay against the level measured in the BHC129
assay, which was high considering the study by Dhaliwal et al., 1996 had found
a correlation coefficient of 0.787 between the type lb assay and the Ortho type
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4.3.4 Ratio of Reactivity to a Homologous Genotype antigen:
Reactivity to a Heterologous Antigen.
Using the methodology described in section 3.2.5 (Figure 4.5), the median
values of both genotypes 1 (combined la and lb) and genotype 3 were
substituted in the formula;
J, _ I Eab /E^aaC




The type-common component was calculated as 54% and the type-specific as
46%.
4.4 Discussion on combined antigens
This confirms the results observed with each antigen that a substantial portion
of an antibody response is directed at type-specific epitopes.
> A genotype specific response is directed at the combination of
antigen used in current screening assays.
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Having found a proportion of the HCV antibody response is directed at type-
specific epitopes, I set out to investigate the effect this had on detection with
commercial assays. Simulating the 5-fold loss in sensitivity observed in non-
genotype 1 infection in commercial assays, I investigated the theoretical effect
on detection. I used the recombinant antigens to screen for individuals who
were seronegative with commercial assay but whose infection could be
confirmed by molecular biology. Using the recombinant antigens of the
predominant infecting genotypes, I screened blood donors and patients with
cryptogenic hepatitis in Pakistan and blood donations from immigrant
Egyptians in Saudi Arabia. Having found no evidence of "missed" infections I
investigated the possibility that recombinant antigens could be used to aid
confirmation of indeterminant results. The samples available for analysis are
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5.2 Theoretical under-detection of anti-HCV antibody-
positive samples of other genotypes.
5.2.1 Introduction
Previous studies by Dhaliwal and colleagues (Dhaliwal et al., 1996) compared
serological responses from individuals infected with viruses of genotypes 1, 2
and 3. The results showed the difference between genotype 1 and genotype 2
were samples statistically significant with both the Ortho 3rd generation EIA
(adjusted difference = 4.12, p=0.005), and the Murex VK48 assay (adjusted
difference = 3.72, p=0.014). These results include an adjustment to account for
the 10.2-fold difference in reactivity found between PCR positive and PCR
negative samples. Additionally, the responses of genotype 1 and genotype 3
sera were significantly different. The reactivity in the Ortho 3rd generation assay
differed by an adjusted difference of4.48 (p<0.00001) and in the Murex VK48
by 2.35 (p=0.007). This meant the detected antibody responses, measured in
antibody units relative to a standard sample, in individuals infected with
genotypes 1 and 3 were between two- and five-fold lower than the response of
individuals infected with genotype 1 virus.
The effect of this 2 to 5 fold loss in sensitivity and the effect on the detection
rate in commercial assays were investigated by previous colleagues (un¬
published results). Their experiment was devised whereby samples from
individuals infected with genotype lb were diluted 1:4.5 in the specimen
diluent and the reactivity measured in an Ortho 3rd generation test. This
experiment mimicked the 4.48- fold difference in relative antibody levels
observed between genotype 1 and genotype 3 samples.
The population that was studied were all infected from a single source over a
limited time frame. In this cohort, after the 17 years since infection, the broad
spectrum of outcomes of infection was represented. The samples were from
individuals who had received an injection of anti-Rhesus D immunoglobulin,
between April 1977 and October 1978, which had been manufactured from a
plasma pool, which contained a HCV positive donation. The infected individual
who had made the donation, which had contaminated the blood product, was
traced. An archived specimen of the original sample was tested by polymerase
chain reaction (PCR) and was found to contain viral sequence. The subtype of
the virus was found to be lb, by sequence analysis of NCR, core and NS5.
132
The extent of resolved infection and chronic infection was representative ofthe
infection pattern observed in the general population. For this reason PCR
positive and PCR negative samples were studied. By observing samples from
genotype 1 infected individuals, diluted to represent the level of reactivity
observed in genotype 3 samples, the sensitivity of the commercial assay with
non genotype 1 samples could be estimated.
Contemporary samples of 101 recipients ofthis blood product were tested. The
individuals tested had already been identified by the BTS as being 3rd
generation Ortho EIA positive and recombinant immunoassay (RIBA) assay
confirmed as positive for anti-HCV antibody. PCR results were available and
RNA sequencing of several regions of the genome had been carried out on the
PCR positive samples. These individuals had completed a medical history
questionnaire and no other risk factors for HCV infection had been identified.
The samples were tested in 3rd generation Ortho EIA according to the standard
operating procedures, with the exception that the sample was diluted 1:90 in
sample diluent instead of the protocol specified 1:20 dilution. At this 1:4.5
dilution, 16 of the 101 samples were below the positive cut-off value for this
screening assay and 3 samples were close to this value. These 19 samples were
PCR negative for viral RNA.
This experiment used dilution in sample diluent rather than dilution in negative
serum. The effects of this on the results were unknown, but since the assay was
designed to have a 20 pi volume of serum in each well and to allow comparison
with the 20 pi serum in both the control positive and negative samples.
To overcome these uncertainties with the previous colleagues experimental
design. I repeated this work. This time, instead ofmeasuring the absorbance at a
certain dilution, the antibody level in each sample was calculated relative to a
standard control sample. By this method the antibody level in each sample








111 91 PCR positive
20 PCR negative
Samples from patients identified as receiving
anti-RhD immunoglobulin contaminated with
HCV genotype lb
The serum samples for this study were from the Dublin and Cork BTS, from the
cohort of individuals who had been exposed to HCV contaminated anti-Rhesus
D immunoglobulin in 1977 or 1978. The 3rd generation EIA result, RIBA score
and PCR status of each of the samples was available. The NS5 region of each of
the PCR positive samples had been sequenced. All of the sequences were
representative of lb subtype. Those who were PCR negative, but seropositive,
had documented evidence of receiving the contaminated anti- Rhesus-D and
can, in the absence of other risk factors, been assumed also to have been
infected with genotype lb. The contemporary blood samples from these women
were taken as described in section 2.1.1.1, and then shipped on dry ice to the
Molecular Virology Laboratory for analysis.
One hundred and eleven samples were analysed in this study. This consisted of
91 PCR positive samples and 20 PCR negative samples, and contained 46 ofthe
samples (31 PCR positive, 15 PCR negative samples) from the earlier
experiment.
5.2.3 Assays
Assays Interpretation of results
Ortho EIA Plate cut-off = O.D. of the mean of 3
negative samples plus 0.6
The 3r generation Ortho EIA was carried out according to the manufacturer's
instructions (section 2.7.3), but modified to allow the calculation of the relative
antibody level in each sample as described (section 2.7.3.1).
The Ortho 3 rd generation assay was obtained through the SNBTS who use this
assay for routine screening ofall blood donations. The standard sample used to
assign an antibody level to each test sample was a large volume high titre
antibody positive serum sample. The anti-HCV antibody negative serum was
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obtained from the SNBTS. The same negative donation was used for all
dilutions in this experiment. The Ortho kit positive control was used according
to the manufacturer's instructions. The anti-HCV antibody negative serum was
used in place of the kit negative control and was used to calculate the plate cut¬
off values.
5.2.4 Methods
The Ortho Assay was performed as described in section 2.7.3.1. The antibody
level in each sample was assigned relative to the standard sample as described
previously in section 2.6.3. The antibody levels assigned to each sample were
then divided by five. This represented a five fold loss of sensitivity.
A dot plot was generated to illustrate the antibody levels in the samples and the
relative antibody level, which represented the positive cut-off level, was
indicated with a line.
5.2.5 Results
All 111 samples were assigned antibody levels, which were greater than the
calculated plate cut-off antibody level value. However, when the antibody level
was divided by five, 14 samples had antibody levels which were below the
positive cut-off value, expressed as a relative antibody level. The distribution of
antibody levels in the PCR positive samples was significantly different to those
of PCR negative samples (p<0.001).
The results are shown in figure 5.1 and figure 5.2. The 14 samples which
became negative at a five-fold reduction were all samples which were PCR
negative. The minimum relative antibody level measure was 0.000987 and the
maximum was 7.920 relative antibody units. At a 1/5 decrease the minimum
relative antibody level measure was 0.000197 and the maximum was 1.584
relative antibody units. The mean antibody level in PCR positive samples was
1.121 compared to 0.003321 in PCR negative samples. At a 1/5 dilution the
mean antibody level in PCR positive samples was 0.224 compared to 0.00664
in PCR negative samples. The lowest relative antibody level recorded in a PCR
positive sample was 0.007 units. Therefore, in this experiment for a PCR
positive sample to fall below the cut-off limit, it would require a 13.2 fold loss
in antibody level.
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All Samples PCR Positive PCR Negative
Minimum 0.000987 0.007 0.000987
Maximum 7.920 7.920 0.013
Mean 0.919 1.121 0.003321
Median 0.709 0.892 0.00253
Figure 5.1 Antibody levels in 111 HCV genotype lb infected anti-Rhesus D
recipients.
The antibody level of each sample measured is represented by one dot. The
PCR status of the sample on the x-axis is plotted against the antibody level on
the y-axis, which is a log10 scale. The average cut-off level for the assay
expressed as an antibody level is represented by the line drawn at 0.00053
relative antibody units. All 111 samples have antibody levels above the assay
cut-off.
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All Samples PCR Positive PCR Negative
Minimum 0.000197 0.001 0.000197
Maximum 1.584 1.584 0.0026
Mean 0.184 0.224 0.00664
Median 0.142 0.178 0.00506
Figure 5.2 Antibody levels in 111 HCV genotype lb infected anti-Rhesus D
recipients divided by five to represent a five-fold reduction in assay sensitivity.
The antibody level of each sample measured is represented by one dot. The
PCR status of the sample on the x-axis is plotted against the antibody level on
the y-axis, which is a logio scale. The average cut-off level for the assay
expressed as an antibody level is represented by the line drawn at 0.00053
relative antibody units. Fourteen of the 111 samples have antibody levels below
the assay cut-off. These samples are PCR negative.
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5.2.6 Interpretation
From these results with samples from individuals infected with genotype 1,
there is evidence that the current screening EIA tests may not detect a number
of PCR negative samples of other genotypes. The samples here are of PCR
negative individuals, perhaps recovering from infection, where the antibody
response is declining. Although PCR negative, the samples that were missed
were RIBA confirmed. The referral guidelines at the time of this work
suggested individuals who have an EIA positive result, which is confirmed by
RIBA testing, should be referred to a Hepatologist or Gastroenterologist. This
indicated that individuals infected with other genotypes who required further
follow-up would not receive this care because their serum samples would be
missed in the current assays. Another consequence of not detecting these
samples in a blood transfusion setting would be that the previous donations
would not be checked for infectivity and the recipients of such donations would
not, therefore, be recalled.
The PCR positive sample with the lowest relative antibody level was 13.2 times
higher than the antibody level plate cut-off value. This suggests that PCR
positive donations of other genotypes would be detected despite the five-fold
loss of sensitivity in current assays. However, the majority of the individuals in
this study were relatively healthy and not co-infected with HBV or HIV.
Perhaps immune suppression as a result of co-infection, other disease
manifestations or immunosuppressive drug therapy may combine to produce an
antibody level below the cut-off.
> A five fold reduction in the sensitivity of anti-HCV antibody
detection by Ortho 3rd generation assay results in under-detection
of individuals with resolved HCV infection.
> A 13.5 loss in sensitivity of this assay would result in under-
detection of active HCV infection.
138
5.3 Screening donor populations in Cairo, Egypt and
Riyadh, Saudi Arabia
5.3.1 Introduction
If screening with commercial assays was currently missing samples from
individuals infected with HCV of genotypes other than genotype 1, then this
would account for the cases ofpost transfusion hepatitis still being reported in
regions where HCV genotype 1 is not the predominant genotype of infection.
Egypt has a very high prevalence of HCV infection due to the lack of
adequately sterilised medical equipment during a WHO Schistosomiasis
eradication campaign. This large reservoir of HCV carriers results in a
continual low level of HCV transmissions (Nafeh et al., 2003). The
predominant genotype of infection is genotype 4. Therefore, this was the ideal
population to study, although, unfortunately, access to a large number ofblood
donor samples from Egypt could not be arranged (only 50 samples were
analysed). The closest alternative was to use blood donations from individuals
in Saudi Arabia where there are a number of immigrant Egyptians (1547
samples were analysed). These samples were screened for genotype-specific
reactivity, using genotype 4 antigens, which corresponded to the genotype 1
antigens in commercial assays. Personnel from Murex Biotech Ltd carried out
the majority of this work. However, analysis of the data and PCR testing of
samples from the Egyptian and Saudi Arabian blood donors were carried out in
the laboratory in Edinburgh.
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5.3.2 Samples
Origin of samples Number Comments
Cairo Liver Centre,
Egypt
55 50 Anti-HCV antibody screen negative





1547 Blood Donors anti-HCV antibody 2nd
generation assay screen negative
693 for Saudi Arabian Nationals
134 from Sudanese Nationals
99 from Yemenis Nationals
621 from Egyptian Nationals
Brentwood Blood
Donor Centre, UK
723 Control anti-HCV antibody negative UK Blood
Donors
5.3.2.1 Cairo, Egypt
Dr A El-Zayadi from the Cairo Liver Centre sent 50 frozen serum samples from
Egyptian blood donors which were known to be negative for anti-HCV
antibody by second generation Ortho EIA and 5 control samples from anti-HCV
antibody positive individuals to be tested with the genotype 4a core and NS4
antigens.
5.3.2.2 Brentwood Blood Donor Centre, UK
Murex Biotech obtained samples from 723 3rd Generation Ortho EIA anti-HCV
screen negative UK blood donors, from the Brentwood Blood Donor Centre.
The samples were used as controls to establish reasonable cut-off levels for the
genotype 4 antigen assays. All 723 samples were tested with the genotype 4
NS4 antigen, 568 were tested with NS3 and 334 with genotype 4 core antigen.
5.3.2.3 Riyadh, Saudi Arabia
Dr AA Saeed of the Department of Pathology, at the Riyadh Armed Forces
Hospital allowed a representative from Murex Biotech Ltd access to the blood
donor samples at the hospital. Samples were available from 1547 second
generation Ortho EIA screen negative individuals. The samples included 693
native Saudi Arabian individuals, 134 from immigrant workers from Sudan, 99
from Yemen and 621 from Egypt. Aliquots of samples were taken and sent to
Murex Biotech for repeat analysis.
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5.3.3 Assays
Samples Laboratory Test Cut-off Comments
Cairo Blood
Donors















Saudi Murex Single antigens
Core
Positive>0.7 Mean of 80
samples plus
0.6O.D. units
Saudi Murex Single antigens
NS3
Positive>0.78 Mean of 80
samples plus
0.6O.D. units
Saudi Murex Single antigens
NS4




ELISA plates had been coated with each of the commercial genotype lb
antigenic sequences for core and NS3. Proteins had been expressed from
genotype 4a sequences to correspond to these antigens. These proteins were
coated onto plates at similar concentrations and under similar conditions to
generate tests with similar sensitivity and specificity (materials and methods
section 2.6). The synthetic branched peptides used in the commercial serotyping
ELISA from NS4 positions 1691-1708 and 1710 -1728 (Figure 4.1)
(Bhattacherjee etal., 1995;Simmonds etal., 1993b) from both genotype lband
4a were also coated onto the solid phase of ELISA plates.
5.3.3.2 PCR
60 Aliquots of serum analysed in the Riyadh Armed Forces Hospital, from
donors ofEgyptian origin, which were reactive (10 seropositive in VK-48 assay
and 50 with measured O.D.>0.25 in one or more single antigen plate), were sent
to the Molecular Virology Laboratory for HCV PCR testing
5.3.4 Methods
The 55 samples from the Cairo Liver Centre, Egypt were tested by PCR
(section 2.1), then the samples were tested in the core and NS4 single antigen
plates of genotype lb and 4a (section 2.6.1).
Murex obtained aliquots of serum from 723 UK seronegative blood donors
from the Brentwood Blood Donor Centre. These samples were tested with the
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genotype 4 core, NS3 and NS4 antigens as a comparison to the Saudi Blood
Donors in order to determine cut-off levels.
A representative from Murex Biotech Ltd visited the Riyadh Armed Forces
Hospital. Samples from 1547 individuals were screened with genotype 4a core,
NS3 and NS4 antigens and 3rd generation anti-HCV screening assays.
The reactivity with the genotype 4 antigens of samples from 554 Ortho 3 EIA
negative Egyptian and 898 Saudi/ Yemenis/ Sudanese was compared to the
Brentwood Blood donors to establish cut-off levels. From this analysis of
reactivity, samples which produced reactivity of greater than 0.25 O.D. units in
one or more genotype 4 antigens were sent for further analysis. Aliquots of
these samples were frozen and shipped on dry ice to Murex Biotech Ltd's office
in Dartford for retesting with the genotype 4a antigen and comparable genotype
lb antigens. These sera were also tested with the commercial genotype lb
sequence Murex VK48 assay.
50 Samples from Blood Donors of Egyptian origin donated in Riyadh Armed
Forces Hospital which were negative in the commercial third generation Ortho
EIA but reactive with genotype 4 antigens were sent for PCR analysis. These
were compared with 10 samples from commercial assay positive individuals.
5.3.5 Results
5.3.5.1 Cairo Samples
The samples from Cairo blood donors were tested in the genotype 4a and lb
Core and NS4 antigens. One of the negative samples was reactive with all
antigens and was found to be PCR positive. On discussion with Dr El-Zayadi
this was found to be wrongly identified as a negative sample. None of the other
negative samples were PCR positive.
One sample was moderately reactive with the core lb antigen (OD 0.816) and
one sample had a weakly reactive reading of 0.417 with the genotype 4a NS4
antigen, but none of the other negative samples had elevated OD readings. The
five control samples from HCV positive individuals were all PCR positive and
were strongly reactive with all of the antigens. This demonstrates a high level of
sensitivity and specificity for this assay.
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5.3.5.2 Saudi Samples
Murex Biotech provided a table with the reactivity of genotype 4 antigens with
Brentwood blood donors. Egyptian origin blood donors and
Saudi/Sudanese/Yemenis blood donors. Also provided was a spread sheet with
the original results of the genotype 4 antigens, the results of the repeated
genotype 4 antigen assays, the results of assay with genotype lb core, NS3 and
NS4 antigens, the Ortho 3 EIA result, and VK48 ELISA results, for 132 sera
from blood donors of Egyptian origin and 59 donors of Saudi/ Sudanese/
Yemenis origin.
5.3.6 Determination of cut-off value for genotype 4a antigen assays.
The reactivity of samples from Brentwood donor centre was compared with the
initial data from the Saudi donor centre. In the core plates the reactivity of
serum from 334 UK donors was compared with 554 donors ofEgyptian origin,
screen negative by Ortho 3 EIA, and 898 donations from Saudi, Yemen or
Sudan nationals of "non Egyptian origin" (Table 5.2). In the Brentwood donor
population 98.8% of donations had reactivity less than OD 0.3. This finding
was similar to the reactivity observed with antigens in the Murex screening
assay. Therefore the OD value 0.3 was considered the cut-off for background
non-specific reactivity. An arbitrary plate cut-off value was assigned as the
mean of 80 samples +0.6 OD units. The cut-off value given for core antigen
was 0.7 units. Samples from individuals with reactivity of above this value
would be considered as having genotype-specific reactivity to this antigen.
Analysis of the reactivity to the NS3 and NS4 antigens was carried out as above
and any sample with a measured reactivity of greater than OD 0.3 was followed
up. Cut-off values were assigned for NS3 and NS4, which were OD 0.78 and
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5.3.7 Ortho 3 EIA
Murex personnel tested the blood donor samples from the Riyadh Armed
Forces Hospital with the 3rd generation Ortho EIA. 33 anti-HCV positive
donors were detected, 31 were of Egyptian origin, one of Sudanese origin and
one of Saudi Arabian origin. 34 samples were not tested
5.3.8 Murex VK48
Two individuals whose samples were not tested by Ortho EIA were VK48
assay reactive. Another 4 individuals were VK48 assay positive alone.
34 individuals were not tested by Ortho 3 EIA. 11 were also not tested by
Murex VK48 Assay due to sample volume. This included one sample which
was repeatedly reactive with all 3 genotype 4 single antigens and the 3 genotype
lb single antigens which Murex also classed as a commercial positive.
5.3.9 Serology Results Single Antigens - Blood Donors of Egyptian
Origin.
Of the 621 Saudi blood donors of Egyptian origin, data were available for 132
individuals. During testing in Saudi Arabia 125 samples produced OD values
greater than O.D.O.25 to one or more genotype 4a antigens. The other 7 of the
132 cases where data were available included one donor who was borderline in
the Ortho 3 EIA and two donors with genotype 4a core antigen reactivity on
retesting in Dartford.
Genotype 4a directed reactivity was found in repeat testing in sixteen donors,
however, only 3 of these provided measurements above the cut-off values set
for each antigen (see Table 5.5). Reactivity to comparable genotype lb antigens
was observed in one of the donors reactive with the NS4 antigen and to the NS3
genotype lb antigen in the individual reactive to both core and NS3.
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No Screened 621 926
Ab>0.25 on one or more
genotype 4a antigens
125 (20.1%) 58 (6.26%)
No of samples retested 123 59
Positive on one or more
commercial 3rd Gen EIA
34 (5.5%) 6 (0.65%)
Borderline on one or more
commercial 3rd Gen EIA
7(1.45%) 0









0 1 (0.11%) 1 (0.11%)
NS3 only 7
(1.13%)
0 2 (0.22%) 0
NS4 Only 6
(0.96%)
2 (0.32%) 3 (0.43%) 0




1 (0.11%) 1 (0.11%)
Core and NS4 0 0 0 0
NS3 and NS4 0 0 0 0
Core, NS3, NS4 0 0 0 0
Table 5.5 The serological reactivity found in the Egyptian Blood Donors Tested
on type 4a antigen.
♦Reading above cut-off value for NS3 antigen only.
Repeatedly reactive samples OD y+0.6 on table 5.6
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5.3.10 Serology Results Single Antigens - Blood Donors of Saudi
Arabian, Yemenis, and Sudanese Origins.
From the 926 samples, analyses data from 59 blood donors' serological assays
were provided, of these 58 had measured initial test OD values greater than 0.25
units to one or more genotype 4a single antigens (leading to a sample being
taken for repeat testing in Dartford) and one had a positive reaction with the
VK48 assay. Two donors were Ortho 3 EIA positive, one of these was also
VK48 positive and a further 4 donors were positive in VK48 alone. The donor
positive with both Ortho and VK48 had positive results for all 3 genotype 4a
single antigens as well as all three genotype lb antigens. The donor only
positive in Ortho 3 EIA was positive only in initial genotype 4a NS4 single
antigen testing. One donor strongly positive in VK48 was not reactive with any
genotype 4a single antigens, one VK48 reactive donor was repeatedly reactive
with genotype 4a NS3 only, one was initially reactive with type 4 NS4 and the
other repeatedly reactive with genotype 4a core and reactive with genotype lb
core.
Among the donors who were commercial serotyping assay negative, two
individuals demonstrated reactivity greater than cut-off levels for genotype 4a
antigens. One individual had reactivity towards the core antigen only and the
other reactivity to genotype 4a core and NS3 antigens. No reactivity to the
genotype lb core was measured in the first individual, but the reactivity was
also demonstrable to the equivalent antigens of genotype lb in the second (see
table 5.5). In the data provided there were no other cases ofreactivity measured
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5.3.11 Reproducibility of the results
The results varied between initial testing in Saudi Arabia and testing in
Dartford. For example 23 of the 72 donors who tested reactive with the
genotype 4a core tested below the cut-off in the assay in Dartford. However,
only 4 donors of the 40 donors who showed reactivity greater than the assigned
cut-off value of0.7 OD units, were below this value in repeat testing and only a
further 3 donor reactivities were above the cut-off which were not above this
value in initial testing (data not shown). Similarly for NS3 12 out of the 18
donors with reactivity were also reactive in repeat testing and no further
reactivity above the cut-off value was discovered in repeat testing (see table
5.7).
The OD values for 179 samples for which both initial and repeat test values
were available for all 3 antigens were used for analysis of the correlation
between initial and repeat testing. The correlation between initial and repeat
testing of the core antigen was 0.958, for NS3 it was 0.939 and 0.933 for NS4
(see figure 5.3).
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Table 5.7 Frequency of reactivity of samples with single antigen tests in the
field in Saudi Arabia and in the laboratory at Dartford.
Reactivity classed as OD >0.3
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5.3.12 Reactivity to genotype lb antigens
Reactivity to genotype lb antigens was observed in most cases where reactivity
to the genotype 4a antigen was detected. The only exceptions to this were in
commercial assay positive donors where the specific reactivity, as measured by
O.D. value, to theNS3 ofgenotype lb was either higher than, or absence in, the
genotype 4a antigen, and in one case where weak reactivity (OD 0.546) was
observed in a donor with initial weak reactivity to genotype 4a NS4 (OD
0.305). The correlation between reactivity ofdonors, as measured in Saudi, for
genotype 4a core to genotype lb core was calculated to be 0.976 and 0.955 for
the repeat testing in the UK. Similarly correlations of 0.713 -0.731 were
observed for NS3 and 0.807 -0.845 for NS5.
Little information about genotype lb reactivity in this population can be derived
since the donors were initially selected on the reactivity to genotype 4a antigen.
5.3.13 Condition of samples during transit.
All samples of the Egyptian commercial assay negative group, that showed
genotype 4a specific antigen reactivity, were PCR negative. These results were
relayed to Murex Biotech Ltd personnel, who expressed concern about the
storage conditions of the samples when they were transported from Saudi
Arabia. It appeared the aliquots of serum were delayed in transit by customs
and most of the samples arrived thawed, therefore the testing for HCV by PCR
was severely hampered because the viral RNA in serum samples was likely to
have degraded. To check the affect of the customs delay on the samples, 11
aliquots of serum which were positive with both the Ortho 3rd generation and
Murex VK48 EIA assay were sent for PCR testing. Viral RNA was found in 7
of these samples (63% positive). This indicated it was likely that there had been
some degradation of RNA, since results obtained by Murex Biotech indicated




The finding of genotype-specific serologically positive samples among the
commercial assays negative group seemed to confirm the theory that samples
were missed. However these samples were negative when tested for viral RNA
and only one of these samples contained reactivity with more that one antigen.
It is possible that the reactivity in these samples was residual from previous
resolved infection, but it could also be attributed to cross reactivity to another
antigen or to non-specific reactivity. The finding ofgenotype-specific reactivity
to the genotype lb antigens among the commercial assay positive and
commercial assay negative populations of Egyptian origin was unexpected,
since the predominant genotype of infection in Egypt was genotype 4.
However, the Egyptian commercial positive samples, which were tested by
PCR, contained 2 genotype 1 samples and 5 genotype 4 samples. Therefore, it
was possible for genotype 1 specific reactivity to be present in these samples, in
the same way that it is possible that genotype 4 infection was present in the
non-Egyptian commercial assay negative individuals with genotype 4 specific
reactivity. Saudi Arabia has a low prevalence of HCV in the native population
and the most prevalent genotypes are types 1 and 2. The immigrant populations
have left regions with high HCV prevalence and, therefore, one would expect
the prevalence in the immigrants to be higher than the native population. The
immigrants go to Saudi Arabia in search ofwork. Therefore, those infected with
HCV would be more likely to be chronic asymptomatic carriers than patients
with cirrhosis. The health care services in Saudi Arabia are very good and the
frequency ofnew transmissions are low. Therefore, the HCV infections in this
population were likely to be long established infections, where a number of
individuals had recovered and several were recovering and clearing the virus.
This would reflect the results obtained. The number of individuals who were
HCV infected, and were positive in all assays, would represent the chronically
infected individuals. The samples with high reactivity to a few antigens,
including those of genotype 4, were representative of those infected several
years ago who had since cleared the virus and now had a declining anti - HCV
response.
> Genotype-specific response was detected by non genotype one
antigenic HCV sequence, however, it is likely that it detected a
depleting immune response in resolving infection
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5.4 Screening Donor populations in Pakistan
5.4.1 Introduction
The failure to detect HCV PCR positive samples from infected individuals,
which were reactive only with antigens expressed from sequence of the
infecting virus genotype in Saudi Arabian blood donors, gave rise to wider
study of blood donor populations. Part of the failure to find examples of PCR
positive reactive samples with genotype-specific activity was attributed to the
fact that the infection rate and disease prevalence in this population was low
and response detected was likely to be from previous exposure. Therefore, the
search for samples with genotype-specific reactivity was repeated in blood
donations from a region where the infection rate was known to be much higher
and the disease was much more prevalent. Dr Saeed Hamid of the Aga Khan
University, Karachi, Pakistan confirmed from his studies that the prevalence of
HCV was 7.5% and in some rural areas around Karachi was as high as 40%
(Personal communication). The blood transfusion service reported that
approximately 1 infectious unit of blood per 100 screened was entering the
supply, despite screening with Abbott 2nd generation EIA. Dr Hamid also
reported that the Liver Unit was experiencing some problems with HCV
transmissions in their renal dialysis unit despite patient screening for HCV
infection. Due to logistical problems it was not possible for samples from Saudi
Arabia to be tested by PCR. However, the smaller number of samples studied
from Pakistan could be PCR tested.
5.4.2 Samples
Origin of samples Number Comments
Karachi Blood 891 2 batches
Transfusion Centre 405 all anti-HCV antibody
negative, 3 anti-HBV antibody
positive.
486 including 5 seropositive and
3 borderline in 2nd generation
anti-HCV antibody assay, 3 with
elevated ALT results.
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Dr Hamid sent 891 serum samples from the Karachi Blood Transfusion Service.
The samples were sent in two batches. The first batch contained 405 samples,
which were screened negative for anti-HCV antibodies, but these included three
samples that were positive for anti-HBV antibodies. The second batch of 486
samples had also been screened for anti-HCV antibodies. However, this batch
included five HCV seropositive samples and three samples that were borderline
in the Abbott 2nd generation assay. Six samples which were positive for anti-
HBV antibody and three samples with elevated ALT results were also included.
5.4.3 Assays
The samples were tested for reactivity in the Murex VK48 commercial
genotype lb screening assay and in equivalent genotype 3a antigens. The
genotype 3 a antigen assay plates were coated with a tripartite recombinant
expressed protein of core, NS3 and NS5, and NS4 branched peptides from the
serotyping assay (see section 2.6.2). The plates were coated at 200ng/well and
were confirmed by Murex to be as near a match to VK48 in sensitivity as
possible.
5.4.4 Methods
The serum samples were all tested in the Murex VK48 assay (section 2.7.5) and
the BHC129 genotype 3a antigen test assay (section 2.6.2).
The first batch of samples were pooled and tested for HCV RNA by PCR of the
5' non-coding region. 50 pi of serum from five samples was mixed together in
one 1.5ml Eppendorf tube and each pool of five samples had the RNA extracted
using the Access RNA extraction method (section 2.1.1.8) and PCR performed
(section 2.1).
Contamination of the primary PCR laboratory during testing of the second
batch of samples resulted in only the samples that were reactive in the HCV
ELISAs being tested by PCR.
The expense of ensuring consistent results was the main reason that only the
seroreactive samples of the second batch were tested. The contamination was
treated by swabbing the bench areas with 1% Hydrochloric Acid and soaking




All the samples were tested in the VK48 and BHC129 ELISAs. Thirteen
samples had absorbance measured as greater than 0.600 OD units in both
assays, 18 were reactive with the genotype lb antigens only and 14 were
reactive with the genotype 3a antigens only (see Table 5.8). PCR analysis was
carried out, in pools of five, on all of the samples in the first batch. In the
second batch of samples, due to contamination of the laboratory, PCR testing
was only carried out on seroreactive samples. Of the thirteen samples that were
reactive with both genotype antigens, seven samples were PCR positive. None
of the samples, reactive in the VK48 assay or in the genotype 3 antigens alone,
were found to be PCR positive. Additionally, there were no further PCR
positive samples identified from the pooling of the first batch of samples. The
samples, which were positive in both assays, contained 4 of the 5 seropositive
and 1 of 3 of the borderline samples in the Abbott 2nd generation EIA. One anti-
HBV antibody positive sample and a borderline Abbott 2nd generation result
sample were positive in the genotype 1 assay, but not in the genotype 3 assay.
The other Abbott 2nd generation positive and borderline samples, the other
samples with anti-HBV antibody and the samples from individuals with
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5.4.6 Interpretation
Eighteen samples were found to be commercial assay reactive with the
genotype lb sequence Murex VK48 assay during the testing in the Molecular
Virology Laboratory. Only 5 samples were reactive and 3 samples borderline
when tested in the genotype 1 a sequence Abbott 2nd generation EIA in Pakistan.
Seven samples were PCR positive, this included 3 of the Abbott 2nd generation
positive samples. This indicated that a number of infectious samples (0.45% - 4
PCR positive samples from 883 with no anti-PICV antibody detected) were
missed by screening in Pakistan, which would account for the reported
infections despite commercial assay screening. However, the use of 3rd
generation Abbott EIA assays should significantly decrease the rate of false
negatives (Barrera et al., 1995).
There were 14 samples, which showed genotype-specific reactivity to the
genotype 3a antigens, and 18 that were reactive with only the genotype lb
antigens (see Table 5.7). These samples with genotype-specific reactivity were
negative when tested by PCR. The 14/891 (1.5% of samples), which contained
reactivity to the genotype 3a antigens only, is similar to the 3/621 (0.48% of
samples) of the commercial assay negative individuals of Egyptian origin,
which contained reactivity to genotype 4a antigens. The reactivity, like that of
the Saudi Arabian blood donors, could be the response to resolved infection or
cross reactivity to another antigen or non-specific reactivity. The 18 samples
that were reactive with the genotype lb antigen alone could reflect the fact that
the genotype lb antigen was a better antigen. This was entirely possible since
the genotype 1 b antigens, as part of the commercial assay, have undergone
many years of testing and refining. It may have also been possible that these
individuals had been infected with genotype 1 infection that had resolved.
Alternatively, the genotype lb antigen may cross-react with other antibodies in
the serum and give rise to false positives.
Genotype 3 is by far the most prevalent genotype in Pakistan, but genotype 1
infections do exist. The samples with elevated ALT and anti-HBV antibodies
were not positive for HCV RNA nor anti-HCV antibody, which showed on this
occasion, that screening for these surrogate markers of HCV infection did not
improve detection. The overall finding was that detection ofHCV seropositive
samples was increased by 1.5% when screened by genotype 3a antigens
compared with a 2nd generation screening assay.
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> Genotype-specific anti- HCV antibody response was detected in the
blood donor population in Pakistan. However, genotype-specific
response to genotype lb was more frequently observed than
response to genotype 3a.
> Detection of anti-HCV positive samples was increased by 1.5%
when screened by 3rd generation compared to second generation
screening assays.
> Detection was not improved by screening for surrogate markers of
ALT elevation and anti-HBV antibody.
5.5 Analysis of RIBA confirmation test results in
Scottish Blood Donors
5.5.1 Introduction
The number of false positive anti-HCV results is high in a low HCV prevalence
setting such as blood donor populations, where only 0.05% are infected
(McOmish et al., 1993). Therefore, anti-HCV antibody positive samples found
in EIA testing were retested in a second test before donors were recalled for
investigation. The Recombinant Immuno-Blot Assay (RIBA) was used as
confirmatory test of HCV infection by blood transfusion services. Each of the
antigenic regions was coated separately and reactivity to each protein could be
estimated. If serum reacted with two or more recombinant proteins, the sample
would be classed as reactive. Ifthe sample reacted with only one antigen, it was
classed as indeterminate. Prior to PCR testing of all blood donations, the
Molecular Virology Laboratory provided a HCV PCR service for all blood
transfusion services in Scotland for PCR confirmation of samples from blood
donors who were EIA positive, but were indeterminate in the RIBA 3rd
generation assay. Frozen aliquots of these RIBA indeterminate serum samples
were stored at -40°C in the Edinburgh laboratory.
The RIBA test contained bands from each of the HCV regions core (c22
peptide), NS3 (c33c expressed recombinant protein), NS4 (5-1 -lp and clOOp
peptides) and NS5 (expressed recombinant protein). It also contains a band with
superoxide dismutase protein and two bands of human IgG. The human
superoxide dismutase (hSOD) band was used because the c33c and NS5
antigens were expressed as a fusion protein in combination with the superoxide
dismutase gene (see Figure 1.9). The c33c recombinant protein was expressed
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in E.coli and the NS5 antigen was expressed in S.cerevisiae. The RIBA hSOD
band was used as a check to confirm that response detected against either ofthe
expressed recombinant proteins was true anti-HCV reactivity and not reactivity
directed against, or cross-reactive with, hSOD. The two human IgG bands were
used for comparison to estimate the magnitude of the anti-HCV response. The
amounts ofprotein coated on the two IgG bands were designated "level 1" and
"level 2", the amount of reactivity to an antigen was assigned according to
comparison with these bands.
The possible outcomes for activity of a RIBA band are:
No band
+/- Inferior to level 1 IgG band, but a discernible band is present
1+ equal to the level 1 IgG band
2+ higher than the level 1 IgG band, but lower than the level 2 IgG band
3+ equal to the level 2 IgG band
4+ greater than the level 2 IgG band
The NS3 antigen in the RIBA test was expressed from a genotype 1 a sequence
amino acids 1192 to 1457. The distribution of HCV genotypes in the Scottish
blood donor population was found to be 50% genotype 1,10% genotype 2 and
40% genotype 3 (McOmish et al., 1994). The nucleotide sequence of the NS3
region varies considerably between the different genotypes; therefore some of
the NS3 antigens may differ between genotypes. If individuals infected with
virus of non-genotype 1 produced an antibody response directed against NS3
sequence of the infection genotype, then it is possible that the response may be
genotype-specific and no response would be detected with genotype 1
sequence. IfNS3 antigens ofother genotypes were included in the RIBA assay,
samples with genotype-specific responses may be detected. Perhaps samples,
which were classed as RIBA indeterminates with core, NS4 or NS5 only bands
reacting, could be resolved into RIBA confirmed cases by the use of NS3
antigens from other genotypes.
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Samples which were RIBA indeterminate, but PCR positive, were rare after the
introduction of 3rd generation screening and confirming assays. However two of
these samples were obtained to test. In addition, blood donations which were
found to be EIA positive and RIBA indeterminate, showed reactivity to the
core, or NS4 or NS5 antigens alone, and were obtained in the first six months of




Scottish Blood 249 63 "core only" RIBA band positives
Transfusion Service blood donors
10 "NS4 only" RIBA band
82 "NS5 only" blood donors
samples
94 anti-HBV, HCV and HIV
antibody negative and HCV PCR
negative blood donors
Serum samples from RIBA indeterminate Scottish blood donors, who donated
in the first six months of 1995, were available for testing for reactivity to NS3
antigens of genotypes other than genotype 1. The samples consisted of: 63
"core only" RIBA band positives (8 samples scored 4+, 10 samples scored 3+,
29 samples scored 2+ and 16 samples scored 1+). Of these, 2 were HCV PCR
positive (1 which scored 4+ and 1 which scored 2+); ten samples were "NS4
only" RIBA band (3 samples scored 4+, 5 samples scored 2+ and 2 samples
scored 1+) and 82 "NS5 only" samples (8 samples scored 4+, 16 samples
scored 3+, 32 samples scored 2+ and 26 samples scored 1+).
As a control group, 94 anti-HBV, HCV and HIV antibody negative and HCV
PCR negative blood donors were also tested for HCV NS3 reactivity.
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5.5.3 Assays
Assays Interpretation of results





Weakly reactive O.D, 0.2-0.6
Moderately reactive O.D, 0.6-1.0
Strongly reactive O.D, 1.0-2.0
Each of the RIBA indeterminate samples was tested in ELISA plates coated
with NS3 antigen of either genotype lb, 2b or 3a sequence. The genotype lb
sequence was the DX458T1 sequence from amino acids 1360 to 1454, which
was used in commercial assays. The genotypes 2b and 3a sequence were the
expressed protein from the corresponding portion of the genotype 2b and 3 a
genome, which had been amplified and cloned from samples LJ823 and LJ516.
The genotype 2b NS3 clone, DX502, and genotype 3aNS3 clone, DX506, were
expanded and the protein expressed in TOP 10 cells at Murex Biotech Ltd and
coated onto ELISA plates at a concentration of 25-50 ng per well as described
in section 2.5.
5.5.4 Methods
All of the indeterminate samples were tested for reactivity with antigen ofNS3
of genotype 2b and 3a sequence. The NS3 genotype lb antigen coated plates
were in short supply; therefore only 22 of the c22 (core) antigen only
indeterminate samples and the 94 control negative blood donors were tested for
reactivity with this antigen. The control blood donors were not tested for
reactivity to genotype 2b antigen. Each sample was tested by adding 20 pi of
the thawed and homogenised serum to 180 pi ofserum diluent and pipetted into
a well of the ELISA plate. Each plate contained 2 wells with 20 pi aliquots of
control positive sample and 3 wells of control negative samples. Both positive
and negative samples used were the control samples supplied with the Murex
VK48 commercial assay. The assay was carried out as described in the protocol
for a Murex VK48 screening assay as described in section 2.6.1.
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5.5.5 Results
The HCV PCR positive RIBA core reactive 4+ sample was not reactive with
any of the NS3 antigens and the RIBA core reactive 2+ sample was not reactive
with the NS3 genotype 2b or 3a antigens and was not tested with the genotype
lb antigen.
The 94 control blood donors were also unreactive in the NS3 genotype lb and
only 3 samples were weakly reactive in NS3 genotype 3a antigen plates (see
Table 5.9).
No reactivity was measured with the genotype lb NS3 antigen, in any of the
116 samples tested.
Five samples were identified which reacted strongly with the non-genotype 1
NS3 antigens, two samples which reacted with genotype 2b and 3a, two which
reacted with genotype 2b only and one which reacted with genotype 3a only.
Three samples (one sample core score 3+, one sample core score 2+ and one
sample NS5 1+) were strongly reactive (absorbance >1 OD units) with the NS3
genotype 3a antigen. The core reactive samples were also strongly reactive on
the NS3 genotype 2b antigen, but not on the NS3 genotype lb antigen. The NS5
reactive sample was not reactive on the genotype 2b antigen and was not tested
on genotype lb antigen.
A further two samples (a core score 1+ and a NS5 score 2+) were strongly
reactive in the NS3 genotype 2b antigen plates but not the genotype 3a plates.
The c22 reactive sample was not reactive with genotype lb antigen and the NS5
reactive sample was not tested with antigen of NS3 genotype lb.
Two samples (both c22 score 3+) were moderately reactive (absorbance 0.6 -
1.0 OD units) on the genotype 3aNS3, both were weakly reactive (absorbance
0.2-0.6 OD units) on NS3 genotype 2b (0.423 and 0.36 OD units), but not
reactive on genotype lb antigen. A further eleven samples (one c22 2+ and
three NS5 3+) had weak reactivity with genotype 2b NS3 antigen, but no
reactivity against genotype 3a antigen was detected. Seventeen samples showed
weak reactivity with NS3 of genotype 3a. Only three of these (c22 reactive





































































Table5.9hReactivityofIBAIndeterminateSamplesf rG no ypl ,2ba d3aNS3A tig n. Weaklyr activew scl ss fi dnODmeasuredbetwe n0.26u its,Mode atelyreactivwal sifiedODme sur dbe w n0.6 and1.0ODu its,Stronglyeactivewacl ss fi daODme suredbetween1.0n>2.0u its 166
The reactive samples were retested for HCV by PCR using amplification
primers for the 5' non-coding region. None of the samples were PCR positive,
although the control dilutions series confirmed positive results to a dilution
containing 1 X 104 copies/ ml.
The eleven samples with the highest NS3 reactivity were tested by the Murex
NS4 serotyping assay. None of these samples had detectable NS4 antibody,
therefore no serotype could be determined.
5.5.6 Interpretation
Reactivity to only one antigen suggests that the reactivity is likely to be cross-
reactive or non-specific. Therefore, many of these RIBA indeterminate samples
are likely to be real false negatives. However, it is possible that some of these
results were a genuine response to a previous, or newly acquired, HCV
infection, as is the case for the two PCR positive samples. The immune
response may only be targeted to a single antigen because the response is just
being mounted or is declining after the infection is resolved.
The RIBA assay, like the commercial screening assays, is also based on a
genotype 1 a sequence. It is likely that the response detected in individuals with
non-genotype 1 infection is also reduced by between 2- to 5- fold. The use of
antigens with sequences from the other HCV genotypes may resolve
indeterminate sample results by detecting genotype-specific reactivity. If the
indeterminate samples have a weak response, an antigen of the infecting
genotype will better detect this.
Five samples were identified which reacted strongly with the non-genotype 1
NS3 antigens, two samples which reacted with genotype 2b and 3a, two which
reacted with genotype 2b only and one which reacted with genotype 3a only.
Each of these samples also has anti-HCV antibodies to another region other
than the NS3 as detected by RIBA. The antibody in these samples may be
evidence of previous HCV infections. The lack of detectable antibody to the
NS4 region prevented detection of a serotype, by competitive ELISA (section
2.7.5), which in the absence of detectable virus by PCR could have proved
infection with a non-genotype 1 virus.
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> Use of NS3 antigens of non-genotype 1 did not allow RIBA
"confirmation" of the two true infection cases (PCR positive
samples).
> Use of the NS3 antigens "confirmed" specific anti-HCV antibody in
5 RIBA unconfirmed cases; these may represent resolved infection.
5.6 Serological Diagnostic Test Results in Hepatitis
Patients from Pakistan
5.6.1 Introduction
PCR positive samples that were commercial screen assay negative, but reactive
with antigens of the infecting virus genotype, could not be found in blood donor
populations. The prevalence of infection is lower in blood donors, therefore,
these samples might be found in populations with a higher prevalence of
infection. This led to the direct search for these samples in cryptogenic hepatitis
patient populations. If samples, from patients in regions where other virus
genotypes were prevalent, were under-detected in commercial assays, then
investigation into patients diagnosed with non A-E hepatitis should yield true
HCV positive infections. In addition, patients with other forms ofviral hepatitis
may also have undiagnosed HCV co-infection, due to false negative anti-HCV
results.
Serum samples were made available from patients attending the Liver Unit in
The Aga Khan University Hospital in Karachi, Pakistan. The cryptogenic
hepatitis patients' samples and those with HBV infection were to be tested by
PCR for HCV RNA and by ELISA for reactivity to NS3 antigen expressed
from genotype 3 a sequence. If type-specific reactivity to genotype 3, the
predominant genotype of infection in Pakistan, affects commercial assay results





Aga Khan University 160 41 cryptogenic hepatitis
Hospital Liver Unit 25 fulminant hepatitis
negative for anti-HCV
(on 2nd generation assay)
and HBV antibody,
17 anti-HBV antibody





8 anti- HCV and HBV
antibody positive
Dr Hamid had previously sent frozen serum samples from 160 individuals to
the Molecular Virology Laboratory in Edinburgh. These hepatitis patient
samples included: 41 with cryptogenic hepatitis and 25 with fulminant hepatitis,
which were anti-HBV and HCV antibody negative; 17 samples which were
anti-HBV antibody positive and anti-HCV antibody negative; 69 samples which
were anti-HBV antibody negative and anti-HCV antibody positive; and 8
samples which were anti-HBV and HCV antibody positive.
5.6.3 Assays
Assays Interpretation of results
VK48 Murex Manufacturer's instructions section
2.7.1
Chiron RIBA Manufacturer's instructions section
2.7.4
Genotype 3 a single antigen Non-reactive O.D.< 0.2
Weakly reactive O.D, 0.2-0.6
Moderately reactive O.D, 0.6-1.0
Strongly reactive O.D, 1.0-2.0 +>2
BHC129 genotype 3a multiple
antigen plates
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The samples were tested for anti-HCV antibody by the laboratory in Pakistan
with the Abbott 2nd generation assay. Information about the HBV antibody
testing in Pakistan was not available. When the serum samples arrived in the
Molecular Virology Laboratory in Edinburgh the samples were allowed to
defrost and were tested by PCR for HCV RNA using primers for the 5' non-
eoding region. (See methods section 2.1)
The samples were tested in the commercial assay VK48 from Murex Biotech
Ltd. as directed by the manufacturer's instructions described in section 2.7.1.
Several samples were rechecked in the Abbott 2nd generation assay by Mr P
McCulloch of the Hepatitis Reference Laboratory. Samples that were of interest
were also tested in the Chiron RIBA 3rd generation assay, which was carried out
according to the manufacturer's instructions as described in section 2.7.4.
Murex Biotech Ltd supplied ELISA plates, which had been coated with antigen
that they had expressed from the clone DX506, which was constructed from an
expression clone containing the cDNA sequence of NS3 from a genotype 3a
sample.
The ELISA with the NS3 genotype 3a antigen was carried out as described in
section 2.6.1 using reagents supplied by Murex Biotech and the absorbance in
the wells measured at 470 nm. Discrepant samples (sample numbers 348, 349,
514 and 515) were tested in the BHC129 assay, which contained the expressed
sequence from genotype 3a core, NS3 and NS5 with NS4 synthetic peptides
derived from genotype 3 sequence. This assay was carried out as described in
section 2.6.2.
5.6.4 Methods
The HCV PCR status of the samples was available from a previous study on
these samples. Of the 41 samples from cryptogenic hepatitis patients, which
were anti-HBV, and anti-HCV antibody negative, 31 were PCR negative, 9
were PCR positive and one sample had insufficient volume to test. Of the 25
fulminant hepatitis patient samples, which were anti-HBV and HCV antibody
negative, 24 were PCR negative and 1 contained insufficient volume to test. Of
17 samples that were anti-HBV antibody positive and anti-HCV antibody
negative, 12 were PCR negative, 4 were PCR positive and one had insufficient
volume to test. The 69 samples, which were anti-HBV antibody negative and
anti-HCV antibody positive, consisted of 15 PCR negative, 51 PCR positive
and 3 samples with insufficient volume to test. Ofthe 8 samples, that were anti-
no
HBV and HCV antibody positive, 5 were PCR negative, 1 was PCR positive
and 2 contained insufficient volume.
Initially, an equal number of PCR positive and PCR negative samples from
each of the non-HBV and HCV patients (5 samples), the HBV patients (2
samples) and HCV patients (7 samples) were selected and assessed for NS3
genotype 3 a reactivity in the single antigen plates. Encouraging results showed
reactivity with genotype 3a NS3 in PCR positive samples which were Abbott
2nd generation negative (Table 5.10). To check for false negatives arising from
the Abbott 2nd generation assay, all samples with anti-HCV antibody negative
results were tested in the commercially available Murex VK48 3rd generation
screening assay. Identified samples which were positive in the VK48 and/or
PCR positive were sent to be retested by the Abbott 2nd generation assay in the
Hepatitis Reference Laboratory and were also tested in the RIBA 3rd generation
assay. The genotype of five of the samples of interest was determined by RFLP
of an amplified sequence from the 5' non-coding region as described in section
2.1.2.1
5.6.5 Results
5.6.5.1 NS3 genotype 3a reactivity.
Of the cryptogenic hepatitis anti-HCV and anti-HBV antibody negative, but
HCV PCR positive samples, 3 of the 5 samples showed reactivity (O.D. > 0.2)
to the HCV genotype 3a NS3 antigen compared with none of the 5 HCV PCR
negative samples. All of the seven HCV PCR positive anti-HCV antibody
positive, but anti-HBV antibody negative, samples contained strong reactivity
(O.D. 1.0-2.0) to the HCV genotype 3a NS3 antigen, compared with only 4 of
the PCR negative samples, which showed strong reactivity and one sample with
moderate reactivity (O.D. 0.6-1.0; measured absorbance 0.627). Of the anti-
HBV antibody positive and anti-HCV antibody negative samples, one of the
two HCV PCR positive samples contained reactivity to the HCV genotype 3 a
NS3 antigen, but neither of the HCV PCR negative samples displayed any
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5.6.5.2 Commercial Assay based on genotype lb sequence (Murex
VK48) results.
All the samples with anti-HCV antibody results from the Abbott 2nd generation
assay in Pakistan were tested in the Murex VK48 commercial assay (see Table
5.11). The serum from the cryptogenic hepatitis anti-HCV and anti-HBV
antibody negative cohort (41 individuals) gave 9 positive results, 31 negative
results and one sample contained insufficient volume to test. The 9 positive
results included seven of the HCV PCR positive samples. The other two HCV
PCR positive samples were negative in the VK48 assay. All of the 25 fulminant
hepatitis patient samples were negative in the VK48 assay. Ofthe 17 anti-HBV
antibody positive, but anti-HCV antibody negative group, 2 samples tested
positive in the VK48 assay, 14 samples tested negative and one sample had
insufficient volume to test. Two of the four PCR positive samples in this group
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5.6.5.3 Discrepant Samples
All samples with a PCR positive result and/or a positive VK48 were retested in
the Abbott 2nd generation assay (with the exception of sample 515 which could
not be located), RIBA 3rd generation and in the genotype 3a NS3 antigen.
The retesting by Abbott 2nd generation assay in Edinburgh, found 5 samples had
been falsely identified as negative in Pakistan (samples 82, 521, 566, 582 and
496) and another sample was found to be borderline in the test (sample 349)
(see Tables 5.12 and 5.13). Of the five false negative samples, four were HCV
PCR positive. The sample, which was borderline in the test, was also PCR
positive. The Abbott 2nd generation result differed from the Murex VK48 result
in six instances (samples 349,480, 514,281, 531 and 557) with the VK48 result
reflecting the PCR result in all but one of the samples (281).
RIBA results detected anti-HCV antibody in all but 3 of the discrepant samples
(numbers 515, 34 and 78). Low levels of clOO and c33c reactivity were detected


































































































































































































Table5.13DiscrepantSamplesfromLiverUnitPati ntsoundtba ti-HBVtibodyposit vei CVnegativyest gi k s . PCRpositivesampl s,wh charecommercial,saynegativeowniboldrin .ThNS3g n type3nt gr u tf rl4highligh d becauseitstheonlyreactivityme sur dnimpl . 177
5.6.5.4 Genotype 3 NS3 Reactivity.
Genotype 3aNS3 reactivity was detected strongly (absorbance O.D. 1.0- 2.0 +
>2) in seven and moderately in two (absorbance O.D. 0.6-1.0) (514 and 496) of
the discrepant samples with weak reactivity above baseline (O.D. 0.2-0.6) in a
further two samples (281 and 34). Reactivity in samples 348, 349, 514 and 515
was tested in the genotype 3a multiple antigen assay. Unfortunately, none of
samples 34 and 78 remained to test in this assay. The genotype 3a assay
detected reactivity in sample 349 and 514, but not in samples 348 and 515.
5.6.6 Interpretation
The Abbott 2nd generation testing in Pakistan is generating false negatives. The
error rate in the cryptogenic hepatitis anti-HBV and HCV antibody negative
group was 12%. Five out of the forty-one samples were falsely reported as
negative. The false negative results may occur because of poor sample
preparation or storage or may be due to operator error in the testing laboratory.
Use of a 3rd generation commercial screening assay may improve the detection
of HCV infections. The VK48 screening assay was much better at detecting
infectious samples, but 4 infections (samples 348, 515, 34 and 78) were
identified which could not be detected by serology. One of these samples
(sample 34) was weakly reactive with recombinant antigen ofNS3 genotype 3a
(0.518 OD units). Unfortunately, none of this sample remained to be tested in
the genotype 3a antigen ELISA. The samples, which were PCR positive and
reactive in both Abbott and Murex tests, were strongly reactive with the
genotype 3a NS3 antigen. The genotype 3a NS3 antigen reactivity was lower
for samples that were Abbott negative or PCR negative, from the group of
individuals without markers for HBV co-infection.
Ofthe samples that were not detected by the screening assays, one sample (348)
had weak reactivity (1+) to the clOO and c33c RIBA antigens. These antigens
correspond to the NS3 and NS4 regions, which are highly variable.
Unfortunately it was not possible to test the sample for genotype 3 NS4
reactivity. The genotype 3 NS3 antigen did not detect the NS3 reactivity
detected by RIBA. The genotype of infection was not known. It is possible,
although unlikely, that the sample was from an individual with genotype 1
infection and the reactivity was genotype-specific and this was the reason no
reactivity was measured with the genotype 3 NS3 recombinant antigen. It is
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also possible that the RIBA NS3 antigen is a better antigen and detects response
much better than the recombinant genotype 3 NS3 antigen.
Two samples (348, 281) that were negative by Abbott 2nd generation, did not
have any detectable anti-core response in the RIBA test. The core antigen is the
most conserved between genotypes and the most cross-reactive response was
measured with this antigen. The negative results with the Abbott 2nd EIA may
have been because the antibody response to the NS3 and NS4 regions was
genotype restricted and did not cross-react with the assay antigens.
> The study of the liver unit patients from Pakistan has identified
two problems with screening for HCV by 2nd generation assay. One
is that the number of false negatives is high; the other is that there
are a number of patients who do not have a detectable antibody
response.
> The use of genotype 3 antigens in this group would not have
improved the detection of HCV in this population.
5.7 Seroconversion Panels
5.7.1 Introduction
Seroconversion panels are sequential samples taken from an infected individual
over a time period, during which the immune response is mounted and becomes
detectable by serological assay. Some of these seroconversion panels have been
obtained, in the past, from blood transfusion services, which pay for donations.
In these centres drug addicts often made frequent repeated donations to help
fund their habit. This allowed study of the immune response in individuals
contracting infections. Large volumes ofserum from different time points since
infection would be available for analysis. Other seroconversion panels were
obtained from monitoring of individuals who were accidentally infected and
"look back" studies on people who received infected blood or blood products.
The seroconversion panels were valuable tools for diagnostic research as these
samples allowed the efficiency of assays to be tested. Seroconversion panels
were a convenient way to test the assays with antigens from non-genotype 1
sequence. The seroconversion may occur earlier with antigens from the
infecting genotype than with conventional assays due to type-specific
immunity.
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Samples from individual J were described as a seroconversion panel; however,
this patient already had detectable response in the initial sample. This patient
cleared HCV infection after IFN therapy. The serology results are included in
this section to demonstrate the extent of the type-specific response in the
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Dr A Widdell of Malmo University, Malmo, Sweden provided serum from 10
individuals infected with genotype 3a virus, where 2 or more sequential
samples were available. These samples came from individuals A - J. A, B and C
were patients with acute hepatitis (2 samples were available for each ofpatients
A and B, and 3 samples from patient C). Individual D was a HCV positive
blood donor, whose antibody negative blood donation had been used in the
treatment of individuals E and F (3 samples were available for individual D and
2 each for individuals E and F). No further information is known of individuals
G, H, I and J other than they were infected with genotype 3 virus (3 samples are
available for individuals G, H and I and 12 samples were obtained from
individual J). A further 10 control samples were included, which contained 4
PCR and serologically HCV negative blood donor samples, 5 samples with
antibody positive and PCR positive results (1 mixed genotype lb and 2b
infection, 1 of genotype 2b viral infection, 2 of genotype 4 viral infection, 1 of
genotype 6a) and 1 sample where the only information available was that the
individual was in the window period of infection with HCV virus.
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These samples had been extensively studied in the laboratory at Malmo
University, Abbott 2nd generation EIA and IMX tests, 3rd generation RIBA,
(3rd generation Ortho EIA had been performed on sample J) PCR and RFLP
had been performed. Only a small volume of sera could be spared for further
testing. Initially 50 pi aliquots of the frozen sera from patients A-J were sent
under blinded code for analysis with NS3 genotype lb and genotype 3a NS3
antigen assay. A further 30 pi frozen aliquot of each sample was sent unblinded
for analysis with the BHC129 genotype 3a multiple antigens ELISA.
PCR test results were not available for seroconversion samples G, H and I. With
only 50 pi and 20 pi samples available for analysis, it was not possible to
confirm the PCR status of these samples.
5.7.3 Assays
The NS3 genotype lb and 3a recombinant antigen coated plates were used
initially for the coded samples and, at a later date, the uncoded samples were
tested in BHC129, the genotype 3a combined antigen assay. Murex Biotech Ltd
provided ELISA plates coated with recombinant protein from NS3 region
amino acid 1360 to 1454, from the commercial assay genotype lb, obtained
from DX45 8 sequence and the genotype 3a recombinant protein expressed from
the clone DX506. BHC 129 assay wells were coated with a tripartite fusion
protein of core NS3 and NS5 as previously described section 2.6.2. Murex
Biotech Ltd supplied sample diluent, goat anti-human IgG conjugate, substrate
and wash buffer and 0.5M sulphuric acid was made up in the laboratory. The
previously described negative control obtained from the SNBTS was used in 2
wells of each assay and the high antibody titre anti-HCV positive sample was
used as a positive control in 2 wells.
5.7.4 Methods
The frozen samples shipped from Malmo University were allowed to thaw and
were mixed gently by pipette, before 20 pi of each sample was added to the
respective well of each assay plate. The assays were carried out as described in
section 2.6.2 and the results expressed as the optical density absorbance at 470
nm in the substrate wells after the addition of 0.5 M sulphuric acid. The results
of the samples, which were received under code, were faxed to Dr Widdell,
who faxed back the key to which code matched which sample.
The PCR status for each of the samples from individual G, H and I was not
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available. Therefore, it was not known if the patient was infected at the time of
the first two samples for each individual. Unfortunately, no further information
was available about these individuals. Assuming these samples were PCR
positive at the time of the first sample, it would be very interesting ifpatient I
had remained serologically negative for 8 years.
Unfortunately, Dr Widdell did not provide the cut-off values for the Abbott 2nd
generation EIA and IMX assays and 3rd generation EIA tests.
5.7.5 Results
5.7.5.1 Individual A
The 14/09/94 sample was reactive with both the BHC129 assay and the Abbott
2nd generation EIA. No reactivity was measured in the genotype lb and
genotype 3a NS3 antigen coated plates. The RIBA test indicated reactivity to
the core antigen. However, since this was the only antigen reactive in this test,
the sample would be classed as indeterminate. In the sample of the 25/10/94 the
IMX and RIBA results were both positive, as was the BHC 129 and Abbott 2nd
generation assays, but neither of the single NS3 antigens tests were reactive,
although reactivity to the RIBA C33c antigen suggests NS3 reactivity. There
was insufficient volume of the sample from 14/12/94 left for testing.
5.7.5.2 Individual B
The 01/09/94 sample was not detected by either of the NS3 antigen coated
plates, but was strongly reactive in the genotype 3a BHC 129 assay and also in
the Abbott 2nd generation EIA but was RIBA indeterminate (c22c only). The
12/10/94 sample was PCR negative; however, antibody was detected in all
assays. The genotype 3a NS3 antigen test measured an OD of > 2 compared
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5.7.5.3 Individual C
In individual C, the EIA positive result was RIBA confirmed in each of the 3
samples. The NS3 single antigen plates did not detect any antibody response.
However, in the 29/09/94 sample, the OD in the genotype 3a NS3 antigen test
(0.354) was higher than that of the genotype lb antigen test and elevated above
background readings. Insufficient volume ofthe 21/07/94 and 29/07/94 samples
prevented testing in the BHC129 assays. The 29/09/94 sample was strongly
reactive in the BHC129 assay (Table 5.14).
5.7.5.4 Individual D
The blood donor's first sample (05/10/93) had no detectable antibody by any
commercial assay, the Abbott IMX measurement of0.5, being the only elevated
value. The sample of 03/11/93 was positive by EIA 2 and IMX and confirmed
by RIBA. This sample was also detected by the BHC129 assay (OD >2). The
NS3 genotype 3a antigen detected low levels of NS3 antibody (0.557)
compared with none in the NS3 genotype lb assay (0.025). The third sample
(27/10/94) was slightly detected by NS3 genotype lb antigen (0.46) compared
with strong detection (>2) in the NS3 genotype 3a antigen and the BHC129
assay.
5.7.5.5 Individual E
The two samples are 2nd generation EIA and IMX positive and RIBA assay
confirmed, although the patient has undergone interferon treatment and cleared
the virus to become PCR negative. Both samples are strongly reactive with the
BHC129 and NS3 genotype 3a assays compared with low reactivity to the NS3
of genotype lb recombinant protein antigen (0.223 and 0.227 first and second
samples respectively).
5.7.5.6 Individual F
This is the second recipient of the infected blood / blood product from
individual D. Again, both samples were Abbott EIA and IMX 2nd generation
positive and RIBA confirmed. The 13/04/94 sample was PCR negative. Both
samples were strongly reactive in the BHC129 assay. The genotype 3a NS3
antigen assay measured a much greater response than the genotype lb NS3
antigen (1.427 and >2 compared with 0.165 and 0.167 for the 18/01/94 and the
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5.7.5.7 Individual G
The first two sequential samples 29/04/94 and 17/11/94 were Abbott EIA
negative and absorbances of 0.38 and 0.44 were observed in IMX assay. The
PCR status was unknown. These samples did not contain any antibody, which
reacted with antigen in either of the NS3 antigen coated plates, or the genotype
3a multiple antigen assay. The third sample taken on 06/03/95 had elevated
results in all assays: 4.25 in 2nd generation EIA, 15.8 in IMX: 3,3,4,0 in RIBA:
1.831 with NS3 antigen of genotype lb; and O.D of 2, in NS3 genotype 3a
antigen and BHC129 assays.
5.7.5.8 Individual H
The samples of 12/10/93 and 14/11/94 were not reactive with any of the assays.
RIBA test results were not available for individual H. The sample of 27/02/95
was strongly reactive in all the commercial assays and the genotype 3a multiple
assay ELISA. This sample was also strongly reactive in the genotype 3a NS3
antigen coated plates, but not reactive in the genotype lb antigen coated plates.
5.7.5.9 Individual I
The first two samples of21/09/87 and 13/06/94 were negative by 2nd generation
EIA with measured absorbance of 0.46 and 0.44 by IMX. The samples were
unreactive with genotype lb and genotype 3a NS3 antigens and the first sample
was unreactive in the genotype 3a multiple antigen assay. The second sample
was not available to test with the BHC129 assay. The third sample (24/02/95)
was reactive in the 2nd generation EIA (2.86) and the IMX (7.18) assays and
RIBA confirmed with 3+ RIBA NS3 and NS4 bands. This sample was reactive
with the genotype 3a NS3 antigen (1.422), but not the genotype lb NS3 assays
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5.7.5.10 Individual J
Individual J was a genotype 3 a infected patient who cleared serum RNA in
response to interferon treatment (details of INF and treatment regime unknown)
and is the opposite of a seroconversion. The date the patient commenced the
treatment was also unknown. The 2nd generation EIA reactivity measured was
increasing until the sample of 18/10/93 (3.3), which then decreased to 0.66 by
the final sample of 10/11/94 (Table 5.17). The 3rd generation measured
reactivity also peaked at the 18/10/93 sample and then declined. The IMX
reactivity measured fluctuates during the time period. The NS3 genotype 3 a
antigen reactivity was considerably greater than the NS3 type lb antigen
reactivity for each sample time point, with NS3 genotype lb antigen reactivity
disappearing (sample taken on 02/11/93) before the NS3 genotype 3a antigen
reactivity (sample taken on 10/08/94).
5.7.5.11 Control samples
Of the control samples included, all of the samples considered negative by Dr
Widdell were unreactive in the experimental assays (Table 5.18). The genotype
lb and 2b mixed infection sample was reactive (>2) in all tests. The genotype
2b sample was detected by the NS3 genotype 3a single antigen assay (>2) and
the genotype 3a multiple antigen assay (1.926), but not the NS3 genotype lb
single antigen assay (0.058). Of the 2 genotype 4 samples, one was reactive to
the genotype 3a multiple antigen assay (>2), the other was not. Both samples
were more reactive in the NS3 genotype lb antigen assay (1.101) than in the
genotype 3a antigen assay (0.174, 0.533). The sample that was identified as a
HCV infection in the window period was reactive in the genotype 3 a multiple












































































































































Control 1 NEG 0.009 0.016 0
Control 2 NEG 0.005 0.004 0
Control 3 NEG 0.036 0.042 0
Control 4 NEG 0.43 0.058 0
Control 5 POS 0.013 0.003 1.343
Control 6 POS 1B/2B >2 >2 >2
Control 7 POS 2B 0.058 >2 1.926
Control 8 POS 4 1.101 0.174 >2
Control 9 POS 4 0.553 0.164 0
Control 10 POS 6 >2 >2 >2
Table 5.18 The Serological Results for the Control Samples Provided by Dr
Widdell.
The genotype of sample 5 was not provided.
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5.7.6 Interpretation
Reactivity to the genotype 3 antigens was stronger than that to the genotype 1
antigens in the majority of the seroconversion panel samples studied. However,
the detection of antibody does not appear to be improved by use of the
genotype 3a antigen assay.
The RIBA test in early samples from individuals A-F detected core antigen as
well as NS3 in the initial response. The lack of sequence variation and the
extent of genotype cross-reactive immunity to this region, may explain why
these samples were equally well detected in the commercial assays.
One control sample (5) was detected by the genotype 3 antigen screening assay
and no other results were available. The information provided about this sample
was that it was in the window period ofHCV infection. Further discussion with
Dr Widdell confirmed that this sample was reactive with 3rd generation
screening assays (Ortho EIA 3), but had been included in the panel since it was
2nd generation screening assay negative (Ortho EIA 2).
The control samples of genotype 4 infection reacted better with the antigens of
genotype lb, whereas, the sample of genotype 2b infection reacted better with
the genotype 3a antigen. This phenomenon may reflect the extent of similarity
of the epitopes between genotype 1 and the genotype 4 infecting virus and
genotype 3 and the genotype 2 infecting virus. Also, the genotype 1 antigen
may be a better antigen as a result of research and development of the assay.
The antibody response to infection persists long after the infection has resolved.
This was observed in individual J, who cleared virus in response to interferon
therapy. The response was still detectable by Abbott 2nd generation IMX test, a
year after the first serum PCR negative result.
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The immune response detected by the genotype 3 antigens was stronger than
that detected by the genotype 1 assay. This suggests either the response is
stronger because of type-specific response or that the genotype 3 assay is more
sensitive. If the genotype 3 assay were more sensitive, then the genotype 4
samples would not be better detected by the genotype 1 assay. It is likely that
the declining response seen in individual J is similar to the response found in
the blood donor populations in Saudi Arabia and Pakistan.
> The O.D. measured in assays with homologous antigen were higher
than heterologous
> No instances of earlier detection in seroconversion panels were
observed with non genotype 1 antigens.
> The response to homologous genotype antigen is detectable for
longer after infection has resolved.
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5.8 Samples PCR positive but conventional antibody
assay negative or discrepant.
5.8.1 Introduction
Having been unable to find samples which were PCR positive and which
contained antibodies which were reactive only with antigen of their infecting
genotype in screening donor populations, cryptogenic hepatitis patients or
seroconversion panels, the "PCR positive - antibody negative" samples were
now examined. These samples, which were negative or discrepant in
commercial assays, may contain an antibody response, which was specific to
the virus of infection and possibly a non-type 1 genotype, which would be
detected with the non-genotype 1 antigen tests.
A number of samples were identified, and sent to the Molecular Virology
Laboratory for supplementary testing and analysis, which were found to be
PCR positive for HCV, but were discrepant in conventional assay or were
without any measurable antibody response. These samples were detected
primarily through PCR testing of blood donations and commercial blood
product testing and one sample from a liver unit patient who tested negative in
commercial assays.
5.8.2 Samples
Mr S Clelland of the SNBTS identified 3 donors from PCR testing of plasma
pools from which blood products were to be manufactured (personal
communication). These samples were antibody negative in third generation
assay when originally tested by SNBTS and when tested by Murex VK48
assay. Of these samples, two were found to be genotype 1 and the third
identified as genotype 3 by RFLP of the amplified 5' non-coding region (as
described in section 2.1.2.1). Dr V Schottstedt of the DRK Blood Transfusion
Service in Hagen, Germany also provided 3 samples. These samples were
identified during PCR screening ofblood donors. The samples were identified
as genotype 1 by RFLP of the 5' non-coding region. A further sample was sent
from Dr R Kaiser of the Rheinische Friedrich-Wilhelms University in Bonn,
Germany. This serum sample came from a patient who was PCR positive for
HCV, but was not positive in commercial serology assays.
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5.8.3 Assays
The SNBTS samples and the sample from Bonn were tested in the genotype lb
and genotype 3a NS3 antigen only plates and all the samples were tested in the
BHC129 genotype 3a antigen assay.
5.8.4 Results
None of the PCR positive antibody negative samples was positive in any of the
antigen assays.
5.8.5 Interpretation
The samples showed no reactivity to antigens ofeither genotype 1 or genotype
3. The samples from Hagen were sequenced in 5' non-coding and in core
regions and showed no abnormalities compared with published sequences. It
seems likely that the antibody response in these samples is immature, or absent,
rather than specific to antigens only present in the infecting virus.
With these blood donor samples it is unknown when infection took place. This
could be a relatively recent occurrence and the individuals could be in the
window phase of infection. Another explanation for this finding could be that
the individuals may have a genetic, or other underlying, condition, which
affects the immune response to these antigens. The sample from the patient who
did not seroconvert could, again, be due to a window phase infection, or
perhaps, the patient is co- infected with HIV or using immuno-suppressive
medication that has caused the immuno-suppression.
> Use of non genotype one single antigens or multiple antigen assay
did not help detect infection in the samples which were PCR





6 Discussion of findings from experimental
work
From investigation of singe recombinant antigen assays;
> A genotype specific response is directed at each antigen used in
current screening assays.
From investigation of combined recombinant antigen assays;
> A genotype specific response is directed at the combination of
antigen used in current screening assays.
Investigation of the impact of type specificity;
> A five fold reduction in the sensitivity of anti-HCV antibody
detection by Ortho 3rd generation assay results in under-detection
of individuals with resolved HCV infection.
> A 13.5 loss in sensitivity of this assay would result in under-
detection of active HCV infection.
Investigation of detection of infection with non genotype 1 antigens in blood
donor populations where other genotypes are predominant;
> In Saudi Arabian blood donor populations, including individuals
of Egyptian origin, genotype-specific response was detected by
genotype 4 sequence antigens alone, however, it is likely that it
detected a depleting immune response in resolving infection
> Genotype-specific anti- HCV antibody response was detected in the
blood donor population in Pakistan. However, genotype-specific
response to genotype lb was more frequently observed than
response to genotype 3a.
> Detection of anti-HCV positive samples was increased by 1.5%
when screened by 3rd generation compared to second generation
screening assays.
> Detection was not improved by screening for surrogate markers of
ALT elevation and anti-HBV antibody.
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Investigation of confirmation of infection with non genotype 1 antigens in
blood donor populations;
> Use of NS3 antigens of non-genotype 1 did not allow RIBA
"confirmation" of the two true infection cases (PCR positive
samples).
> Use of the NS3 antigens "confirmed" specific anti-HCV antibody in
5 RIBA unconfirmed cases; these may represent resolved infection.
Investigation of detection of infection with non genotype 1 antigens in patient
populations where other genotypes are predominant;
> The study of the liver unit patients from Pakistan has identified
two problems with screening for HCV by 2nd generation assay. One
is that the number of false negatives is high; the other is that there
are a number of patients who do not have a detectable antibody
response.
> The use of genotype 3 antigens in this group would not have
improved the detection of HCV in this population.
Investigation of time scale of detection of infection with non genotype 1
antigens in seroconversion panels of non genotype 1 infection;
> The O.D. measured in assays with homologous antigen were higher
than heterologous
> No instances of earlier detection in seroconversion panels were
observed with non genotype 1 antigens.
> The response to homologous genotype antigen is detectable for
longer after infection has resolved.
Investigation of detection of infection with non genotype 1 antigens in
infections where HCV RNA can be detected but anti-HCV antibody can not be
detected by conventional assay;
> Use of non genotype one single antigens or multiple antigen assay
did not help detect infection in the samples which were PCR
positive but commercial assay negative
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The first aim of this project was to investigate whether the immunogenic
regions and epitopes are influenced by the genetic variability of HCV, and to
investigate the implications this has for the effectiveness ofanti-HCV antibody
screening. The results showed type-specific immune responses are directed
against each antigen contained in an EIA and demonstrated that the HCV
directed antibody response to non-genotype 1 viral infections is under-detected
in 3rd generation assays. However, there is no evidence that the lack of
detection compromises the safety ofblood transfusion as the donors found to be
falsely-negative in genotype 1-based serology assays were invariably non-
viraemic.
6.1 Investigation of the level of detection of
heterologous HCV genotype infection
In a previous study, by Dhaliwal and colleagues (Dhaliwal et al., 1996), it was
shown that antibody levels were higher in donors who were actively infected
with HCV with detectable viral RNA in plasma. Furthermore, mean antibody
reactivity in genotype 1 -infected individuals (ie. homologous infection), was
4.5-fold greater than in genotype 2 and 3 infection. Using samples from a wider
range of individuals, I have been able to confirm these findings, and
demonstrated that the combination of non-genotype 1 infection and lack of
detectable HCV RNA resulted in substantial under-detection of infection with
the current screening assays.
Detection of a type-specific response to genotype 2, 3 and 4 antigens, in
seronegative blood donors, suggested that some previously HCV infected
donors are undetected with 3rd generation EIA (sections 5.3, 5.4 and 5.5).
6.2 To investigate if the use of heterologous antigens
can detect infections undetectable by current
serological methods, but detected by molecular
biology
Thorough analysis of seronegative PCR positive blood donations,
seroconversion panels and sera from liver unit patients provided no evidence
that the use of heterologous antigens could aid serological detection of anti-
HCV antibodies. There are several possible reasons for this, but the most likely
reason is that the immune response was too immature to be detected. In these
instances isolation of viral RNA is the only way to detect infection.
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6.3 To investigate if use of heterologous HCV genotype
antigens can resolve confirmational assay
indeterminate samples
In the investigations described, the use of heterologous antigens did not
increase the rate ofconfirmation ofPCR positive RIBA indeterminate samples
(section 5.5). However, few PCR positive samples were available for analysis.
The use of heterologous antigens did increase the rate of detection in PCR
negative, anti-HCV antibody indeterminate donors. Detection of reactivity
directed against two HCV antigens confirmed the reactivity is not likely to be
non-specific or cross-reactive. It is likely that the individuals detected had
previously been infected with HCV and spontaneously resolved the infection.
6.4 Investigation if heterologous HCV antigen assays
can increase sensitivity of detection in the "window
phase"
Through study of both seroconversion panels (section 5.7) and reported
serologically negative PCR positive individuals (section 5.8), no evidence was
found that use ofheterologous antigens would decrease the time to detection of
seroconversion.
6.5 The overall aim is to ascertain which combination
of antigens best detects infection with all genotypes
From these studies, I concluded that adding antigens of other genotypes does
not greatly enhance the sensitivity of screening in a blood donor setting. While
some (past, resolved) HCV infections may be undetectable using commercially
available type 1-based screening assays, the lack of viraemia in these samples
provides no evidence, at present, that these serological "misses" influence the
safety of blood transfusion. However, the results do indicate that a proportion
ofpast HCV infections may remain undetected by current diagnostic methods.
This work demonstrated that the main cause for concern in the hospitals and
blood transfusion services studied was the extent of false negative results
generated by the Abbott 2nd Generation EIA. It is likely that this is the true
reason for the reported transmission of HCV, despite screening, in these
centres.
The most reliable method of screening blood is to test for viral RNA. This,
unfortunately, may be too costly for the countries where HCV is most
prevalent.
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6.6 Nucleotide Amplification Technology
Since July 1999 every blood donation has had to be additionally tested by PCR
for HIV and HCV RNA. The testing by PCR is estimated to reduce the time of
the window period, that is the time between infection and the individual having
sufficient markers of infection to detect, to between 10-29 days. In the year
following the introduction of testing SNBTS have identified three infective
samples that were serologically negative. This means that prior to PCR
screening 1:840 000 donations was infectious.
6.7 How has this work advanced the current
understanding of HCV serology?
The main finding is that the magnitude of the antibody response to infection is
not influenced by the genotype of infection. The lower serological reactivity
detected in conventional serology assays results from the presence of type-
specific epitopes present in the recombinant antigens.
Although the use of heterologous antigens does not increase the rate of
detection of new infections or resolve indeterminate results, it does allow the
detection of many previous infections. This may be beneficial in
epidemiological studies or in estimates of rates of HCV resolution in
populations.
The introduction of heterologous antigens in current screening assays would
reduce assay specificity, and therefore increase the number of false positive
results that would have to be resolved by supplementary or confirmatory
antibody tests and PCR. However, this work demonstrated that a large number
of "false" negative results are still generated in areas of high prevalence.
The majority of the individuals studied in this thesis were healthy blood donors,
and it is possible that greater improvement in the detection rate of non-type 1
genotypes would be achieved in individuals with impaired immune responses to
infection and incomplete antibody repertoires. The effect ofconcurrent disease,
coinfection, genetic factors and immunosuppressive drugs are each likely to
diminish the detectable immune response. In these cases the use of
heterologous antigens may be useful and should be further investigated.
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Appendix 1
Serum Extraction Mix Final Concentration
0.11M Sodium Chloride BDH Lutterworth UK
55mM Tris(hydroxymethyl)methylamine hyrochloride (Tris-HCl) BDH
l.lmM EDTA Kodak
0.5 % Sodium Dodecylsulphate Sigma Poole, Dorset
2mg/ ml Poly A Amersham Little Chalfont, UK
1 Omg/ ml Proteinase K Roche Lewes, UK
10 X TBE Solution
108g Tris Base
55g Boric acid
9.3 g Na2 EDTA.2H20
Tris EDTA (TE) Solution nH8
lOmM Tris -Hcl
ImM EDTA
SOC Medium 100 ml pH 7
2g Bacto-Tryptone
0.5g Bacto-Yeast extract
1 ml 1M NaCl
0.25 ml 2M Mg2+stock (1M NaCl2.6H20)
Add Bacto-Tryptone, Batco-yeast extract, NaCl and KC1 to 97 ml distilled
water. Stir to dissolve. Autoclave and cool to room temperature. Add 2M Mg2+
stock and 2M glucose, each to a final concentration of 20mM. Bring to 100 ml






Adjust to pH 7 with NaOH
217
LB Agar
Add 15g agar to 11 of LB Broth
Glucose Tris Lvsozyme GTE Solution
0.9g glucose
2 ml 0.5M EDTA
2.5 ml Tris-HCl
NaOH SDS Solution 10 ml
400 gl 5M NaOH
1 ml 10%SDS
8.6 ml distilled water
KOH/ Glacial Acetic Acid Solution (Solution IIP
29.5% Glacial Acetic acid
KOH pellets to pH 4.8
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Appendix 2
Nucleotide sequences of the expressed clonesfrom Core, NS3 and NS5 regions
Numbering according to Choo et al., 1991.
Core genotype lb
DX501 nucleotides 0-420
ATG AGC ACG AAT CCT AAA CCT CAA AGA AAA ACC AAA CGT AAC ACC AAC
CGC CGC CCA CAG GAC GTC AAG TTC CCG GGC GGT GGT CAG ATC GTT GGT
GGA GTT TAC TTG TTG CCG CGC AGG GGC CCC AGG TTG GGT GTG CGC GCG
ACT AGG AAG ACT TCC GAG CGG TCG CAA CCT CGT GGA AGG CGA CAA CCT
ATC CCC AAG GCT CGC CGG CCC GAG GGC AGG GCC TGG GCC CAG CCC GGG
TAT CCT TGG CCC CTC TAT GGC AAT GAG GGC ATG GGG TGG GCA GGA TGG
CTC CTG TCA CCC CGT GGC TCT CGG CCT AGT TGG GGC CCC ACG GAC CCC
CGG CGT AGG TCG CGT AAT CTG GGT AAG GTC ATC GAT ACC CTC ACA TGC
GGC TTC GGC GAC CTC ATG GGG TAC ATT CCG CTC GTC
Core genotype 3 a
DX760 nucleotides 0-420
ATG AGC ACG AAT CCT AAA CCT CAA AGA AAA ACC AAA AGA AAC ACC ATC
CGT CGC CCA CAG GAC GTT AAG TTC CCG GGT GGC GGA CAG ATC GTT GGT
GGA GTA TAC GTG TTG CCG CGC AGG GGC CCA CGA TTG GGT GTG CGC ACG
ACG CGT AAA ACT TCT GAA CGG TCA CAG CCT CGC GAA CGG CGA CAG CCT
ATC CCC AAG GCG CGT CGG AGC GAA GGC CGG TCC TGG GCT CAG CCC GGG
TAC CCT TGG CCC CTC TAC GGT AAC GAG GGC TGC GGG TGG GCA GGG TGG
CTC CTG TCC CCG CGC GGC TCC CGT CCA TCT TGG GGC CAA AAT GAC CCC
CGG CGA AGG TCC CGC AAC TTG GGT AAA GTC ATC GAT ACC CTC ACG TGC




ATG AGC ACG AAT CCT AAA
CGC CGC CCA ATG GAC GTT
GGA GTT TAC TTG TTG CCG
ACT CGG AAA ACT TCG GAG
ATC CCC AAG GCG CGT CGA
TTT GCA TGG CCC CTT TAC
CTC TTG TCC CCC CGT GGT
CGG CGG AGG TCC CGC AAT
GGC CTC GCC GAC CTC ATG
0-420
CCC CAA AGA AAA ACC
AAG TTC CCG GGT GGT
CGC AGG GGC CCC CGG
CGG TCG CAA CCT CGT
TCC GAG GGA AGG TCC
GGT AAT GAG GGT TGC
TCT CGA CCG TCT TGG
TTG GGT AAA GTC ATC
GGG TAC ATT CCG CTC
AAA CGT AAC ACC AAC
GGT CAG ATC GTT GGC
TTG GGT GTG CGC GCG
GGA AGA CGC CAG CCT
TGG GCA CAA CCA GGA
GGG TGG GCA GGA TGG
GGC CCA AAT GAT CCC





CCC AAC AUC GAG GAG GUG GCU CUG UCC AAC ACU GGA GAG AUC CCC UUC
UAU GGC AAA GCC AUC CCU AUU GAG ACC AUC AAG GGG GGG AGG CAC CUC
AUU UUC UGC CAC UCC AAG AAG AAG UGU GAC GAA CUC GCU GCA AAA CUG
GUG GGC CUC GGU AUC AAU GCU GUA GCG UAU UAC CGG GGC CUU GAU GUG
UCC GUC AUA CCG GCC AGC GGA GAC GUC GUU GUU GUA GCA ACA GAC GCU
CUA AUG ACG GGC UUU ACC GGC GAC UUU GAC UCA GUG AUC GAC UGU
NS3 genotype 3 a
DX506 nucleotides 4079-4361
CCU AAC AUU GAG GAG GUG GCC CUG GGU UCU GAA GGU GAG AUC CCU UUC
UAC GGC AAG GCU AUA CCA AUA GCC CUG CUC AAG GGG GGG AGG CAC CUU
AUC UUU UGC CAU UCC AAG AAA AAG UGC GAU GAG AUA GCA UCC AAA CUC
AGA GGC AUG GGG CUC AAC GCU GUA GCA UAC UAU AGA GGU CUC GAU GUG
UCC GUC AUA CCA ACA ACA GGG GAU GUC GUA GUU UGC GCU ACU GAC GCC
CUC AUG ACU GGA UUC ACU GGG GAC UUC GAC UCC CUG AUC GAC UGU
NS3 genotype 4a
DX499 nucleotides 4079-4361
CCU AAC AUU GAG GAG GUC GCC CUG CCA ACA ACG GGG GAA AUA CCC UUU
UAC GGC AAG GCG AUC CCU CUG GAG CUG AUU AAG GGG GGC AGA CAU CUC
AUC UUC UGC CAC UCA AAG AAA AAG UGU GAU GAA CUG GCC AGA CAA CUG
ACA UCU CUU GGU CUG AAU GCC GUA GCC UAC UAC AGA GGC UUA GAC GUU
UCG GUG AUU CCC ACG UCU GGG GAC GUC GUG GUA UGC GCC ACG GAC GCC
CUC AUG ACG GGU UUU ACC GGC GAC UAU GAC UCC GUC AUC GAC UAC
221
NS5 genotype 3 a
DX507 nucleotides 6712-6961
GGA TCC AAT ATT ACT CGC GTG GAG TCT GAA ACA AAG GTT GTG ATT CTT
GAT TCG TTC GAA CCC CTG AGA GCC GAA ACT GAC GAC GCC GAG CTC TCA
GTG GCT GCG GAG TGT TTG AAG AAA CCT CCC AAG TAC CCT CCA GCT CTT
CCT ATT TGG GCT AGG CCA GAT TAC AAT CCT CCA CTA TTG GAC CGC TGG




Derivation of the formula to calculate the percentage of type-specific and type-common
antibody response.
Assume:
1. Reactivity of a type A serum for a type A antigen is 1 unit.
Eaa=1
2. The same is true for a type B serum with type B antigen.
Ebb=1
3. The reactivity equals the type-common and type-specific components
Tc + Ts=l
4. The reactivity of a type B serum for a type A antigen is a product of the overall
"antigenicity" times the type-common component.
Eba = Aab X Tc
5. The antigenicity Aab is the antigenicity of a genotype A antigen relative to the
antigenicity of a genotype B antigen.
6. Reactivity of a sample of type B for type B antigen compared to reactivity of a




7. Reactivity of a sample of type A for antigen of type B compared to reactivity of a












From this the proportion of type-common reactivity can be derived as follows:
j, _ I Eab/Eaa
\ Ebb/Eba
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Assays that detect antibody to hepatitis C virus (HCV) are used to screen blood donors and patients with
hepatitis. Current enzyme-linked immunosorbent assay (ELISA)-based methods are invariably based upon
antigens from expressed recombinant proteins or oligopeptides from HCV type 1. Some HCV antigens used in
screening assays are coded by regions of the HCV genome that show extensive variability; therefore, HCV type
1-based assays may be less effective for the detection of antibody elicited by infection with other genotypes. In
this study, we have measured antibody reactivity of sera from 110 hepatitis C patients infected with type lb,
3a, or 4a to genotype-specific and cross-reactive epitopes present in recombinant proteins from HCV genotypes
lb (core, NS3, and NS5), 3a (NS3, NS5), and 4a (core, NS3), corresponding to those used in current third-
generation screening ELISAs. By comparing the serological reactivities of sera to type-homologous and type-
heterologous antigens, we detected a significant type-specific component to the reactivity to NS3 (61 to 77% of
the total reactivity) and NS5 (60% of the total reactivity). Furthermore, despite the similarities in the amino
acid sequences of the core antigens of type lb and type 4a, we also found significantly greater reactivity to
type-homologous antigens, with approximately 25% of reactivity being type specific. These findings are con¬
sistent with previous findings of fivefold weaker reactivity of sera from HCV type 2- and HCV type 3-infected
blood donors in the currently used third-generation ELISAs and suggest that these assays are suboptimal for
screening populations in which the predominant genotype is not type 1.
Detection of antibody to hepatitis C virus (HCV) has be¬
come the principal method for the diagnosis of HCV infection
in individuals with chronic hepatitis and for the screening of
blood donors. Although the original assay based upon the
c 100-3 recombinant proteins derived from NS4 showed non-
specificity and insensitivity, the more recently developed assays
that use recombinant proteins from the core and NS3 regions
of the HCV genome (second-generation assays) and the NS5
region of the HCV genome (third-generation assays) have
proved to be more effective for the screening of blood donors.
Their use has led to a substantial reduction in the incidence of
posttransfusion hepatitis. In prospective studies, the incidence
of HCV transmission among recipients of blood screened by
first-generation assays was 1.5% in Spain (15), 3.7% in Japan
(27), and 11% in Taiwan (6). Screening by second-generation
assays reduced or would have reduced the incidence to 0.9% in
Japan (27), 1% in Spain (15), 2% in Greece (20), and 2.5% in
Taiwan (6).
One reason for the failure to detect antibody to HCV in
donated blood specimens that transmit HCV infection is that
the blood was collected from an individual with acute infection
before seroconversion for antibody. This so-called "window"
period is long for HCV compared with other viruses for which
blood from donors is screened, such as human immunodefi¬
ciency virus, with means of 88 to 66 days in second- and third-
* Corresponding author. Mailing address: Department of Medical
Microbiology, University of Edinburgh, Teriot Place, Edinburgh,
United Kingdom. Phone: 44 131 650 3138. Fax: 44 131 650 6531.
E-mail: Peter.Simmonds@ed.ac.uk.
generation assays, respectively (9). By measuring the incidence
of HCV infection in blood donors, it has been estimated that
the current residual risk of HCV transmission through collec¬
tion of "window" samples is 1 per 100,000 donations in the
United States (24). This frequency of infection is similar to the
residual risk of infection from blood screened by third-gener¬
ation assays from French blood donors (10).
In addition, samples false negative for antibody have been
reported for a small proportion of immunocompetent individ¬
uals persistently infected with HCV (2, 17). Indeed, even in
anti-HCV-positive individuals, there is considerable variability
in the frequency of reactivity to the individual HCV proteins
used in supplementary assays, such as the Ortho 3rd genera¬
tion recombinant immunoblot assay (RIBA-3), and in the titer
of antibody to HCV among persistently infected individuals.
Among 90 anti-HCV-positive blood donors, antibody reactivity
in the Ortho third-generation screening assay varied over a
range of 5,000-fold, with some serum samples having antibody
levels only just above the cutoff for the assay (12).
HCV can be classified into at least six major genotypes,
whose nucleotide and inferred amino acid sequences over the
whole genome differ by approximately 30%. This degree of
amino acid sequence variability is similar to that observed
between variants of other RNA viruses (e.g., dengue virus
types 1 to 4), in which significant antigenic differences have
been documented and which form the basis of their classifica¬
tion into serotypes. We have previously measured the serolog¬
ical reactivities of individuals infected with different HCV ge¬
notypes to antigens used in two third-generation anti-HCV
assays (Ortho 3rd generation anti-HCV EIA; Murex VK48).
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Samples from HCV type 1-infected individuals showed an ap¬
proximately five times greater reactivity than those infected
with HCV type 2 or 3, and the reactivity was independent of
other factors that may have influenced the antibody response,
such as the degree of viremia, donor age, and severity of
hepatitis as assessed by alanine aminotransferase measure¬
ments.
In the current study we have addressed two of the main
shortcomings of the first study. First, we have measured sero¬
logical reactivities to the individual component antigens used
in a third-generation assay (core, NS3, and NS5). These mea¬
surements extend previous investigations of type-specific and
cross-reactive serological reactivity to the NS4 antigen used in
the first-generation screening assays and in second- and third-
generation confirmatory assays (1, 5, 14, 21, 26, 28). Second, we
have carried out titrations with antigens derived from HCV
type 1 as well as corresponding proteins from other HCV
genotypes (types 3a and 4a). This allows levels of antibodies to
both type-homologous and type-heterologous antigens to be
measured, allowing for a more rigorous assessment of the
relative levels of type-specific and type-common reactivity to
each.
MATERIALS AND METHODS
Samples. Samples LJ516, EG21, and ED43 were obtained from individuals
infected with genotype 3a (LJ516) or 4a (EG21 and ED43 [3, 25]). Sequences
amplified from the core, NS3, and NS5 regions of types 3a and 4a were used for
the synthesis of antigens for antibody screening. Recombinant antigens from the
core (amino acid positions 1 to 140), NS3 (amino acid positions 1360 to 1454),
and NS5 (amino acid positions 2234 to 2318) (numbered according to Choo et al.
[7]) regions of HCV-UK (type lb) were derived from an existing, commercially
available anti-HCV assay (VK48).
Serum samples were obtained from 110 anti-HCV-positive individuals with
chronic hepatitis C attending hospital liver clinics in Edinburgh and London,
United Kingdom; Karachi, Pakistan; and Cairo, Egypt. Among the samples, we
selected 33 infected with genotype lb, 34 infected with genotype 3a, and 43
infected with genotype 4a. Genotypes were identified by restriction fragment
length polymorphism analysis of the 5' noncoding region as described previously
(11).
Development of enzyme-linked immunosorbent assays (ELISAs) based upon
type 3a and 4a antigens. RNAs from samples LJ516 (type 3a), EG21 (type 4a),
and ED43 (type 4a) were extracted as described previously (16): Reverse tran¬
scription was carried out with avian myelobastosis virus reverse transcriptase and
RNasin (both from Promega, Southampton, United Kingdom), in each case by
using the external antisense primer, and incubation at 42°C for 30 min as de¬
scribed previously (4). The sequences were amplified by using the following heat
cycle: 94°C for 18 s, 45°C for 21 s, and 72°C for 90 s for 30 cycles, followed by 6
min at 72°C with the primers listed in Table 1. The core region of type 4a was
amplified with primers 954 and 410, followed by amplification with primers D236
and 597. The NS3 region was amplified with primers 751 and 753, followed by
amplification with primers 594 and 593 (type 3a) or 750 and 007 and then primers
594 and 593 (type 4a). For the type 4a NS3 region, a third PCR was carried out
with the product of the second PCR by using the same inner primers. The NS5
region of genotype 3a was amplified by using primers 991 and 993, followed by
amplification with primers 3155 and 3156. The amplified sequences were cloned
and sequenced as described previously (23).
Expression of recombinant proteins. The sequences of the core, NS3, and NS5
regions from the different HCV genotypes indicated above were subcloned into
Escherichia coli or baculovirus expression vectors, as appropriate, by standard
molecular biology techniques. The NS3 and NS5 sequences of each genotype
were cloned into the E. coli vector pTrcHis (Invitrogen BV, Leek, The Nether¬
lands) and were expressed in TOP10 cells by standard isopropyl-p-D-thiogalac-
topyranoside induction. Core sequences were cloned into the baculovirus expres¬
sion vector pBlueBacHis2 (Invitrogen), and recombinant virus was derived by
cotransfection into insect cells along with linear Antographa californica nuclear
polyhedrosis virus DNA. Recombinant antigens were produced in Sf.9 insect
cells in an LH Series 210 bioreactor by infection at multiplicity of infection of 2
for 48 h.
Both the E. coli and baculovirus vector expression vectors place a tract of six
histidine residues at the amino terminus of each recombinant protein. Recom¬
binant proteins were therefore subsequently prepared by metal chelate chroma¬
tography on Probond nickel affinity resin (Invitrogen) to approximately 90%
purity.
ELISA for detection of antibody to core, NS3, and NS5 regions. To optimize
plate coating, purified antigens were titrated to levels giving acceptable specificity
and sensitivity and approximately equivalent amounts of protein per well (25 to
TABLE 1. Primers used for amplification of core,
NS3, and NS5 regions
Primer no. Sequence"
954 ACT GCC TGA TAG GGT GCT TGC GAG
410 GAG CGG AAT GTA CCC CAT GAG GTC GGC
D236 GGT AGA CCG GAT CCC ATG AGC ACG AAT CCT AAA
597 GAA AGA AGC TTA GAC GAG CGG AAT GTA CCC
751 TTY CGG GCN GCY GTG TGC ACC
753 GCG TCA TAG CAC TCA CAG AGG AC
594 ACC RCT GCA GAY CCY AAC ATN GAG GAR GT
593 CAC AAG CTT ARC AGT AGT CKA TSA CNG ART C
750 TGG TYA CNN GNN AYG CYG ATG TCA TYC C
007 ACC TCG AGT ATC CCA CTG ATG AAG TTC CAC AT
991 TGG CNA GCT CNT CNG CNA GCC A
993 GGC TCC CCC TCA AGG GRG GCA TRG A
3155 GGA TCC AAY ATN ACY CGY GTR GAG TCW SA
3156 AAG CTT GTG GTG GYA AGG CAC AYC C
" International Union of Pure and Applied Chemistry ambiguity codes were
used: Y, C/T; R, A/G; N, G/C/AT; K, G/T; S, C/G; W. A/T. Cleavage sties for
restriction enzymes are underlined: CTGCAG, PstI; AAGCTT, Hindlll; GGA
ICC, BamHl.
50 ng). Binding of antigen was assessed both by functional enzyme immunoassay
(EIA) with positive and negative sera and by probing for the histidine tag present
on each protein by using horseradish peroxidase chemically modified to bind
nickel ions. All antigens were coated overnight in 50 mM Tris (pH 8.5) contain¬
ing 0.02% sodium dodecyl sulfate. The plates were then blocked by the addition
of 2% degraded gelatin and were finally dried to ensure stability.
For each antigen assay, each serum sample was diluted 1:10, 1:40, 1:160, and
1:640 in anti-HCV-negative sera. Aliquots of 20 pi from each titration were
added to 180 pi of sample diluent, mixed, and then added to a well of the ELISA
plate. A solution of 1:50 E. coli blocker was added to the diluent for all assays for
NS3 genotype 3a antigen. The plates were then incubated at 37°C for 1 h,
followed by five washes in glycerate-borate buffer. Bound antibody was detected
by the addition of 100 pi of horseradish peroxidase-labelled antibody to human
immunoglobulin G conjugate and by incubation for 30 min at 37°C. After wash¬
ing, 100 pi of 3,3',5,5'-tetramethylbenzidine substrate was added, and the mix¬
ture was incubated for 30 min at 37°C. The color development reaction was
stopped by the addition of 50 pi of 2 M H2S04, and optical densities (ODs) were
measured at 470 nm. All assay plates included a dilution series of the reference
genotype la sample (dilutions of 1:2 to 1:2,560) for calculation of antibody levels.
The NS3 genotype 3a recombinant antigens were expressed in E. coli and re¬
quired the addition of 1:50 E. coli blocking solution in the sample diluent for all
assays.
Quantification of antibody levels. Antibody reactivity to each recombinant
protein in each of the test serum samples was determined by titration and
reference to a standard positive control as described previously (12). This
method is based upon the observation of a linear relationship between OD (over
the range of values of 0.02 to 1.0) and concentration of antibody in both ELISAs
based upon single antigens, as in the current study and in the currently used
third-generation screening assays from Ortho and Murex (12). Because of this
relationship, the antibody reactivity of a test sample can be expressed relative to
that of a reference control by the following formula: test antibody level = (test
OD x reference concentration)^reference OD x test concentration). Antibody
levels were obtained for each sample in each antigen assay in this way.
Estimation of relative proportions of type-specific and cross-reactive antibod¬
ies. The ratio of antibody levels measured to type-homologous and type-hetero¬
logous antigens indicates the relative proportions of type-specific and cross-
reactive reactivities. This calculation is complicated by the possible existence of
differences in the antigenicity or presentation of proteins from different geno¬
types in the ELISA and differences in antibody levels elicited by infection with
different genotypes.
The proportion of antibody reactivity that is cross-reactive between genotypes
is measured by reciprocal assays of reactivity between sera and antigens from two
genotypes, genotypes A and B. In the following relations, EBA represents the
antibody reactivity of a serum sample infected with genotype B with antigen of
genotype A,Aab is the overall antigenicity of the genotype A antigen relative to
that of the genotype B antigen, and Tc and Ts are the proportions of the antibody
response that are type common and type specific, respectively, such that Tc +
Ts = 1.
Ebb
_ EBB ^ 1
Eba Ebb x Aab x Tc Aab x Tc
EAb
_ EAA x {HAab) x Tc ^ Tc
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FIG. 1. Comparison of the inferred amino acid sequences of antigens expressed from recombinant clones of (A) core (HCVUPCP, type lb; DX387, type 4a), (B)
NS3 (HCVUPCP, type lb; DX506, type 3a; DX499, type 4a), and (C) NS5 regions (HCVUPCP, type lb; DX507, type 3a) with representatives of each of the major
HCV genotypes and subtypes. Periods indicate identity with the HCV prototype sequence, HCV-PT (7). Numbers refer to amino acid positions on HCV-PT.
Therefore,
Ebb/EBA
_ ^AB _ 1
Eab/Eaa ~ Aab X (Tc)2 ~ (Tc)2




A"" = V(Em/EM) X (EBAIEBB)
These relations make the assumption that the relative proportions of type-
specific to type-common reactivity in a type A antiserum are the same as those
found in a type B antiserum.
Nucleotide sequence accession numbers. The sequences obtained in the
course of this project have been submitted to Gen Bank and bear the following
accession numbers: DX387, AF029298; DX506, AF029297; DX499,
AF029296; DX507, AF029299.
RESULTS
Variability of core, NS3, and NS5 region sequences. The
amino acid sequences of the recombinant proteins used in the
ELISA were deduced from the nucleotide sequences of the
corresponding clones and were compared with other published
sequences of these regions of HCV (Fig. 1). In the core protein
only 9 amino acids differed between genotypes lb and 4a over
the 140-amino-acid length (6% divergence). Substitutions were
generally conservative, where only one resulted in a change in
the ionic charge. The NS3 sequences exhibited more variabil¬
ity, with the sequence of genotype lb differing from that of
genotype 3a by 15 of 95 amino acids (16% divergence) and
from that of genotype 4a by 13 amino acids, while genotypes 3a
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FIG. 1—Continued.
and 4a differed from each other by 14 amino acids. In the NS5
sequence there were 23 differences between genotypes lb and
3a over a length of 85 amino acids (27% divergence). Six of
these substitutions affected the charge of the protein: four
substitutions of nonpolar amino acids for basic groups and two
substitutions of acidic groups for nonpolar groups.
Quantitation of antibody reactivity to core, NS3, and NS5
antigens. The serological reactivities of sera from 33 individ¬
uals with genotype lb, 34 individuals with genotype 3a, and 43
individuals with genotype 4a HCV infections to each of the
recombinant antigens from genotypes lb, 3a, and 4a were
measured. To investigate the reproducibility of the method
used to quantify antibody levels, each of the serum specimens
was assayed in replicate against the type lb and 4a core pro¬
teins (Fig. 2). A close correlation was observed between the
two measured antibody levels, with nonparametric correlation
coefficients being 0.877, 0.889, and 0.862 for type lb, 3a, and 4a
antisera, respectively. For the type 4a core antigens, the cor¬
responding correlation coefficients were 0.784, 0.721, and
0.802.
There was also a close correlation between reactivity to the
core protein of type lb and that to type 4a (Table 2), with
correlation coefficients of 0.834, 0.765, and 0.767 for type lb,
3a, and 4a antisera, respectively. Significant correlations were
also consistently observed between the reactivities of antisera
to NS3 proteins of types lb, 3a, and 4a, as well as between the
reactivities of antisera to NS5 proteins of type lb and 3a. In
contrast, there was little if any correlation between antibody
reactivity to different regions of the genome. For example, the
reactivity of sera from type lb-infected individuals to the type
lb core protein showed no correlation with reactivity to type lb
NS3 or NS5 proteins (correlation coefficients, -0.118 and
—0.181, respectively; Table 2). The only exceptions were weak
correlations (0.443 and 0.471) between the reactivities to 3a
NS3 and NS5 (but only for type lb sera) and between NS5 of
type lb with NS3 of 4a (restricted to type 3a sera).
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FIG. 2. Measurement of the reproducibility of measurement of levels of
antibody to type lb (A) and type 4a (B) core protein by sera from study subjects
by repeat testing. The correlation is indicated by a regression line.
Genotype dependence of serological reactivity. Sera col¬
lected from individuals infected with different genotypes varied
in their frequency of reactivity to NS3 and NS5 antigens of
different genotypes (Table 3). For NS3, frequencies of reactiv¬
ity for type lb, 3a, and 4a antisera to type-homologous NS3
proteins were 85, 100, and 76%, respectively, compared with a
range of 44 to 76% for type-heterologous combinations. Sim¬
ilarly, the frequency of reactivity of type lb sera with type lb
NS5 antigen (65%) was higher than that of heterologous sera
(47 and 51%), as was reactivity to type 3a NS5 (58% type-
homologous reactivity, compared with 24 and 45% for type-
heterologous combinations). In the core region, high frequen¬
cies of reactivity were observed for both type-homologous (95
to 97%) and type-heterologous (86 to 97%) combinations, indi¬
cating the greater antigenicity of this region of the genome and/or
a greater proportion of shared epitopes between genotypes.
To compare the strength of reactivity with type-homologous
and type-heterologous antigens, antibody levels relative to
those for the positive control calculated from OD readings at
dilutions ranging from 1:10 to 1:640 were used to calculate
antibody levels relative to those for the positive control (Fig.
3). There were significant differences in antibody reactivity to
the type lb core protein between samples from individuals
infected with genotype lb and those from individuals infected
with genotype 4a (P = 0.033) but not those with genotype 3a
(P = 0.811). The distribution of antibody levels directed to the
genotype 4a core antigen showed no significant difference be¬
tween genotypes.
Antibody reactivity against NS3 was frequently undetectable
among sera from individuals infected with HCV with type-
heterologous antigen (Table 3; Fig. 3C). The distribution of
levels of antibody to type-homologous antigens was consis¬
tently greater than those to type-heterologous antigens. For
example, the median level of antibody to type lb NS3 in type
lb sera was 0.225, which was substantially greater than the
median reactivities of type 3a and 4a sera to this protein (0.003
[P = 0.004] and 0.02 [P = 0.005], respectively). Similar, pre¬
dominant type-specific reactivities against type 3a and 4a an¬
tigens were observed (Fig. 3D and E).
Only 54% of the samples reacted with the NS5 genotype lb
antigen and 43% reacted with the genotype 3a antigen. The
median antibody level of genotype lb sera (0.031) was eight¬
fold higher than that for type 3a samples (0.004) and threefold
higher than that for type 4a (0.012). The distribution of anti¬
body levels among genotype lb samples was significantly
higher than that among genotype 4a samples (P = 0.029) but
not genotype 3a samples. The reactivity of type 3a sera against
TABLE 2. Correlation between reactivity to different antigens
Correlation for the following antigens
Antigen HCV and genotypes":
and geno¬ genotype Core NS3 NS5
type in serum









lb lb -0.118 0.023 (1)
3a 0.133 0.279 (1)
4a 0.100 -0.035 (1)
3a lb -0.270 -0.066 0.456 (1)
3a 0.153 0.274 0.363 (1)
4a 0.159 0.030 0.627 (1)
4a lb 0.048 0.224 0.710 0.518 (1)
3a 0.215 0.130 0.570 0.393 (1)
4a -0.058 -0.087 0.497 0.272 (1)
NS5
lb lb -0.181 -0.220 0.150 0.275 0.157 (1)
3a 0.066 0.000 0.218 0.265 0.471 (1)
4a 0.058 -0.192 0.069 0.168 0.055 (1)
3a lb -0.141 -0.43 0.247 0.443 0.348 0.630 (1)
3a 0.051 0.172 0.216 0.266 0.202 0.649 (1)
4a -0.076 -0.108 0.186 0.179 0.041 0.303 (1)
" Correlation is indicated by Spearman's rank correlation coefficient. Separate
values are provided for antisera of each genotype. Significant values (P < 0.05)
are underlined.
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TABLE 3. Frequency of reactivity to core, NS3, and NS5 proteins
No. of specimens reactive to the following antigen/total no. of specimens (%):
Antiserum Core NS3 NS5
lb 4a lb 3a 4a lb 3a
Type lb 32/33 (97) 32/33 (97) 28/33 (85) 25/33 (76) 24/32 (76) 21/33 (64) 8/33 (24)
Type 3a 33/34(97) 30/34(88) 15/34(44) 33/33(100) 9/33(27) 16/34(47) 18/31 (58)
Type 4a 37/43(86) 41/43 (95) 31/43 (72) 27/43(63) 31/41 (76) 22/43(51) 19/42(45)
NS3 of genotype 3a was significantly greater than that of the
type lb or 4a sera (P = 0.002 and 0.01, respectively).
Ratio of type-specific and cross-reactive reactivities. The
ability to measure the reactivity of the same antiserum to
antigens of different genotypes allowed for an estimation of the
relative levels of genotype-specific and cross-reactive serolog¬
ical reactivities. For the core proteins, the levels of antibody to
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FIG. 3. Distribution of antibody reactivity of sera from individuals infected with type lb, 3a, and 4a to core proteins of genotypes lb and 4a (A and B, respectively);
NS3 of genotypes lb, 3a, and 4a (C, D, and E respectively); and NS5 of types lb and 3a (F and G, respectively). Median values are indicated by short horizontal bars.
Pairwise comparison of the distributions of values was carried out by the nonparametric Kruskall-Wallis test.











FIG. 4. Ratios of reactivity of type lb and 4a sera to type lb/type 4a core
antigens. Median ratios are indicated by short horizontal bars. Pairwise compar¬
ison of the distributions of values was carried out by the Kruskall-Wallis test.
Ratios of reactivities to other antigens are presented in Table 4.
divided by their levels to the genotype 4a antigen (Fig. 4; Table
4). The median ratio of reactivity to type lb/reactivity to type
4a antigens for type lb antisera was 1.49, compared with a
median ratio of 0.809 for the type 4a antisera. This indicates
that type lb sera react more strongly against the type lb (ho¬
mologous) core protein, while the type 4a sera react slightly
more strongly against the type 4a antigen. If it were shown that
both core proteins were coated equivalently on the solid phase
and showed equal antigenicity, then the type-specific reactivity
to these proteins could be calculated from the difference from
the ratio of 1 that would be expected from exclusively type-
common reactivity. However, it is possible that some antigens
are present at higher available concentrations than others
through differences in binding to the solid phase or solubility.
These differences were taken into account by using the deri¬
vation described in Materials and Methods. In this instance,
the term EAB/EAA represents the median of the ratio of reac¬
tivity between type 4a antisera with type lb and type 4a anti¬
gens (0.809). The term EBB/EBA is similarly represented by the
median ratio of the type lb antisera (1.49). Therefore, the
proportion of type-common reactivity can be calculated as
0.74, with type-specific reactivity forming the remainder of the
reactivity (0.26).
The median ratio of reactivity of the type 3a sera to type 3a
and lb NS5 antigens (0.654) was substantially lower than that
of type lb sera (median, 4; Table 4). Therefore, the propor¬
tions of type-common and type-specific reactivity were 40 and
60%, respectively; i.e., the majority of the serological reactivity
to this antigen was type specific. Finally, three sets of pairwise
comparisons can be made for the NS3 region, in which anti¬
gens for all three genotypes were available. Sixty-two percent
of the serological reactivity between type lb and 3a proteins
was type specific, similar to the proportions of 61% between
type lb and 4a proteins and 77% between type 3a and 4a
proteins (Table 4).
DISCUSSION
Antigenic variability of HCV. The aim of this study was to
investigate the degree of type-specific serological reactivity to
antigens used in current, third-generation screening assays.
The use of recombinant antigens expressed from different ge¬
notypes in the enzyme immunoassay allowed reciprocal mea¬
surements of type-homologous and type-heterologous reactiv¬
ity to be made, and these provided a more rigorous assessment
of the type-specific components of reactivity to the core, NS3,
and NS5 regions. This addresses a potential criticism of previ¬
ous investigations that showed weaker reactivity of sera from
individuals infected with non-type 1 genotypes in either of the
screening ELISAs or to individual antigens in the confirmatory
recombinant immunoblot assay (5, 8, 12, 14, 21, 28), in that
there is a possibility that these observations resulted from a
generally weaker serological response to infection than that
elicited by type 1. In the current study we were able to consis¬
tently show stronger reactivity of sera to antigens of a homol¬
ogous type than to antigens of heterologous types.
From pairwise reciprocal measurements of antibody reactiv¬
ity (such as type lb and 4a antisera against type lb and 4a
antigen), it was possible to quantify the relative contributions
of type-specific and cross-reactive antibody reactivities by using
the relation derived in Materials and Methods (Table 4). These
calculations were independent of possible differences in the
strength of the serological response elicited by infection with
different genotypes and were also independent of differences in
antigen concentration or overall antigenicity between proteins
of different genotypes (expressed as the ratio Aab). This re¬
moves the potential criticism that the coating efficiency of
antigens from different genotypes onto the solid phase was not
compared prior to measurement of antibody levels. From this
analysis we found a relationship between the degree of amino
acid sequence divergence between recombinant proteins and
their degree of cross-reactivity. The sequence of the core pro¬
tein was the most conserved and the core protein showed
approximately 25% type-specific reactivity, while the more di¬
vergent sequences, those of the NS3 and NS5 regions, showed
substantially greater proportions of type-specific reactivity.
These results are consistent with previous comparisons of the
type-specific component of reactivity to peptides correspond¬
ing to linear epitopes in NS4. By absorption in solution with
peptides of heterologous genotypes, it was shown that reactiv¬
ity to type-homologous peptides was reduced but was rarely
eliminated (1, 26), allowing development of a sensitive and
specific serological typing assay. The type-specific component
of serological reactivity to NS4 and, in some studies, to the core
protein has been also used in typing assays without cross-
absorption, because it has consistently been observed that re¬
activity to type-homologous antigens in these (13, 19, 22) and
other regions (29) is stronger.
Implications for screening assays. The effect of the demon¬
strated antigenic variabilities of the components of third-gen-
TABLE 4. Type-specific and type-common serological reactivity







A B A B Tc Ts
Amino aid
divergence"
Core 4a lb 0.809 1.49 <0.001 74 26 6.4
NS5 3a lb 0.654 4.0 0.014 40 60 27
NS3 3a lb 0.053 0.373 0.001 38 62 16
4a lb 0.016 0.107 <0.001 39 61 14
4a 3a 0.049 0.939 <0.001 23 77 15
" Ratio of reactivity to antigens of genotypes A and B.
" Comparison of the distribution of ratios of reactivity of individual antisera to
antigens of genotypes A and B by the Kruskall-Wallis nonparametric test.
c Degree of amino acid sequence divergence between antigens of genotypes A
and B.
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eration screening assays on their overall sensitivity for screen¬
ing is difficult to estimate with precision for two reasons.
Individuals vary in their serological responses to different an¬
tigens, and therefore in the extent to which these responses
may result in cross-reactivity with antigens of heterologous
genotypes. For example, if reactivity were directed solely to the
core protein, this protein would cross-react with antigens of
heterologous genotypes, whereas sera monoreactive with NS3,
such as is found upon seroconversion, would be expected to be
predominantly type specific.
Furthermore, each of the three antigens investigated is likely
to contain a range of linear and conformational epitopes, and
these will vary in their degree of cross-reactivity. Recognition
of different epitopes in the antigens may be one explanation for
the wide range of ratios of reactivity to type-homologous and
type-heterologous antigens observed between sera of the same
genotype (Fig. 4). In the extreme case, it is possible that reac¬
tivity confined to epitopes in the core protein that are type
specific would lead to poor or absent reactivity to the core
protein of other genotypes. Conversely, the high degree of
cross-reactivity observed between certain sera with NS3 or NS5
proteins of heterologous genotypes may have resulted from
their recognition of shared epitopes.
The observed differences in reactivity of sera to homologous
and heterologous proteins would only lead to false-negative
results on serological screening if antibody levels in samples to
be tested were close to the cutoff sensitivity of the assay. In a
previous study, we measured antibody reactivity in the Ortho
third-generation assay and found a wide range of antibody
levels (approximately 5,000-fold) among samples from blood
donors infected with genotypes 1, 2, and 3, with the lowest level
found to be 0.0007, which is just above the cutoff value of the
test (12). Low antibody levels and reactivity to a restricted
range of epitopes, such as those in NS3, are found in acutely
infected individuals (18), and it is likely that earlier detection
of seroconversions, and therefore a reduction in the window
period associated with non-type 1 infection, may be achieved
by assays containing NS3 and other antigens from a wider
range of genotypes.
The finding of significant antigenic variability of antigens
used for serological screening will form the basis for a number
of future investigations. Now that antigens from other geno¬
types have been produced, it will be possible to carry out
large-scale screening of populations infected with non-type 1
genotypes (for example, with the type 4a antigens for testing
individuals in the Middle East). This may reveal the frequency
with which anti-HCV samples are being missed by conven¬
tional assays and may ultimately help reduce the frequency of
posttransfusion hepatitis further, particularly when popula¬
tions with a high frequency of acute infection are screened.
Similarly, the incorporation of antigens from other genotypes
(particularly NS3) in confirmatory assays may resolve the re¬
sults for a number of the indeterminate samples identified in
blood donor screening and for which interpretation of results is
currently problematic.
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